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ABSTRACT 
Pulmonary hypertension (PH) is characterized by structural remodelling of pulmonary 
arteries and arterioles, the result, at least in part, of excessive cell proliferation, resistance 
to cell death and hyperactive inflammatory reactions. Currently available treatments 
targeting the hyper-proliferative and pro-inflammatory pathology are limited. Epigenetic 
programming, dynamically regulated by histone acetylation, is an important mechanism 
for cell proliferation and survival. Aberrant changes of histone acetylation, modulated by 
histone deacetylase (HDAC), are shown in many proliferative and inflammatory disorders, 
especially cancer, and may contribute to the phenotypical changes in remodelling and 
overall to the development of PH. Hypothetically, HDAC inhibitors have therapeutic 
potential by reversing the imbalance of acetylation. 
I examined the correlations between HDAC expression and PH development, followed by 
evaluation of the pharmacological effects and possible mechanisms of two HDAC 
inhibitors, class I inhibitor valproic acid (VPA) and pan-HDAC inhibitor suberoylanilide 
hydroxamic acid (SAHA), on animal models and cellular systems. 
Altered HDAC expression, specifically increased HDAC1 and HDAC5 along with 
elevation of anti-apoptotic marker Bcl-2, were found in lungs from patients with 
idiopathic pulmonary arterial hypertension and chronically hypoxic rats. In in vivo studies, 
VPA and SAHA ameliorated the established PH in both hypoxia- and monocrotaline- 
induced PH rat models, by reducing pulmonary arterial pressure, right ventricular 
hypertrophy and pulmonary vascular muscularization, in parallel with increasing histone 
acetylation. In in vitro studies, VPA and SAHA inhibited stimulated cell growth of 
pulmonary artery smooth muscle cells and cytokine release from endothelial cells. 
Biochemical analysis indicated these two inhibitors exert anti-proliferative effects 
comprising cell cycle arrest by upregulation of p21 and apoptotic induction by 
downregulation of Bcl-2. 
Collectively, this study shows the contribution of abnormal HDAC activity to vascular 
pathology of PH and provides a preclinical basis to further explore the therapeutic 
potential of HDAC inhibitors in human PH. 
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1. Pulmonary Arterial Hypertension 
1.1. Definition and Classification 
Pulmonary hypertension (PH), an abnormal sustained elevation in pulmonary arterial 
pressure (PAP), is a progressive, intractable and lethal vascular disease. First described 
over 100 years ago in a patient with right heart failure 1, PH is recognized to arise from 
diverse causes, which in common lead to dysfunction in the pulmonary circulation. It may 
occur in isolation without demonstrable aetiology, when it is known as idiopathic 
pulmonary arterial hypertension (IPAH) or formerly primary pulmonary hypertension 
(PPH), or result from existent medical conditions including left heart failure, pulmonary 
parenchymal or vascular diseases, coagulation disorders, or a combination of different 
factors. On the basis of clinical and pathological criteria, PH is classified into five groups 
(Table 1.1) 2. 
According to the classification, pulmonary arterial hypertension (PAH), group 1 of PH, 
includes IPAH, heritable PAH, drug- and toxin-induced PAH, PAH associated with other 
diseases (connective tissue diseases, HIV infection, portal hypertension, congenital heart 
diseases, schistosomiasis and chronic haemolytic anemia), persistent pulmonary 
hypertension of the newborn and pulmonary veno-occlusive disease (PVOD) and/or 
pulmonary capillary hemangiomatosis (PCH). 
The pathogenesis of PAH is complicated but typically characterized by vasoconstriction, 
vascular remodelling and thrombosis in situ and increasingly inflammation. As the 
consequence of progressively increased pulmonary vascular resistance (PVR) to blood 
flow, right ventricle (RV) is compelled to compensate the excessive workload by raising 
right ventricular systolic pressure (RVSP) to preserve cardiac output until eventual failure, 
which accounts for the major cause of death in patients with PAH 3. 
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Clinical Classification of Pulmonary hypertension (Dana Point, 2008) 
 
1. Pulmonary arterial hypertension (PAH) 
1.1 Idiopathic PAH 
1.2 Heritable 
 BMPR2 
 ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia) 
 Unknown 
1.3 Drug- and toxin-induced 
1.4 Associated with 
 Connective tissue diseases 
 HIV infection 
 Portal hypertension 
 Congenital heart diseases 
 Schistosomiasis 
 Chronic hemolytic anemia 
1.5 Persistent pulmonary hypertension of the newborn 
1.6 Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH) 
 
2. Pulmonary hypertension owing to left heart disease 
2.1 Systolic dysfunction 
2.2 Diastolic dysfunction 
2.3 Valvular disease 
 
3. Pulmonary hypertension owing to lung diseases and/or hypoxia 
3.1 Chronic obstructive pulmonary disease  
3.2 Interstitial lung disease 
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4 Sleep-disordered breathing 
3.5 Alveolar hypoventilation disorders 
3.6 Chronic exposure to high altitude 
3.7 Developmental abnormalities 
 
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
5.1 Hematologic disorders: myeloproliferative disorders, splenectomy 
5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis:  
lymphangioleiomyomatosis,  neurofibromatosis, vasculitis 
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders 
5.4 Others: tumoural obstruction, fibrosing mediastinitis, chronic renal failure on dialysis 
ALK1 = activin receptor-like kinase type 1;  BMPR2 = bone morphogenetic protein receptor type 2;  
HIV = human immunodeficiency virus. 
 
Table 1.1. Updated clinical classification of pulmonary hypertension2. 
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The most common clinical manifestation of PAH is exertional dyspnoea, which is due to 
insufficient exercise tolerance and can be evaluated functionally through a six-minute 
walk test. The golden standard for diagnosis, however, is made by invasive 
haemodynamic assessment at right cardiac catherterization 4. The clinical definition of 
PAH, by international agreement, is a mean PAP of more than 25 mmHg at rest or more 
than 30 mmHg during exertion 5. 
Currently, PH in all its forms is estimated to affect up to 100 million people with an 
incidence of 1 in 500000, which is rare in comparison with systemic hypertension 2; the 
general outcome is very poor. It was reported that the medical survival of IPAH patients 
was less than three years in the 1980s 6. In recent years, spectacular advances have been 
made in treatment options of PAH, which have improved the prognosis to a certain degree. 
A recent report revealed 10-year and 3-year survival rates of 83% and 58% respectively 7. 
Unfortunately, the mortality rate of PAH remains high. Once failing to respond to the 
current pharmaceutical therapies, patients have no choice but cardiopulmonary 
transplantation. Better understanding of the pathogenesis and new treatment options are 
eagerly required.  
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1.2. Pathogenesis of PAH 
The pathogenesis of PAH is complex and involves vasoconstriction, vascular remodelling 
and thrombosis in situ, which suggest imbalances between vasodilators and 
vasoconstrictors, proliferative and apoptotic factors, coagulants and anticoagulants, 
involving all the vascular elements accompanied with circulating factors 8. Increasingly 
inflammation is believed to play an important role. Elucidation of these underlying 
molecular mechanisms has provided current therapeutic targets and insights into 
innovation in the future (Figure 1.1).  
 
 
Figure 1.1. Schematic summary of pathogenesis of PAH, mainly featured as vasoconstriction, vascular 
remodelling and thrombosis 9. 
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1.2.1. Pulmonary vasoconstriction 
Pulmonary vasoconstriction originates from abnormal regulation of vessel tone which is 
thought to be a result of endothelial dysfunction. Serving as the main source of various 
vasodilators, such as prostacyclin and nitric oxide, and vasoconstrictors, especially 
endothelin, the endothelium plays an essential role in maintaining pulmonary vascular 
homeostasis. Several related vasoactive mediators have been well studied in PAH and 
parts of them have been developed to be the targets of medical treatment currently in use 
10
. 
 Prostacyclin is synthesized in endothelial cells from prostaglandin H2 (PGH2) by 
prostacyclin synthase. It induces vasodilation and inhibits platelet aggregation via 
cyclic adenosine monophospate (cAMP)-dependent pathway 11 in contrast with 
thromboxane A2 (TXA2), generated in active platelets, causing vasoconstriction and 
activating new platelets for aggregation 12. In patients with PAH, prostacyclin 
synthase expression is decreased in pulmonary arteries of lungs 13 and urinary 
metabolites of prostacyclin are reduced while urinary metabolites of TXA2 are 
increased 14. Furthermore, clinical studies show that intravenous infusion of 
prostacyclin (epoprostenol) significantly prolong survival in patients with PAH and 
also improve quality of life, exercise capacity and haemodynamics 15. On the other 
hand, inhibition of TXA2 seems to be less convincing as a therapeutic choice in 
human 16. 
 Nitrix oxide (NO) is a potent vasodilator, synthesized  by nitric oxide synthase (NOS) 
in three isoforms, endothelial (eNOS), neuronal (nNOS) and inducible (iNOS), as 
well as an inflammatory mediator produced from phacocytes in response to 
inflammation. NO secreted from endothelial cells of vessels serves as signal 
transmitter to surrounding smooth muscle cells. Diffusing freely across membrane, 
NO activate soluble guanylate cyclase (sGC) in smooth muscle cells, converting 
guanosine triphosphate (GTP) to its active form cyclic guanosine monophosphate 
(cGMP), which is downregulated by phosphodiesterase type 5 (PDE5). 
Accumulation of cGMP leads to vasorelaxation and also inhibits cell growth, platelet 
aggregation and leukocyte adhesion to endothelium 17. 
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NO from eNOS is the principle mediator by which endothelium controls vessel tone 
in pulmonary vasculature. Multiple impairments have been proved in eNOS-NO-
cGMP pathway in PAH, including decreased eNOS expression 18 and low NO 
bioactivity19. In animal models, deficency in eNOS increases susceptibilty to 
hypoxia-induced pulmonary hypertension while gene transfer of eNOS provides 
resistance 20. Endothelial availability of tetrahydrobiopterin (BH4), a cofactor in 
eNOS synthesis, has been shown to regulate the pathophysiological response to 
hypoxia in the pulmonary circualtion 21. Restoring eNOS-NO-cGMP signaling has 
been shown to an effective strategy underpinning currently available medical 
treatment in PAH, including oral PDE5 inhibitors and inhaled NO 22, 23.  
 Endothelin-1 (ET-1), a potent endothelium-derived vasoconstrictor and mitogen 24, 
regulate vessel tone via two receptors, ETA and ETB. Binding to both receptors on 
pulmonary arterial smooth muscle cells leads to increased intracellular calcium and 
subsequent vasoconstriction, whereas binding to ETB on endothelial cells induces 
nitric oxide and prostacyclin release 25. Circulating levels of ET-1 along with local 
production in pulmonary vasculature are significantly increased in patients with PAH 
26, 27
. Strong correlations between expression levels of ET-1 and severity of disease as 
well as prevalence of ETA and pulmonary resistance arteries indicate ETA –dominant 
regulation in PAH and provide the foundation for treatment with endothelin receptor 
antagonists 28.  
 Natriuretic peptides, atrial natriuretic peptide (ANP) and brain natriuretic peptide 
(BNP), are cardiac hormones secreted in response to excess myocardial stretch and 
causing diuretic and vasorelaxant effects. Binding to their receptors, NPR-A and 
NPR-B, which are membrane-bound guanylate cyclases, converts intacellular GTP to 
cGMP 29. Circulating levels of BNP correlates to the extent of RV dysfunction and 
prognosis, and are elevated in patients with PAH 30.Genetic disruption of NPR-A 
augments PAH development while continuous infusion of ANP attenuate PAH 
phenotype in animal models 31, 32. Although rapid degradation of natriuretic peptides 
may challenge long-term administration for treatment, alternatively, inhibition of 
neutral endopeptidase, responsible for metabolism of natriuretic peptides can be 
potential as a novel approach in PAH 33. 
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 Rho-kinase system regulates numerous cellular processes related to vasoconstriction 
and vascular remodelling in PAH including cell motility, cell survival, and cytokine 
release 34. Controlling the myosin light chain dynamics in smooth muscle cells, Rho 
kinase contributes critically to refractory vasoconstriction and interacts with other 
vasoactive mediators, such as ET-1, TXA2 and serotonin 35. The Rho kinase inhibitor, 
fasudil, ameliorates vasoconstriction in experimental PAH models 36 and causes 
acute vasodilator effects in patients with PAH 37. However, inevitably systemic 
vasodilation accompanies this effect and reduces enthusiasm for the approach. 
 Serotonin (5-hydroxytryptamine, 5-HT), a monoamine neurotransmitter believed 
to be important in emotion control, was first implicated in PAH associated with 
chronic use of the appetite suppressant dexfenfluramine, which is serotoninergic, and 
increases the risk of PAH 38. Synthesized in endothelial cells of pulmonary arteries, 
5-HT stimulates pulmonary arterial smooth muscle cells and fibroblasts, leading to 
vasoconstriction and remodelling 39.  5-HT transport, 5-HTT, is overexpressed in 
pulmonary arterial smooth muscle cells from patients with IPAH while treatment 
with 5-HT favours the development of hypoxic PAH in rats 40. Administration with 
selective serotonin reuptake inhibitors (SSRIs) can protect against hypoxia-induced 
pulmonary hypertension in mice 41and tends to be associated with a reduction in the 
risk of death in a cohort study of PAH patients 42. 
 Vasoactive intestinal peptide (VIP), a 28 amino-acid peptide belonging to the 
glucagon-growth hormone–releasing factor secretion superfamily, acts to increase 
cardiac contractility, vasodilation, glycogenolysis, scavenge reactive oxygen species 
(ROS), inhibit platelet activity and relax smooth muscle. Mice lacking VIP develop 
moderate PH 43. The VIP receptor is highly expressed in human lungs and 
upregulated. Circulating VIP levels are reduced in patients with PAH 44. VIP 
substitution selectively benefits pulmonary haemodynamics and improves cardiac 
function with minimal systemic effects both in animal models and patients 45, 46. 
Similar to natriuretic peptide, the medical application of VIP is restricted by its short 
half-life. Modern dosing strategies for controlled release are under investigation for 
using VIP in PAH. 
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 Adrenomedullin (AM) is a ubiquitously expressed vasodilator with a variety of 
biological functions such as reduction of oxidative stress and endothelial cell 
apoptosis, via many signalling pathways including NO-cGMP and PI3K 
(phosphatidylinositol-3-kinase)/Akt 47. It is elevated in hypoxic animals and patients 
with PAH and administration of AM demonstrates protective effects 48, 49. Inhalation 
of AM attenuates PAH phenotypes in monocrotaline (MCT) induced PAH in rats 
50and humans, suggesting the therapeutic potential 51. However, the effects of AM on 
systemic circulation are still undetermined.  
 Voltage-dependent potassium (Kv) channel, a membrane-spanning protein forming 
potassium-selective pores, regulates vessel tone by maintaining resting membrane 
potential and gating voltage-gated calcium channels. Downregulation of Kv channels 
promotes intracellular calcium in smooth muscle cells, resulting in constriction. 
Additionally, Kv channels also control survival signals and dysfunction leads to cell 
proliferation and resistance to apoptosis, which contributes to vascular remodelling. 
Inhibition of Kv channel activity by stimuli such as hypoxia 52or anorexigens 
53initiates pulmonary vasoconstriction and PAH development. Expression and 
activity of Kv channels, particularly Kv1.5, are decreased in human and experimental 
PAH 54, 55. Restoration of Kv1.5 activity has been considered as a therapeutic strategy 
in experimental PAH models. Moreover, Kv channel downregulation is also found in 
other proliferative disorders, especially cancer, suggesting some shared properties 
between cancer and PAH 56.  
 
1.2.2. Pulmonary vascular remodelling 
Pulmonary histology provides strong evidence that vascular structural remodelling is 
extensively presented in almost all types of PAH, evident as intimal growth, medial 
thickening and deposition of extracellular matrix. This process involves all the vascular 
cells, including endothelial cells, smooth muscle cells, fibroblasts, platelets, inflammatory 
cells, progenitor cells as well as extracellular matrix (ECM) components such as collagen, 
elastin and fibronectin 8.  
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Injury to endothelial cells is believed to select apoptosis-resistant cells to proliferate, 
forming the complex plexiform lesions, which are characteristically found in PAH patients 
at the late stage 57. The resultant exposure of smooth muscle cells to stimuli promotes 
proliferation and extends smooth muscle into distal peripheral arteries, which are normally 
nonmuscular 58. Accumulation of extracellular matrix, attributed to imbalance between 
matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs), 
takes part in neointimal formation and smooth muscle cell growth, further thickening 
vascular wall 59. Moreover, adventitia also participates in the remodelling process, that 
differentiating myofibroblasts from pericytes and intermediate cells in precapillary vessels 
marscularize small vessels. Adventitial fibrblasts are activated in response to injurious 
stimuli and undergo proliferation, differentiation, migration, secretion of paracrine factors, 
and collagen production, which profoundly increase adventitial thickness and jeopardize 
arterial capacitance 60.  
The consequent occlusion of the vessel lumen along with the loss of vessel numbers 
results in obliterative pulmonary circulation. Vascular remodelling indicates an imbalance 
between proliferation and apoptosis, manifesting excessive and uncontrollable cell growth, 
which is analogous to cancer phenotypically 61.  
Increasing attention has been concentrated on genetic and molecular mechanisms 
underlying the process of pulmonary vascular remodelling. A previous study showed a 
decrease in the pro-apoptotic/anti-apoptotic gene expression ratio in lungs from patients 
with PAH 62. Several mediators have been implicated in the process of remodelling. 
 Platelet-derived growth factor (PDGF), a potent mitogen for cells of mesenchymal 
origin, acting via its receptor tyrosine kinase, has been implicated in recruitment of 
smooth muscle cells and endothelial dysfunction 63. PDGF signalling is upregulated 
selectively in pulmonary vasculature in IPAH patients, and PDGF ligands and 
receptors are overexpressed in lungs patients with severe PAH 64, which is also 
observed in sheep with chronic intrauterine pulmonary hypertension 65. The PDGF 
receptor antagonist, imatinib, has been shown to reverse the PH phenotype by 
attenuating vessel remodelling, in both hypoxic and MCT models 66. Initial clinical 
studies are in favour of its potential as a novel therapy. Further investigation are 
ongoing 67.  
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 Vascular endothelial growth factor (VEGF), the principle mediator in 
vascularization and angiogenesis, dominates endothelial cell survival 68. Binding to 
its receptor type 2 (VEGFR-2) results in the downstream signalling including 
increased prostacyclin and NO synthesis through akt- and src-mediated pathways 69. 
The role of VEGF in PAH is still controversial and complex. VEGF and VEGFR-2 
are reported highly expressed in the plexiform lesions in patients with PAH 70. VEGF 
is upregulated in chronically hypoxic rats but downregulated in MCT-induced PH 
rats 43, 71. Blockade of VEGFR-2 with the antagonist SU-5416 combined with chronic 
hypoxia generates severe pulmonary hypertension associated with remarkable 
proliferative vasculopathy 72. Overexpression of VEGF by gene transfer inhibits the 
development of experimental PH in animals 73, 74, but, conversely, treatment with 
VEGF in rats with established pulmonary hypertension worsens the disease 75while 
VEGFR-2 blocker, sorafenib, attenuates experimental pulmonary hypertension in rats 
76, 77
. Although the uncertainty of VEGF in PAH prevents its therapeutic application, 
better understanding of the role of VEGF is needed to help to unravel the 
pathogenesis. 
 Matrix metalloproteinases (MMPs) are a family of proteolytic endopeptidases 
capable of degrading ECM, as well as various biological functions, such as cell 
proliferation, migration, differentiation, angiogenesis, apoptosis and cytokine 
activation. MMPs are categorized into several groups such as collagenases and 
gelatinases based on substrate specificity. Secreted as proenzymes, MMPs require 
extracellular activation and are regulated by TIMPs 78. An imbalance between MMPs 
and TIMPs, containing excessive TIMP-1 and MMP-2 but decreased MMP-3, leads 
to ECM deposition in patients with IPAH 79. Intervention in MMP activity exerts 
beneficial effects in MCT-induced PH rats 80. The wide range of MMP functions in 
tissue homeostasis promises their therapeutic potential and investigation in more 
detail is deserved. 
 Survivin is a member of the “inhibitor of apoptosis” family, selectively expressed in 
cells undergoing oncogenic transformation. Thought to be exclusive in cancer 
previously, survivin was found to be expressed in pulmonary arteries from patients 
with PAH and MCT-induced PH rats 81. Gene therapy targeting survivin reverses 
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established PH and improves survival in the MCT rat model and inhibition of 
endogenous survivin induces vascular mitochondria-dependent apoptosis and 
prevents vascular remodelling. In contrast, gene transfer of wild type survivin results 
in the opposite effects 81. The clinical value of using a survivin inhibitor is under 
evaluation in oncology currently and could be explored in PAH 82. 
 Nuclear factor activated T cells (NFAT), a transcription factor that regulates T cell 
activation, is expressed in most immune cells and also involved in cardiac 
development and hypertrophy. NFAT promotes proliferation of pulmonary arterial 
smooth muscle cells and reduces expression of Kv1.5. The activation of NFAT is 
shown in human and experimental PH, and seems to contribute to the 
hyperpolarization of mitochondria in smooth muscle cells. Inhibition of NFAT 
alleviates the PAH phenotype by upregulating Kv1.5 and downregulating Bcl-2 (B 
cell lymphoma 2), the anti-apoptotic protein, in both hypoxia- and MCT-induced PH 
models. Knockout of NFATc3 in mice protects against pulmonary vascular 
remodelling in response to chronic hypoxia 83. 
 Osteoprotegerin (OPG) is a cytokine receptor and member of the tumour necrosis 
factor receptor superfamily 84. OPG regulates osteoclast differentiation and induces 
apoptosis via binding to receptor activator of nuclear factor kappa-light-chain-
enhancer of activated B cells (NFκB) ligand (RANKL) or tumour necrosis factor-
related apoptosis-inducing ligand (TRAIL), and plays an essential role in 
inflammation 85. Overexpression of OPG in pulmonary vascular smooth muscle cells 
resulting from inflammatory stimuli evokes cell proliferation and migration. In 
patients with IPAH, increased OPG expression is evident in pulmonary lesions and 
circulating levels are elevated 86. 
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1.2.3. Inflammation 
Accumulating evidence highlights the role of inflammation in the pathogenesis of PAH, 
involving monocytes/macrophages, lymphocytes (B and T cells), dendritic cells (DCs) and 
mast cells, and a variety of cytokines and chemokines. The contributions of inflammation 
to PAH are: 
 Perivascular accumulation of inflammatory cells has been well-documented in 
both animals and humans with pulmonary hypertension. Histological examination 
shows mononuclear cells (MNCs), mostly T cells and macrophages, infiltrating 
around remodelled vessels, particularly plexiform lesions. Inflammatory cell 
infiltration is also observed in nearly all the animal models commonly in use, such as 
MCT-, chronic hypoxia-, SU5416-, and schistosomiasis-induced PH rats and mice 
deficient in bone morphogenetic protein (BMP) receptor type 2 (BMPR2). Moreover, 
serum level of DCs is increased in patients with IPAH 58, 87. 
 Circulating levels of certain cytokines/chemokines are elevated in patients with 
IPAH and some of them predict the clinical outcome 88. These include interleukin 
(IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, tumour necrosis factor (TNF)-α, 
transforming growth factor (TGF)-β, RANTES (Regulated upon Activation, 
Normally T cell Expressed and Secreted)/CCL5, fractalkine/CX3CL1, interferon γ 
(INF-γ)-induced protein 10 (IP-10/CXCL10) and monocyte chemoattractant protein 1 
(MCP-1/CCL2) 88-92. The role of cytokines in the pathogenesis of PAH is further 
supported by increased IL-1β and IL-6 in the MCT model. Overexpression of IL-6 or 
injection with IL-6 to rats induces PH 93, 94, while IL-6 deficiency protects mice from 
developing PH in response to hypoxia 95. In addition, IL-6 can modulate BMPR2, an 
identified genetic factor in human PAH, epigenetically through certain microRNA 
clusters 96. On the other hand, excessive chemokines, such as RANTES, MCP-1 and 
fractalkine, are found in pulmonary endothelium or surrounding lymphocytes, which 
may contribute to recruitment and adherence of other inflammatory cells to 
endothelium 89, 90, 97The cytokines/chemokines profiles implicated in pulmonary 
vascular inflammation are summarized in Table 1.2 
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Cytokine       
Chemokine Source Target Function 
IL-1β Macrophages, lymphocytes, EC, PASMC Many cell types 
Pro-inflammatory, EC and 
PASMC activation 
IL-4 
Th2 cells, mast cells 
 
B cells, T cells, mast cells, 
macrophages, hemotopoietic 
progenitors 
Proliferation and 
differentiation of B cells and 
Th2 cells 
IL-6 Macrophages, T cells, EC, PASMC B cells, T cells, EC, PASMC 
Differentiation of myeloid 
cells, PASMC activation 
IL-8 Monocytes, T cells, EC Neutrophils, T cells, 
monocytes 
Pro-inflammatory, leukocyte 
arrest 
IL-10 Macrophages, B cells, Th2 
cells, Treg cells, mast cells 
Macrophages, B cells,              
T cells 
Anti-inflammatory, 
differentiation of B cells 
IL-12 Th1 cells T cells, macrophages Pro-inflammatory, cytotoxic 
activity 
IL-13 Many cells, especially Th2 
cells Similar to IL-4 
Allergic and parasitic 
reactions 
TNF-α Macrophages, B cells,          T cells, NK cells, PASMC Many cell types 
Pro-inflammatory, tumour 
necrosis, anticoagulant 
TGF-β 
Platelet, macrophages,        
B cells, Th2 cells, Treg 
cells, PASMC 
Many cell types 
Anti-inflammatory, 
profibrotic, angiogenesis 
Suppress Th1/Th2 responses 
MCP-1 
CCL2 
Many cells including EC, 
PAMSC 
Monocytes, memory T cells, 
DC, basophils 
Monocyte migration to 
become macrophage 
RANTES 
CCL5 
T cells, EC 
 
monocytes, eosinophils, 
basophils, T cells (any cells 
expressing CCR5 receptor) 
Chemoattractant for 
monocytes and T cells,   
may induce ET-1 
IP-10 
CXCL10 
Monocytes, EC, fibroblasts 
in response to INF-γ 
Monocytes, macrophages,   
T cells, NK cells, DC 
Chemoattractant, promote T 
cell adhesion to EC 
Fractalkine 
CX3CL1 
Macrophages, T cells, EC, 
PASMC 
CD4+ and CD8+ T cells, 
monocytes, activated EC 
Chemoattractant,    
leukocyte adhesion to EC, 
growth factor of PASMC 
Abbreviations: CCL, chemokine (C-C motif) ligand; CCR, chemokine (C-C motif) receptor; CD, cluster 
differentiation; CX3CL1, chemokine (C-X3-C motif) ligand 1; CXCL, chemokine (C-X-C motif) ligand; 
CXCR, chemokine (C-X-C motif) receptor; DC, dendritic cell; EC, endothelial cell; ET-1, endothelin-1; 
IFN-γ, interferon-gamma; MCP-1, monocyte chemotactic protein 1; NK,  natural killer; PASMC, pulmonary 
artery smooth muscle cell; RANTES, regulated by T cells, activation upon secretion; TGF-β, transforming 
growth factor beta; Th, T helper; TNF-α, tumour necrosis factor alpha ; Treg, T regulatory . 
Table 1.2. Cytokines/chemokines implicated in pulmonary vascular inflammation 87. 
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 Infection/inflammation/immune disorders can predispose to the development of 
PH. Infectious pathogens can raise inflammation and luminal obliteration in 
pulmonary vessels. Latent viral infections with human immunodeficiency virus 
(HIV), human herpes virus-8 (HHV-8), Epstein–Barr virus (EBV) and 
cytomegalovirus (CMV), have been linked to PAH. Parasitical infection with 
schistosmiasis, affecting over 200 million people, is highly associated with PAH 98. 
Furthermore, immune disorders, specifically autoimmune disease, covering 
scleroderma (SSc), systemic lupus erythematosus (SLE), Hashimoto disease and 
other connective tissue diseases are, with different frequencies, complicated by PAH, 
suggesting a role of immunopathology in PAH 99-102. 
 Anti-inflammatory therapies seem to benefit experimental PH. Recent studies 
indicate that treatment with steroids has positive effects on MCT-induced PH rats and 
improves survival 103. Immunosuppressants via other molecules like IL-1, MCP-1 
and NFAT also prevent PH development 83, 104, 105. Case studies report that PAH 
patients with mixed connective tissue disease or SLE respond to treatment with 
cyclophosphamide and glucocorticoids 106. Noticeably, prostacyclin, which is one of 
current therapies in PAH, influences monocyte function and downregulates INF-γ-
stimulated cytokines 107. Another example of immunotherapy in PAH is the 
promising effects of imatinib, which causes immunosuppresion through PDGF 
inhibition 66, 67. Although both the experimental and clinical findings make it logical 
to apply anti-inflammatory therapies, a formal trial with randomized controls in 
humans is still required. 
The connection between inflammation and vascular remodelling can be attributed to a 
possible injurious hit to the vascular wall, followed by interactions among endothelial 
cells, smooth muscle cells, inflammatory cells and circulating cytokines/chemokines 
(Figure 1.2). The nature of the initiator has been unclear though; the impact of 
inflammation has to be taken into consideration in designing novel treatments. 
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Abbreviations: IL, interleukin; TNF-α, tumour necrosis factor alpha; MCP-1, monocyte chemotactic protein 
1; RANTES, regulated on activation, normal T cell expressed and secreted; IP-10, interferon γ-induced 
protein 10; PDGF, platelet derived growth factor; EGF, epidermal growth factor. 
Figure 1.2. The role of inflammation in the pathogenesis of PAH. Initial inflammatory stimuli can occur in 
the form of infection, autoimmune disease or other injurious hits, causing inflammatory cell activation, 
cytokine/chemokine release, and endothelial cell dysfunction. The resultant events form the characteristic 
complex of PAH, vascular remodelling and thrombus formation.  
1.2.4. Thrombosis 
Hypercoagulability is one of the major pathogenic features of PAH. Endothelial 
dysfunction is responsible for vascular thrombosis by secreting various coagulation factors 
such as thrombomodulin, tissue type plasminogen factor and von Willebrand factor (vWF) 
108
. The coagulation initiator, tissue factor, is highly expressed in the pulmonary 
vasculature in humans and animals with PH 109while circulating factors like fibrinopeptide, 
plasminogen activator inhibitor 1 and vWF are increased in patients with IPAH 110. 
Hypercoagulable phenotype is also exhibited in patients with IPAH by calibrated 
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automated thrombography 111.  Platelet aggregation is enhanced in PAH which can be 
attributed to the interaction with endothelial cells and involvement of associated 
vasoactive mediators: prostacyclin, TXA2 and NO 14.  
1.2.5. Genetics 
Heterozygous mutations in BMPR2, a serine/threonine kinase receptor belonging to the 
TGF-β receptor superfamily, have been found in approximately 80% of cases of familial 
PAH, which accounts for around 10% of patients of IPAH, and 10-40% of sporadic IPAH 
cases 112. Bound to its ligands BMPs, BMPR2 initiates intracellular smad-signalling gene 
transcriptions, mainly targeting DNA-binding gene inhibitors (IDs) 113. The loss of 
BMPR2-smad signalling induces cell proliferation and resistance to apoptosis in 
pulmonary arterial endothelium. BMPR2 is found to be expressed in the plexiform lesions 
in humans and growth responses to TGF-β and BMPs of pulmonary arterial smooth 
muscle cells from patients with IPAH are altered 114. Mice deficient in BMPR2 are 
predisposed to the development of PAH while mutants with overexpression of BMPR2 are 
resistant to vascular remodelling 115. 
The low prevalence of BMPR2 mutations (10-20%) in nonfamilial PAH and even 
penetrance in familial PAH (25%) suggest that a “second hit” is required, which has been 
undetermined yet. Attempts at treatment by restoring BMPR2 function in experimental PH 
have been variably successful. Gene therapy with BMPR2 attenuates chronically hypoxic 
PH but fails to rescue MCT-induced PH 116. Nevertheless, a recent study shows that 
inhibition of TGF-β signalling via activin-like kinase type 5 (ALK5) prevents 
development and progression of MCT-induced PH, which may be a consequence of 
inhibiting pulmonary arterial smooth muscle cell migration 117. 
Other genetic mutations, such as ALK1, a member of the TGF-β receptor family, are 
reported in PAH 118. Additionally, a polymorphic variant of the 5-HTT gene promoter has 
a high prevalence (65%) in IPAH compared with 27% in the control group 40; 
notwithstanding, adequately powered cohorts are needed to verify this. 
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1.2.6. Right ventricular hypertrophy 
RV function is a crucial determinant of survival in PAH. RV hypertrophy, as a result from 
compensatory response to increased pulmonary resistance, highly correlates to the 
morbidity and mortality of PAH 119. Responding to the excessive workload, RV augments 
the cardiac mass through increasing protein synthesis and thus thickens the ventricular 
wall until decompensation, dilatation and failure. Along with enlargement in myocyte size, 
fibrosis can occur and further worsen myocardial performance. Preserving RV function 
has become an important consideration in treatment strategies. A recent study indicated 
that inhibition of PDE5, highly expressed in hypertrophied RV, improves cardiac 
contractility and suggests the potential of RV targeted therapy 120.  
1.3. Treatment of PAH 
It is only in the past 25 years that efficacious treatment options have become available. 
Current medical therapies are composed of three categories, namely prostanoids, 
endothelin receptor antagonists (ERA) and phosphodiesterase type 5 inhibitors (PDE5-I) 
121(Figure 1.3). Unfortunately, despite delaying the progression, no definite cure exists 
still. Failure to respond to these therapies is unfortunately very common and the final 
therapeutic option, cardiopulmonary transplantation, is costly and limited by donor 
availability. Novel treatments are desperately in need. 
1.3.1. Current available therapies 
 Conventional therapies comprise oxygen supplementation, diuretic and inotropic 
agents. Since right heart failure usually signals the dying process in late-stage PAH, 
diuretics, reducing preload, and inotropic agents such as digoxin, enhancing cardiac 
contractility, are used to preserve RV function. These treatments offer symptomatic 
relief but evidence of long-term benefit is lacking. Oral anticoagulants are 
recommended empirically as an adjuvant therapy in most patients without 
contradictions 122.  
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Figure 1.3. Targets of current therapies in PAH. The core of current therapy is composed of intervention in 
three major pathways, which are prostacyclin, phosphodiesterase type 5 and endothelin pathway, targeting 
the abnormal vasoconstriction and proliferation in PAH 3. 
 
 Calcium channel blockers (CCB), one of the standard treatments in systemic 
hypertension, act to relax muscle contraction in heart and vessels, resulting in 
decreased cardiac contractility and vasodilation. Long-term treatment with CCBs 
may prolong survival in a certain group of PAH patients (less than 10% of all 
patients). Acute vasodilator challenge during right heart catheterization with inhaled 
NO, adenosine or intravenous prostacylin, identifies patients who likely benefit from 
chronic CCB treatment 123. 
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 Prostanoids, a group of stable prostacyclin analogues, have proven a very important 
therapeutic option for PAH. By raising prostacyclin production, prostanoids exert 
potent vasodilation and simultaneously anti-thrombotic, anti-proliferative, anti-
mitogenic, and immunomodulatory functions. Continuous intravenous infusion of 
epoprostenol was first used as a bridge to transplantation in PAH and found to 
prolong survival. New generation of compounds promise higher stability, perhaps 
less cost and alternative choices of administration, including subcutaneous 
(treprostinil), oral (beaprost) or by inhalation (iloprost) 121.  
 Phosphodiesterase type 5 inhibitors (PDE5-I), including sildenafil and tadalafil, 
result in vasodilation in pulmonary circulation by inhibiting cGMP metabolism. 
Randomized controlled studies show that treatment with PDE5-I has positive and 
durable effects on patients with PAH haemodynamically and functionally and is well 
tolerated 124. 
 Endothelin receptor antagonists (ERA) inhibit vasoconstriction and proliferation 
through blockade of ETA and ETB on smooth muscle cells whereas lessen NO and 
prostacyclin production through inhibition of ETB on endothelial cells. Due to the 
predominance of ETA in pulmonary vasculature, the overall effects of ERA are 
against vasoconstriction and vascular remodelling. The non-selective ERA, Bosentan, 
was first approved for clinical use, which improves haemodynamics, exercise 
capacity, and functional class 125. Selective blockers against ETA (ambrisentan, 
sitaxsentan) have been developed but whether they confer additional advantages have 
been not yet been demonstrated 126.  
Combination therapy using two or more agents from prostanoids, PDE5-I and ERA is 
now common in patients with poor response to monotherapy. Since these three classes act 
on different pathways, synergic effects are expected. However, statistical significance that 
combination therapy offer long-term benefits over monotherapy and the optimal 
combination remain unclear. With this concern, few studies are undergoing to establish 
evidence-based treatment strategies. For example, a randomized controlled study, 
AMBITION, compares first-line combination therapy (ambrisentan and tadalafil) versus 
first-line monotherapy (ambrisentan or tadalafil) in patients with PAH 121. Figure 1.4 
shows an algorithm of treatment strategies currently adapted in clinical use (Figure 1.4). 
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Abbreviations: ERA, endothelin receptor antagonists; FC, functional class; INH, inhaled; IV, intravenous; 
PDE5-I, phosphodiesterase type 5 inhibitors; SC, subcutaneous. 
Figure 1.4. Treatment algorithm for pulmonary arterial hypertension. *Licensed indications for individual 
agents with respect to functional class vary between countries. 121. 
 
1.3.2. Emerging therapeutic options 
Since the prognosis remains poor despite treatment, new therapeutic options are needed. 
Several candidates aiming at vasorelaxant mechanisms are under development, such as 
prostacyclin receptor agonists, sGC activators and VIP. One of the biggest challenges is to 
achieve pulmonary selectivity, avoiding systemic effects.  
Recently, attention has been drawn to the fact that the three major treatment options 
predominantly intervene in the desregulation of vessel tone while influences on vascular 
remodelling are relatively indirect and secondary. In order to achieve maximal efficacy, 
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new approaches must target the pro-proliferative mechanisms that contribute to the 
remodelling. Several anti-proliferative drug types, mostly originally designed for cancer 
therapy, have been investigated for translational possibilities as PAH treatments 127.  
Tyrosine kinase inhibitor, Imatinib (STI571 or Gleevec), which antagonizes the PDGF 
receptor, is currently licensed for the treatment of chronic myelogenous leukemia (CML) 
and malignant gastrointestinal stromal tumours (GIST). Upregulated PDGF signaling is 
seen in the lungs of patients with PAH and takes part in pro-proliferative abnormalities in 
PAH. Treatments that target PDGF signalling are expected to be beneficial. Imatinib 
treatment improves pulmonary haemodynamic and RV function with reversal of 
pulmonary vascular remodelling in experimental PH models 66. Case studies report 
positive clinical responses to imatinib in patients with refractory IPAH 123. A pilot study 
revealed that imatinib treatment in patients failing to respond to standard treatment 
improves haemodynamics but not exercise capacity 128. Sorafenib, another tyrosine kinase 
inhibitor with a wider spectrum of tyrosine kinase inhibition, has been shown favourable 
effects on pulmonary vascular remodelling and haemodynamics in animal models 77. In a 
phase Ib trial, oral sorafenib improves exercise capacity and RV function 129. However, 
cardiotoxicity, particularly left ventricular dysfunction, resulting from prolonged use of 
tyrosine kinase inhibitor may undermine its clinical adaptability 130.  
Metabolic alternation is another interesting focus of anti-proliferative therapy in PAH. In 
1924, Otto Warburg described a shift of glucose metabolism from oxidative 
phosphorylation to glycolysis that might be responsible for the resistance to apoptosis in 
cancer cells, and is now known as the Warburg effect 131. A paradoxically high glycolytic 
rate despite adequate oxygen supplement is widely found in cancer cells, resulting in 
extreme inefficiency in energy production and magnified glucose demand. Excessive 
metabolites from aerobic glycolysis increase mitochondrial membrane potential and 
intracellular potassium and thereby restrain mitochondria from releasing several pro-
apoptotic mediators. Also, reduced oxidative phosphorylation inhibits the production of 
superoxide, which further reduces apoptosis. Several glycolytic enzymes, such as Akt and 
glycogen synthase kinase 3 (GSK3), have been linked to the regulation of apoptosis and 
interaction with oncoproteins 132. Recent studies have indicated that aerobic glycolysis is 
not exclusive in tumour cells but in non-malignant proliferating cells, including 
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endothelial cells from IPAH patients. Increased glucose uptake, typically observable in 
cancer, is shown in patients with PAH by tracking with 18F-fluorodeoxyglucose positron 
emission tomography (18F-FDG-PET) 133. Accordingly, correction of the metabolic 
alternation is expected to restore the apoptotic susceptibility and eventually reverse 
vascular remodelling in PAH. 
Dichloroacetate (DCA), an orally available small molecule which has been used in 
treating lactic acidosis for decades, is under investigation as a treatment for cancer. DCA 
inhibits pyruvate dehydrogenase kinase (PDK) and subsequently activates pyruvate 
dehydrogenase (PDH), which functions as the gatekeeper for the entry of pyruvate into 
mitochondria. During glycolysis, inactivated PDH retains pyruvate in the cytoplasm where 
accumulative pyruvate is converted to lactate dehydrogenase (LDH). By inhibiting PDK, 
DCA boosts the conversion of pyruvate to acetyl-CoA, which enter the Krebs cycle to 
drive oxidative phosphorylation, and restore normal mitochondrial function 134. DCA was 
found to activate mitochondria-dependent apoptosis in cancer cells and reduce tumour size 
in vivo and in vitro without affecting non-transforming tissues 56. In animal PH models, 
DCA promotes apoptosis, reverses vascular remodelling, normalizes haemodynamics, 
attenuates RVH and improves survival 135, 136. Biochemically, in these studies, DCA 
treatment increases oxidative phosphorylation, depolarizes mitochondrial membrane 
potential, increases ROS production, activates Kv channel expression and function, 
induces apoptosis and inhibits vascular proliferation. Noticeably, DCA does not affect 
normal vascular cells, suggesting the specificity for treatment. Moreover, DCA was found 
beneficial to patients with left heart failure by increasing ventricular mechanical efficiency 
and probably confers additional advantages to PH treatment 137. 
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2. Histone Deacetylase (HDAC) 
2.1. Epigenetic modification 
Classic genetics alone cannot explain the diversity of phenotypes within a population. Nor 
does classic genetics explain how, despite their identical DNA sequences, monozygotic 
twins 138or cloned animals 139can have different phenotypes and different susceptibilities 
to a disease. The concept of epigenetics offers a partial explanation of these phenomena. 
First introduced by C.H. Waddington in 1939 to name "the causal interactions between 
genes and their products, which bring the phenotype into being” 140, epigenetics was later 
defined as heritable changes in gene expression that are not due to any alteration in the 
DNA sequence 141. As the genetic code is like a well-tuned piano, epigenetics plays the 
role of pianist who produces the tune.  Epigenetic mechanisms are essential for normal 
development and maintenance of tissue-specific gene expression patterns in mammals. 
Disruption of epigenetic processes can lead to altered gene function and malignant cellular 
transformation. Global changes in the epigenetic landscape are a hallmark of different 
diseases. The initiation and progression of disease, traditionally seen as a genetic disease, 
is now realized to involve epigenetic abnormalities along with genetic alterations.  
Epigenetic modulation is effected through several mechanisms, such as DNA methylation, 
nucleosome positioning, small RNA transcripts and histone modifications. These systems 
can act alone but more frequently in a multiple interacting complex.  
2.1.1. DNA methylation 
DNA methylation is a covalent modification formed by addition of a methyl group at the 
5’ carbon of cytosine in the sequence context CpG dinucleotides of the DNA molecule. 
DNA methylation is a common epigenetic modification existing in all types of cells. The 
methylation can silence DNA and hence downstream transcription. DNA methylation 
precludes detrimental expression such as viral genes or other adverse insertions into the 
genome as well as programs cells to be tissue specific during the development 142, 143. 
Packaging DNA into nucleosome affects DNA accessibility by transcription factors (TFs): 
while some TFs can bind nucleosome-packed DNA, the majority of TFs cannot bind 
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nucleosome-packed DNA. Knowledge of nucleosome positioning is essential for 
understanding mechanisms of the regulation of gene expression in eukaryotic cells.  
2.1.2. RNA transcripts 
RNA transcripts primarily refer to three categories of small RNAs (~20-30 nucleotides), 
short interfering RNAs (siRNAs), microRNAs (miRNAs) and piwi-interacting RNAs 
(piRNAs), manipulating endogenous gene expression at post-transcriptional levels in both 
somatic and germline lineages. These noncoding RNAs originate from cleavage of 
double-strand RNAs (dsRNAs) and in most cases, silence specific genes by a mechanism 
known as RNA interference whereby binding to the messenger RNAs (mRNAs) prevents 
translation and protein synthesis. miRNA have been recognized as mediators of 
endogenous genes while siRNA protectors of invasive events like viral infection or 
transposon insertion, respectively. The small RNA-induced silencing has been recognized 
to be involved in diverse biological processes and widely employed as a powerful research 
tool due to the predictability and controllability 144. 
2.1.3. Histone covalent modification 
Histone modification is the predominant post-translational modification in gene regulation. 
In eukaryotes, an octamer of histones H2A, H2B, H3 and H4 is wrapped by 147 bp of 
DNA to form a nucleosome – the fundamental unit of chromatin 145. As the core 
components of chromatins, histones act as spools around which DNA wind and wrap the 
whole genomes in the nuclei and maintain the chromosomal structure. Post-translational 
modifications of histones, specifically the states of amino-acid residues on histone tails, 
result in structural changes and consequent accessibilities of various transcriptional 
regulators that binds to specific DNA sequences to promote or repress certain 
physiological or pathological signallings. Therefore, histone modification governs 
widespread gene expression and generates effects on nearly all forms of biological events. 
Histones are subject to a wide variety of modifications including but not limited to, lysine 
acetylation, lysine and arginine methylation, serine and threonine phosphorylation, and 
lysine ubiquitination and sumoylation as well as adenosine diphosphate (ADP)-
ribosylation and carbonylation 146. These modifications occur primarily within the histone 
amino-terminal tails protruding from the surface of the nucleosome as well as on the 
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globular core region 147. The combination of histone modifications is believed to form a 
unique well-established “histone code”, recognized by other proteins to lead to the distinct 
downstream pattern. 
The histone-modifying enzymes affect histones either locally, through targeted 
recruitment by sequence-specific transcription factors 148, or globally throughout the 
genome in an untargeted manner affecting virtually all nucleosomes 149. The best 
characterized histone modifications are acetylation, and methylation.  In 'normal' cells, 
genomic regions that include the promoters of tumour-suppressor genes are enriched in 
histone-modification marks associated with active transcription, such as acetylation of H3 
and H4 lysine (K) residues and trimethylation of K4 of H3 (H3K4me3) 150  while other 
heterochromatic regions are deacetylated but characterized by trimethylation of specific 
lysine residues, which function as repressive marks 151, 152. However, many active and 
inactive genes have overlapping patterns of histone modifications. Nevertheless, it is clear 
that aberrant regulation of histone modification can affect gene activity and therefore 
oncogenic potential exists. Histone modifications are proposed to affect chromosome 
function through at least two distinct mechanisms.  The first mechanism suggests 
modifications may alter the electrostatic charge of the histone resulting in a structural 
change in histones or their binding to DNA. The second mechanism proposes that these 
modifications are binding sites for protein recognition modules, such as the 
bromodomains or chromodomains, which recognize acetylated lysines or methylated 
lysine, respectively.  
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2.2. Histone Deacetylase 
2.2.1. Histone-modifiying enzymes 
For each modification, enzymes exist which either lay down the appropriate mark or 
remove it. Major players in this regulation are the histone acetyltransferases (HAT), which 
acetylate the histone tails and induce chromatin decondensation, histone deacetylases 
(HDAC), which remove the acetyl groups and promote a tighter binding of histones to 
DNA, histone methyltransferases (HMT) which promotes or inhibits transcription 
depending on the target histone residue and histone demethylases (HDM) which 
counteracts the HMTs.  
2.2.2. Histone deacetylase (HDAC) 
HDAC proteins occur in four groups depending on their sequence similarity and cofactor 
dependency. The first two groups are considered "classical" HDACs whereas the third 
group is a family of nicotinamide adenine dinucleotide (NAD)+-dependent proteins with 
distinct homology from other HDACs. The fourth group is considered an atypical 
category of its own, based solely on DNA sequence similarity to the others. HDACs are 
divided into the following classes: class I (HDAC1-3, 8), class II (HDAC4-7, 9, 10), class 
III (sirtuin1-7) and class IV (HDAC11). All class I, class II and class IV are zinc-
containing in the catalytic sites. Based on phylogenetic analyses, these classes can be 
further divided into class Ia (HDAC1 and 2), Ib (HDAC3) and Ic (HDAC8); class IIa 
(HDAC4,5,7 and 9), IIb (HDAC6 and 10). Individual HDACs are found different in not 
only structure but also enzymatic function, cellular localization and tissue distribution. 
Class I HDACs are generally localized in the nucleus and ubiquitously expressed while 
class II HDACs shuttle between nucleus and cytoplasm (IIb are mostly cytoplasmic). 
Recent studies have gradually elucidated the roles of specific HDACs that class I HDACs 
are implicated in proliferation and cell survival and functions of class II HDACs are 
diverse and maybe tissue-specific. Sirtuins can be nuclear, cytoplasmic or mithochondrial 
in localization, depending on the subtype, and are linked to aging and metabolism (Table 
1.3) 153, 154.  
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Class HDAC 
Subcellular 
localization 
Tissue distribution Substrates 
Knockout 
phenotype 
I 
HDAC1 Nucleus Ubiquitous 
Androgen receptor, 
SHP, p53, MyoD, 
E2F1, STAT3 
Proliferation 
defects, increase in 
p21 and p27 
HDAC2 Nucleus Ubiquitous 
Glucocorticoid 
receptor, YY1, 
Bcl-6, STAT3 
Cardiac 
malformation 
HDAC3 Nucleus Ubiquitous 
SHP, YY1, 
GATA1, RELA, 
STAT3, MEF2D, 
CDK9, SP1, PP4c 
Gastrulation 
defects 
HDAC8 Nucleus Possibly 
ubiquitous  
Craniofacial 
defects 
IIa 
HDAC4 Nucleus/cytoplasm Heart, brain, 
smooth muscle 
GCMA, GATA1, 
HP1 
Chondrocyte 
differentiation 
defect 
HDAC5 Nucleus/cytoplasm Heart, brain, 
smooth muscle 
GCMA, SMAD7, 
HP1 
Exacerbated 
cardiac 
hypertrophy 
HDAC7 Nucleus/cytoplasm Heart, brain, pancreas, placenta PLAG1, PLAG2 
Maintenance of 
vascular integrity, 
increase in 
MMP10 
HDAC9 Nucleus/cytoplasm Brain,           
smooth muscle  
Exacerbated 
cardiac 
hypertrophy 
IIb 
HDAC6 Mostly  cytoplasm Heart, liver, kidney, placenta 
α-Tubulin, HsP90, 
SHP, SMAD7 
Increased tubulin 
acetylation 
HDAC10 Mostly cytoplasm Liver, spleen, kidney   
III Sirtuin1-7 
Nucleus, 
cytoplasm, 
mitochondria 
 
FOXO, Ku70, 
E2F1, TGF-β and 
NF-κB 
Premature aging, 
reduced lifespan, 
cardiac 
hypertrophy 
IV HDAC11 Nucleus/cytoplasm 
Heart, brain, 
smooth muscle, 
kidney 
  
Abbreviations: HDAC, histone deacetylase; SHP, small heterodimer partner; Bcl-6, B cell lymphoma 6; 
STAT3, signal transducers and activators of transcription 3; MEF2D, myocyte-specific enhancer factor 2D; 
CDK9, cyclin-dependent kinase 9; HP1, heterochromatin 1; MMP10, matrix metalloproteinase 10; Hsp90, 
heat shock protein 90; HIF-1α, hypoxia-inducible factor-1α; FOXO, Forkhead box class O; TGF-β, 
transforming growth factor-β; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells. 
 
Table 1.3. Identified HDAC characteristics 153-155 
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2.2.3. Histone acetyltransferase (HAT) 
In the contrast, HATs catalyze the acetylation of lysine residues on histone and non-
histone proteins. Based on the cellular origin and functions, they are classified into nuclear 
HATs (type A) and cytoplasmatic HATs (type B) and further divided into to five families 
according to the structural homology. Three of them have been explored extensively, 
which are GNAT (GCN-5-related N-acetyltransferase) family, PCAF (p300/CBP 
associated factor) and the MYST family 156. Relative to HDACs, the knowledge of the 
role of individual HATs in human diseases is less established. Functioning in opposition, 
HATs and HDACs achieve a dynamic balance, dominating the histone acetylation state. 
2.2.4. Histone acetylation 
Histone acetylation-deacetylation balance controls the higher-order structure of 
chromatins, acetylation of lysine residues within histone tails neutralizes the positive 
charges and thereby relaxes chromatin structure, allowing more accessibility of 
transcriptional factors to their target genes. By contrast, deacetylation of histones leads to 
compacted chromatin structures which incline to transcription repression. The balance 
between deacetylation and acetylation is maintained dynamically by HDACs and the 
opponent enzymes, HATs (Figure 1.5). Importantly, HATs and HDACs also act directly 
on non-histone proteins, mostly transcriptional factors such as NF-κB, hypoxia-inducible 
factor (HIF)-1α and tumour suppressor p53, and influence their activities. More than 50 
non-histone substrates of known function have been identified, which may be acetylated 
by HDACs 153.  
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Figure 1.5. Schematic diagram of HDAC and HAT function. The chromatin structure is modulated by the 
counteraction between HDAC and HAT. This balance determines the accessibilities to the target genes of 
transcriptional factors and hence the following transcription. HDACi, HDAC inhibitor. 
HDACs have attracted great attention due to their regulatory role in huge numbers of gene 
expression and protein activities. HDAC modifications are highly related to proliferative 
transformation, possibly through multiple mechanisms including cell-division cycle, 
intrinsic and extrinsic apoptosis, angiogenesis, senescence, ROS-facilitated reactions, 
mitotic autophagic cell death, DNA repair and inflammatory reactions 157. Aberrant 
overexpression and the corresponding hypo-acetylation histone levels have been 
demonstrated commonly in a variety of cancer types, which is thought to be, at least 
partially, responsible for malignant transformation 158-160. HDACs have been identified to 
be a new target for novel treatment of proliferative disorders, especially malignancy, and 
data to date indicate therapeutic potential. 
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2.3. Histone Deacetylase Inhibitor 
2.3.1. Histone deacetylase inhibitor: general view 
Owing to the extensive involvement of histone acetylation in biological functions, it is 
expected that global inhibition of HDAC would lead to universal depression of gene 
expression. Nevertheless, HDAC inhibition, specific or systemic, with certain inhibitors is 
well tolerated in vivo and seems to selectively shut down gene expression profiles 
associated with diseases. The phenomenon that transformed cells are more susceptible to 
HDAC inhibition-induced anti-proliferative effects is presumably attributed to distinctive 
signalling pathways or failure in defective rescue 161. HDAC inhibitors exert anti-
neoplastic capacities and are emerging as a new class of cancer treatment. The exact 
mechanisms underlying the effects of HDAC inhibitors on cancer are still to be defined. 
Several explanations have been introduced. First, HDAC inhibitors alter the acetylation 
status of gene promotors or repressor and subsequent gene expression 162. Second, 
acetylation results in chromatin relaxation, allowing more transcription, which can be 
promotive or inhibitory 163. Third, HDAC inhibitors jeopardize deacetylation of 
transcription factors and thus influence activities 164. Furthermore, HDAC inhibitors can 
directly modify non-histone proteins, comprising transcriptional factors, hormone 
receptors, DNA repair enzymes, signalling and inflammatory mediators, structural and 
chaperone proteins, and manipulating their functions 157. Finally, the inhibitors may break 
down the equilibrium among different HDACs 165. Up to date, several HDAC inhibitors 
have been developed for evaluation in preclinical and clinical studies. Current available 
HDAC inhibitors can be grouped into four types based on chemical structure, which are 
hydroxamic acids, cyclic tetrapeptides, short-chain fatty acids and benzamide. More than 
ten of them have entered clinical trials, among which two compounds (Vorinostat and 
Isodax) have be approved for treatment of cutaneous T cell lymphoma (CTCL) in humans 
whereas valproic acid (VPA) had been clinically used for a long time in neurology and 
psychiatry (Table 1.4) 166. 
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Group Example Specificity Status Indication in Monotherapy 
Hydroxamic 
acid 
Trichostatin Pan-HDAC Preclinical  
Suberoylanilide 
hydroxamic acid          
(Vorinostat) 
Pan-HDAC 
Approved for 
cutaneous T 
cells lymphoma 
NSCLC, soft tissue sarcoma, 
MDS, sickle cell disease 
Panobinostat        
(LBH589) 
Pan-HDAC Phase I > II > III 
RCC, thyroid cancer, MM, 
Hodgkin’s lymphoma,            
non-Hodgkin’s lymphoma, SCLC, 
prostate cancer 
Belinostat Pan-HDAC Phase I > II 
Lymphoma, MM,                     
non-Hodgkin’s lymphoma, 
peripheral T cell lymphoma, 
Cyclic 
tetrapeptide 
Romidepsin                                     
(FK228) 
HDAC 1&2 
Approved for 
cutaneous T 
cells lymphoma 
Non-Hodgkin’s lymphoma, 
lymphoma, MDS, lung cancer, 
colorectal cancer,                    
head and neck cancer, 
Short-chain 
fatty acid 
Valproic acid Class I & IIa Phase I > II > III 
Chronic lymphocytic leukemia, 
head and neck cancer 
Phenyl butyrate Class I & IIa Phase I > II Alpha 1-antitrypsin deficiency 
AN-9 Class I & IIa Phase I > II 
Malignant melanoma,             
leukemia, lymphoma 
Benzamide 
Entinostat              
(MS-275) 
HDAC 1&3 Phase I > II 
Hodgkin’s lymphoma, MDS, 
breast cancer 
Mocetinostat HDAC 1&3 Phase I > II 
Chronic lymphocytic leukemia, 
lymphoma, MDS, non-Hodgkin’s 
lymphoma 
N-Acetyldinaline HDAC 1&3 Phase I > II > III Advanced myeloma 
Abbreviations: HDAC, histone deacetylase; NSCLC, non small cell lung cancer; MDS, myelodysplastic 
syndrome; RCC, renal cell carcinoma; MM, multiple myeloma; SCLC, small cell lung cancer. 
 
Table 1.4. Overview of HDAC inhibitors 166. 
 Trichostatin A (TSA), an antifungal antibiotic, is a potent, non-selective and 
reversible inhibitor of class I and II HDACs. TSA has been shown to increase histone 
acetylation and promote apoptosis in transformed cells in a seeming specific manner. 
The mechanisms are likely owing to cell cycle arrest, induction of differentiation and 
upregulation of apoptosis-related gene programs. Though TSA seems to be 
promising as an anti-cancer therapy in a series of preclinical studies, there have been 
few clinical trials 167, 168.  
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 Valproic acid (VPA) is one of the most widely prescribed anticonvulsants and 
mood-stabilizers worldwide, primarily used in epilepsy, bipolar disorder and some 
other psychiatric diseases. Several functional roles of VPA in neuropsychiatry have 
been established, such as GABA enhancer, N-methyl-D-aspartate (NMDA) inhibitor, 
sodium channel blocker 169. VPA has been recently recognized as an effectve 
inhibitor of class I HDAC activity and emerged as potential therapeutic choice for 
cancer treatment. A series of the preclinical and early clinical trials have revealed 
encouraging results of VPA in treatment of several cancer types, including leukemia, 
glioma, multiple myeloma, melanoma and many solid tumours. Whole genome 
microarray of patients with cancer shows that VPA upregulates genes relevant to 
ribosomal proteins, oxidative phosphorylation, mitogen-activated protein kinase 
(MAPK) signaling; focal adhesion, cell cycle, antigen processing and presentation, 
proteasome, apoptosis, PI3K, Wnt signaling, calcium signaling, TGF-β signaling, 
and ubiquitin-mediated proteolysis among others 170. VPA is oral available and 
generally well tolerated. The relatively easy administration and manageable side 
effects make it less challenging to translate to clinical application. 
 Suberoylanilide hydroxamic acid (SAHA, Vorinostat), structurally analogous to 
TSA, is the first drug approved by FDA in human cancer therapy for relapsed and 
refractory CTCL, under the trade name Zolinza. Similar to TSA, SAHA is a broad- 
spectrum (class I, II and IV) HDAC inhibitor but with less potency. It acts as a 
competitive antagonist occupying the binding sites of zinc containing domains of 
HDACs. SAHA-induced accumulation of acetylated histones and proteins influence 
cell proliferation, apoptosis, protein stability, cell motility, angiogenesis, ROS-
facilitated cell death and inflammatory reactions 171. The multiple targets of HDAC 
inhibition may account, in part, for the efficacy of SAHA as an anti-cancer agent. 
Currently, many clinical trials of SAHA are ongoing for various cancers, both 
haematological malignancies and solid tumours.  
 Romidepsin (depsipeptide, FK228), after SAHA, this agent is the second HDAC 
inhibitor approved as a treatment for CTCL in humans. With a relatively unique 
structure in all HDAC inhibitors, Romidepsin is a prodrug activated in cells to 
interact with zinc in the catalytic site of Zn-dependent HDAC. It preferentially acts 
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on HDAC1 and HDAC2 and is considered a more isoform-specific HDAC inhibitor 
172
. In addition to CTCL, it is also linked to other cancers such as leukemia, 
melanoma and some solid tumours. Similar to SAHA, Romidepsin is believed to 
reprogram aberrant gene alterations, which are responsible for cell proliferation, 
differentiation and resistance to apoptosis in transformed cells. However, caution 
have been raised due to the risk of haematological disorders and cardiac toxicity 173. 
2.3.2. Histone deacetylase inhibitor in cancer 
HDAC inhibitors have been demonstrated to suppress cell proliferation and induce 
apoptosis both in vivo and in vitro cancer studies. Various molecular mechanisms have 
been unravelled that shows the anti-neoplastic effects of HDAC inhibitors are 
multifactorial via epigenetic and non-epigenetic modification. Some mechanisms have 
been elucidated (Figure 1.6). 
 Cell cycle arrest is one of the most common features of HDAC inhibition in most 
cell types. The cell cycle is controlled by several gatekeeper proteins, such as p21, 
p27 and p53, constituting checkpoints to protect cells against external stresses and 
internal errors. Dysfunction in these checkpoints is seen widely in transformed cells, 
which prevent cells with DNA damage from being repaired or undergoing apoptosis. 
HDAC inhibitors arrest cell cycle at G1 phase in low concentrations while G2/M 
phase in higher concentrations 174. Disruption of cell cycle checkpoints by HDAC 
inhibitors contributes to selective cytotoxicity in transformed cells by driving cells to 
enter an abortive mitosis, culminating in apoptosis 175 . HDAC inhibitor-induced cell 
cycle arrest is commonly associated with upregulation of the cyclin-dependent kinase 
(CDK) inhibitor p21, leading to retinoblastoma protein (pRb) dephosphorylation and 
inhibition of E2F in a p53-independent manner 176. On the other hand, p53 can be 
directly hyper-acetylated by HDAC inhibition and this increases p21 expression 177. 
Other studies also suggest the role of p27, another CDK inhibitor and regulator of the 
cell cycle, in HDAC inhibitor-induced arrest 178, 179. In addition to p21, HDAC 
inhibitors halt cell growth by suppressing DNA synthesis via related enzymes, such 
as thymidylate synthase and cytidine triphosphate synthatase 180. 
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 Apoptosis induction is a major pathway in HDAC inhibitor-induced cell death. 
Apoptotsis comprises two forms, extrinsic or death-receptor and intrinsic or 
mitochondrial pathway, both of which are implicated in HDAC inhibitor-induced cell 
death. In the extrinsic pathway, HDAC inhibition increases the expression of death 
receptors and cognate ligands selectively in transformed cells but not normal ones, in 
vitro and in vivo 181. These include Fas and its ligand, TRAIL and its receptor, death 
receptor (DR-5). Conversely, inhibitor of death receptor signalling is downregulated 
by HDAC inhibition, for example, c-FLICE-like inhibitory protein (FLIP) 182.  
The intrinsic apoptosis pathway is dominated by mitochondria, permeabilization of 
which releases of cytochrome c and initiates a caspase cascade. The mechanism is 
under control of pro- and anti-proapoptotic proteins of Bcl-2 family. Nearly all the 
HDAC inhibitors have been reported either of both upregulation of pro-apoptotic 
genes, Bim, Bmf, Bax, Bak and Bik 183-185, or downregulation of anti-apoptotic genes, 
Bcl-2, Bcl-xL, Bcl-w, Mcl-1 183, 185, XIAP (X-linked inhibitor of apoptosis protein) 
and survivin 186-188. These modifications undermine the characteristic resistance to 
apoptosis in transformed cells and shift the imbalance toward cell death. Additionally, 
some HDAC inhibitors can stimulate p53-mediated apoptosis by enhancing p53 
stability and further activating pro-apoptotic transcriptors like Bax 181.  
 Angiogenesis is a hallmark in cancer progression especially in the transition from 
hyperplasia to neoplasia and favours cancer cell expansion and invasion. In the past 
few decades, anti-angiogenesis has become a promising target in cancer therapy and 
a few angiogenesis inhibitors are available in cancer treatment currently 189. For 
example, Bevacizumab, targeting VEGF, is shown effective in several solid tumours 
190
. HDACs are linked to angiogenesis by their hypoxia-triggered repression of p53 
and von Hippel-Lindau protein (vHL), both of which responsible for degradation of 
angiogenic transcription factor HIF-1 and HIF-2. Several HDACs (HDAC1,3,4,6 and 
7) are involved in HIF-1α stability under hypoxic stimuli 191. HDAC7 translocates to 
nucleus to activate HIF-1α under hypoxic conditions 192. Early reports described that 
HDAC inhibitors promote p53 and vHL transcriptions and thereby degrade HIF and 
downregulate its downstream VEGF. Moreover, HDAC inhibition influences 
angiogenesis in a vHL-independent way, which is an acetylation-ubiquitination 
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proteasomal signalling as the result form direct acetylation of HIF-1α 193. The fact 
that HDAC inhibitors prevent vascular endothelial cells from answering to VEGF 
makes it rational to be combined with VEGF inhibitors in anti-tumour treatment 194.  
 Reactive oxygen species (ROS). Apart from apoptosis, HDAC inhibitors induce cell 
death via other pathways, such as mitotic failure, autophagic cell death and ROS 
accumulation. HDAC inhibitors exert ROS-derived cell death by inhibiting 
thioredoxin (TRX) activity in transformed but not normal cells. TRX provides 
hydrogen to activate several proteins, including ribonucleotide reductase which is 
essential for DNA synthesis, and antioxidant NF-κB. Inactivation of TRX by HDAC 
inhibitors leads to ROS accumulation in cells and thus cell death 195. However, 
downregulation of TRX can promote apoptosis through pro-apoptotic Bim, 
suggesting ROS acculumation may result from intrinsic apoptosis 196. Furthermore, a 
study indicates that SAHA selectively enhances TRX function in non-transformed 
cells, supporting the increased sensitivity of transformed cells ROS-derived cell 
death 161. Growing evidence has agreed that HDAC inhibitor-induced ROS 
generation may be important in the malignancy-specific cytotoxicity and 
therapeutically potential 161. 
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Abbreviations: ROS, reactive oxygen species; HIF-1α, hypoxia-inducible factor-1α; TBP2, thioredoxin 
binding protein 2; TRX, thioredoxin. 
Figure 1.6. The mechanisms of HDAC inhibitors in cancer. Acetylation of histone and non-histone proteins 
affects a wide range of signalling pathways, such as cell cycle, angiogenesis and apoptosis. These 
abnormalities are generally exclusive in cancer cells and consequently can be therapeutic targets. 
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2.3.3. Histone deacetylase inhibitor in inflammation 
Recent advances in the field of histone modifications have revealed that HDACs play a 
key role not only in oncogenic biology but also in immunological pathways. Current 
understanding concludes that protein acetylation is involved in innate and adaptive 
immune regulation, associated with numbers of inflammatory mediators, including 
cytokines, chemokines and MMPs, acting on different immune cells (Table 1.5). Some 
mechanisms have been identified, such as Toll-like receptor (TLR) and interferon  
signalling in innate immune system as well as lymphocyte development and function in 
acquired immunity. The role of HDACs in immune control can be dual and isoform-
specific. For example, gene profiling reveals that HDACs promote TLR target genes 
encoding major inflammatory mediators, including IL-6, IL-12, TNFs, MCP-1, IP-10, 
MMP-9 and ET-1 197, 198. In contrast, HDACs can negatively regulate TLR-mediated 
inflammatory responses through NF-κB inactivation 199. Moreover, HDAC5 is 
upregulated during differentiation of monocytes to macrophages 200whereas HDAC3 
downregulate myeloid cell differentiation 201.  
HDAC inhibitors are shown beneficial in animal models of non-cancerous inflammatory 
disorders, such as arthritis, inflammatory bowel disease, ischemia-reperfusion injury, 
septic shock, airway inflammation, multiple sclerosis and neurodegenerative diseases 202. 
The therapeutic effects are possibly attributed to mechanisms including suppressing the 
destructivity of innate immunity and intervening in the development of adaptive immunity. 
For example, SAHA is found to promote differentiation of antigen presenting cells along 
with reduction in cytokines, IL-6, IL-12 and TNF-α, as well as augment regulatory T cell 
in mice 203. SAHA is also able to reduce circulating IL-1β, IL-6, TNF-α and INF-γ in 
experimental endotoxemia 204, suggesting the immunomodulatory activites of HDAC 
inhibitors. Furthermore, HDACs are presumed to be involved in the reverse transcription 
of HIV infection because they control the chromatin structure. Studies show that HDAC 
inhibitors can reactivate the viral expression in latent cellular reservoirs, supporting the 
promise of combination of HDAC inhibitors with current anti-retroviral agents for viral 
eradication 205. Contradictorily, some studies indicated that HDAC inhibitors may 
compromise host immune 198and worsen atherosclerosis 206. The causes and effects of 
HDAC inhibition in immunomodulation remain to be investigated.  
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Class HDAC Immune cell Function 
I 
HDAC1 
B cells Promote proliferation 
T cells Negative feedback regulator 
Macrophages and 
non-immune cells 
Enhance HIF-1α function, 
promote INF signalling, repress NF-κB function 
HDAC2 
B cells Promote proliferation 
Macrophages 
Repress MTA1 function, 
promote GR-mediated repress NF-κB function 
HDAC3 Macrophages Enhance HIF-1α function, repress NF-κB function 
HDAC8 Unknown Unknown 
IIa 
HDAC4 
T cells Repress IL-5 promoter 
Macrophages 
Enhance HIF-1α function, Control 
LXR-mediated repression of TLR-inducible genes 
HDAC5 
B cells Unknown 
T cells Unknown 
Monocytes/macrophasges Unknown 
HDAC7 
CD4+CD8+ thymocyes Control positive and negative selection 
Unknown Enhance HIF-1α function 
HDAC9 CD25+ regulatory T cells Inhibit FOXP3 function 
IIb 
HDAC6 
T cells Regulate immune synapse formation 
Unknown Promote Hsp90 chaperone function 
CD25+ regulatory T cells Inhibit regulatory T cells function 
HDAC10 Unknown Unknown 
IV HDAC11 Antigen presenting cells 
Inhibit IL-10, 
promote expression of co-stimulatory molecules 
Abbreviations: HIF-1α, hypoxia-inducible factor-1α; INF, interferon; NF-κB, nuclear factor kappa-light-
chain-enhancer of activated B cells; MTA1, metastatic tumour antigen 1; GR, glucocorticoid receptor; IL, 
interleukin; LXR, liver X receptor; TLR, toll-like receptor; Hsp 90, heat shock protein 90; FOXP3, forkhead 
box P3. 
 
Table 1.5. Known functions of individual HDACs in the immune system 191. 
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2.3.4. Histone deacetylase inhibitor in cardiovascular system 
In a series of knockout studies, HDACs have been shown to contribute to the development 
and differentiation of cardiac tissue. Deletion of HDAC2 causes multiple cardiac 
malformations while overexpression leads to cardiac hypertrophy through modulation of 
the Akt-GSK-3β signalling pathway 207. HDAC1 and HDAC2 may cooperate to manage 
cardiac morphogenesis, growth and contractility 208. HDAC3 serves a crucial role in 
maintaining cardiac energy metabolism through the nuclear receptor, peroxisome 
proliferator-activated receptor (PPAR)-α 209, and endothelial integrity through Akt 
activation 210. However, overexpression of HDAC3 suppresses CDK inhibitors and 
promotes cardiac hyperplasia but not hypertrophy 211. Cardiac-specific deletion of 
HDAC5 or HDAC9 leads to exacerbated cardiac hypertrophy and governs gene 
expression related to myocyte proliferation, differentiation and morphogenesis 212. 
Although the global permanent absence of HDACs cannot reflect the real biological 
alternation in pharmacological manipulation, it indicates the essential involvement of 
HDACs in the developmental process. 
In vascular biology, HDACs have been also implicated a key role maintaining the vascular 
cell homeostasis, specifically the proliferation, migration and apoptosis of endothelial and 
smooth muscle cells. For examples, HDAC7 is essential in vascular integrity and 
endothelial function 213. HDAC7 can be mediated by VEGF signalling and performs as a 
switch of the downstream angiogenesis process 214. Interacting with beta-catenin, HDAC7 
can keep endothelial cells in a low proliferation stage while silencing HDAC7 inhibits 
endothelial cell migration via upregulation of PDGF signalling 215, 216. Knockdown of 
HDAC5 promotes endothelial migration and sprouting whereas knockdown of HDAC7 
and HDAC9 decreases 217. HDAC1 was reported involving in oxidative-stress-induced 
apoptosis of smooth muscle cells via interaction with p53 218. Class III HDACs have been 
also described the importance in cardiovascular biology. Sirtuins, especially SIRT1, are 
suggested to regulate angiogenesis and vessel tone, contributing to endothelial 
homeostasis and function, and might be beneficial in vascular disease, such as 
atherosclerosis 219, 220. Several underlying mechanisms have been explored, such as 
inhibition of proliferation and migration via cyclin D1-dependent cell cycle arrest 221, and 
vascular relaxation by activating eNOS 222. 
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Attempts have been made to evaluate the therapeutic potential of HDAC inhibitors in 
cardiovascular diseases. In an aorta-banding mice model, inhibition of class I HDAC 
prevents cardiac hypertrophy induced by angiotensin II 223. Other studies also show that 
HDAC inhibitors partially recover pre-existing hypertrophy and improve cardiac function 
in animal models 224, suggesting potential in heart failure. In addition, as described in 
2.2.2, HDAC modifications are highly connected to VEGF signalling pathway, and 
HDAC inhibitors have shown their potential as anti-angiogenesis agents. For example, 
SAHA, TSA and LBH589 are found to prevent human umbilical vein endothelial cells 
from sprouting and forming capillary-like structures by VEGF downregulation. This effect 
is specific in endothelial cells but in neither smooth muscle cells nor fibroblasts 194. 
Histological evaluation of tumour blood vessel in xenograft models showed a significant 
reduction of angiogenesis in terms of both size and number 189. Furthermore, TSA and 
another broad-spectrum inhibitor Scriptaid can inhibit vascular smooth muscle cell 
proliferation and neointima formation via induction of CDK inhibitors, such as p21, and 
subsequently arrest cell cycle 225, 226. 
2.3.5. Histone deacetylase inhibitor in pulmonary hypertension 
The present understanding of epigenetic modifications affecting phenotypic responses 
during pulmonary vascular remodelling is very limited but modern studies suggest 
epigenetic components in the pathogenesis of PAH. Archer et al have reported tissue-
specific, epigenetic deficiency in mitochondrial superoxide dismutase-2 creates a heritable 
form of PAH with proliferative and apoptosis-resistant pulmonary artery smooth muscle 
cells 227.   
Targeting the proliferative pathology underlying vascular remodelling is essential in PAH 
treatment. HDAC inhibitors may offer such efficacy. An early study showed that VPA 
inhibits right ventricular hypertrophy induced by pulmonary artery banding (PAB) and 
MCT 228. Furthermore, the presence of pro-inflammatory fibroblasts with an 
epigenetically altered phenotype due to increased HDAC activity has been reported in 
severe hypoxic pulmonary hypertension 229. However, TSA has been described to 
exacerbate right ventricular RV dysfunction in rat PAB models 230. 
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2.3.6. The limitation of histone deacetylase inhibitor  
Although majority of evidence so far supports the therapeutic potential of HDAC 
inhibitors, many challenges have to be met and overcome. Most importantly, the 
understanding of individual HDAC function is still emerging. While some of them exert 
pathological events, others may offer protection. The fact that HDACs interact with one 
another seemingly provides a rationale to develop selective HDAC inhibitors. However, 
whether truly specific inhibitors can actually be developed is questionable because 
HDACs in cells usually locate in large protein complex containing other HDACs and the 
structural similarities may impede the specificities too. In addition, the exact mechanisms 
of sensitivity to HDAC inhibitors in transformed cells are not known, which raises 
concern with safety and long-term use. Better understanding of the nature of HDAC is 
urgently required to establish a more robust mechanistic conviction for clinical translation. 
2.3.7. Epigenetics in pulmonary hypertension  
Recently, possible epigenetic components in PAH have been described, especially DNA 
methylation and histone acetylation. These epigenetic abnormalities, also identified in 
cancer, may contribute to the development and phenotypic variability of PAH and could 
be therapeutically reversed 231. This emerging recognition of the cross-talk between 
genetics and epigenetics provides a novel field for pharmacological intervention in PAH. 
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3. Hypothesis 
Epigenetic modification, such as the alteration of histone acetylation status, may influence 
specific gene expression profiles leading to the abnormal, proliferative and dysfunctional 
cells contributing to the vascular pathology of pulmonary arterial hypertension. Histone 
deacetylase inhibitors, by modulating transcriptional factors to inhibit proliferation or 
induce apoptosis, have therapeutic potential in pulmonary arterial hypertension.  
 
4. Objectives of study 
 To clarify the role of HDAC-modulating histone acetylation in the pathogenesis of 
pulmonary hypertension. 
 To evaluate the pharmacological effects of HDAC inhibition in experimental 
pulmonary hypertension models. 
Specifically,  
 To investigate HDAC expression in parallel with pathological changes 
during the development of PH. 
 To investigate the pharmacological effects of HDAC inhibitors in chronic 
hypoxia-induced PH models. 
 To investigate the pharmacological effects of HDAC inhibitors in 
monocrotaline-induced PH models. 
 To investigate the pharmacological effects of HDAC inhibitors in 
proliferative human pulmonary endothelial cells and smooth muscle cells 
 To identify the possible molecular mechanisms underlying the involvement 
of HDAC inhibition in pulmonary hypertension. 
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Chapter 2:  
MATERIALS AND METHODS 
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1. Introduction 
To test the hypothesis in a translational pre-clinical design, my study includes human 
samples, in vivo animal models and in vitro cell systems. This chapter contains all the 
materials and methods used in my study. Specific experimental designs are described in 
detail in the following chapters. 
2. Materials 
2.1. Human samples 
Human lung tissues were obtained with the informed consent of each individual and the 
approval of the Brompton Harefield & NHLI and Hammersmith Hospitals Research 
Ethics committees. Human lung samples (lobectomy and IPAH) were obtained from the 
Imperial College Pulmonary Hypertension biorepository (ethics reference numbers: 01-
210 & 2001/6003). The patients characteristics have been described previously 232. 
Samples for histology were originally fixed in 10% formal-saline and embedded in wax, 
and sections were processed for immunohistochemistry. 
2.2. Animals 
All the animal experiments were conducted in accordance with the UK Home Office 
Animals (Scientific Procedures) Act 1986 (London, UK). 
2.2.1. Mice 
The BMPR2-mutant mice (BMPR2) were introduced from Cambridge group and 
originally established by Beppu and colleagues via targeted gene disruption. Because 
homozygous BMPR2-mutant mice die in utero, breeding of BMPR2+/- mice was carried 
out by crossing BMPR2+/- mice with wild-type mice (C57/BL6 mice). Genotyping of the 
offspring was performed after weaning. The mutated BMPR2 allele in the mice was 
identified by a polymerase chain reaction with primer pairs 5_-GCTAA AGCGC ATGCT 
CCAGA CTGCC TTG-3_ and 5_-AGGTT GGCCT GGAAC CTGAG GAAAT C-3_.15 
The amplification conditions were as follows: 1 cycle of 120 seconds at 95°C; 30 cycles 
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of 30 seconds at 95°C, 30 seconds at 63°C, and 90 seconds at 72°C; and 5 minutes at 72°C 
233
. 
2.2.2. Rats 
Adult male Sprague-Dawley rats (body weight = 200-250g) were from Charles River 
(Marget, UK), housed in plastic cages in a temperature-controlled room and used for all 
the rats experiments. 
2.3. Cells 
2.3.1. Human pulmonary smooth muscle cells (HPSMCs) 
Human pulmonary smooth muscle cells (HPSMCs) were obtained from Cambridge group 
and maintained in Dulbecco’s modified eagle medium (DMEM, high glucose, Invitrogen, 
Paisley, UK) with 10% foetal bovine serum (FBS, Invitrogen) and 1% antibiotic-
antimycotic (AA, Invitrogen), referred to as SMC medium. The medium were changed 
every 3 days. 
Cells in use for all experiments were from passage 5 up to 10. Cells were passaged at 
approximately 80% confluence and split in a 1 to 2 ratio. The passage involved harvest of 
cells by incubation with trypsin-Ethylenediaminetetraacetic acid (EDTA) (Invitrogen) at 
37°C for 5 minutes. Cells were then neutralized in serum-containing medium and spun 
down in a centrifuge at 1200 rpm for 5 minutes, and the pellet were resuspended in 
DMEM with 10% FBS. Aliquots of cells were suspended in serum free cell freezing 
medium-Dimethyl sulfoxide (DMSO) (Sigmal-Aldrich, Dorset, UK) and kept at -80°C. 
2.3.2. Human pulmonary artery endothelial cells (HPAECs) 
Human pulmonary artery endothelial cells (HPAECs) were acquired from PromoCell 
(Heidelberg, Germany) and cultured in fibronectin-coated flasks at 37°C, 5% CO2 in 
Promocell Endothelial Cell Medium 2 with SupplementMix (referred to as EC medium), 
which ends up with 2% FBS, 5 ng/ml epidermal growth factor (EGF) 10 ng/ml basic 
fibroblast growth factor (FGF), 20 ng/ml insulin-like growth factor (IGF), 0.5 ng/ml 
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VEGF, 1 µg/ml ascorbic acid, 22.5 µg/ml heparin, 0.2 µg/ml hydrocortisone and 1% 
antibiotic-antimycotic. The medium were changed every other day. 
Cells were passaged at approximately 80% confluence in a 1 to 3 ratio and used up until 
passage 8. The passage and storage were similar to HPSMC as previously described but 
resuspended in EC medium. 
2.4. Drugs 
2.4.1. Valproic acid (VPA) 
VPA sodium salt was purchased from Sigma-Aldrich. For in vivo experiments, VPA was 
dissolved in tap water at aimed concentration and freshly prepared every other day; for in 
vitro experiments, VPA was dissolved in absolute ethanol to 1M as stock and kept at -
20°C.  
2.4.2. Suberoylanilide hydroxamic acid (SAHA) 
SAHA was purchased from Chemos GmbH (Regenstauf, Germany). For in vivo 
experiments, SAHA was solubilized in 5 molar equivalents of 2-hydroxypropyl-β-
cyclodextrin (HOP-β-CD, Sigma-Aldrich) in tap water, heated until fully dissolved and 
cooled to room temperature 234. The solution was freshly prepared every other day. For in 
vitro experiments, SAHA was dissolved in DMSO (Sigma-Aldrich) to 100mM as stock 
and kept at -20°C. 
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3. Methods 
3.1. In vivo pharmacological study 
The pharmacological effects of histone deacetylase inhibitors, VPA and SAHA, and 
related molecular mechanisms were investigated based on two rat models of PAH, chronic 
hypoxia and MCT. 
3.1.1. Reagents 
• VPA and SAHA were prepared as previously described and administrated through 
drinking water. Animals were weighed every other day before making up treating 
solutions in order to adjust the concentration to the aimed dose according to daily 
drinking amount. Control group was given tap water with or without HOP-β-CD 
at the same concentration with SAHA-treated group. 
• Normal saline was freshly prepared before every experiment as 0.9% sodium 
chloride in sterile water. 
• Haparin was dilute in normal saline at 10 U/ml for catheter flushing and 1 U/ml 
for organ flushing. 
• Anesthesia: Fentanyl/fluanisone (Hypnorm, VetaPharma, Leeds, UK) was used to 
anesthetize through intramuscular injection at 1 ml/kg body weight, followed by 
intraperitoneal injection with 0.8 ml/kg body weight midazolam (Hypnovel, 
Roche, Welwyn Garden City, UK). 
3.1.2. Animal models 
• Chronic hypoxia-induced PAH model: Sprague-Dawley rats with initial body 
weight 220-250g were kept in a normobaric hypoxia chamber (FiO2 = 10%) 
(Figure 2.1). Excessive CO2 accumulation was extracted by sodalime and 
maintained under 0.2%. The chamber was opened once daily for less than 30 
minutes for drug administration and body weight measurement. 
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Figure 2.1. Hypoxia chamber schematic illustration. 
 
• MCT-induced PAH model: MCT (Sigma-Aldrich) was fully dissolved in 1M 
HCl. Normal saline was added to reach the aimed concentration 40 mg/ml and 
the pH was adjusted to 7.4 using 10M NaOH. The MCT solution was injected 
subcutaneously to Sprague-Dawley rats weighing 220-250g. Control group was 
injected with normal saline. The body weight and health condition were followed 
daily according to the specific protocol. 
3.1.3. Haemodynamic measurements 
At the end of treatment course, animals were weighed, anaesthetized (Hypnorm 1 ml/kg 
i.m; Hypnovel 0.8 ml/kg i.p) and placed on a controlled warming pad to keep body 
temperature. A midline surgical incision was executed. Haemodynamic parameters, 
including PAP, RVSP and others, were measured via a pre-curved, catheter inserted 
through the right jugular vein, passed by the RV and into the pulmonary artery (PA). 
Systemic blood pressure (BP) was measured by cannulating the left carotid artery. These 
catheters were filled with heparinized saline (10 U/ml) during the whole measurement and 
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connected to the pressure transducer of a pressure transducer (PowerLab Data Acquisition 
system, ADInstruments Ltd, Chalgrove, UK) and pressure measurements were recorded 
from stable tracings. The whole surgery was managed to last for no more than 30 minutes. 
3.1.4. Tissue collection 
The animals were then sacrificed, plasma collected from inferior vena cava, heart 
harvested, individual chambers dissected carefully and weighed. The ratio of right 
ventricle to left ventricle plus the septum mass (LV+sep) was assessed as RV hypertrophy 
(RVH) index. Lungs were flushed gently with diluted heparinized saline (1 U/ml). The 
left lung and a piece of RV were fixed by inflation with 10% formalin in phosphate-
buffered saline and then embedded in paraffin blocks for histology assessment. 
Additionaly, one of the right lung lobe was inflated and embedded in OCT mounting 
medium (VWR Intl Ltd) prior to freezing for later on laser capture microdissection. 
Collected tissues, including lungs, RV, LV, livers and kidneys, were snap frozen in liquid 
nitrogen and stored at -80°C for biochemical measurements.  
3.1.5. Histological analysis 
Vascular remodelling in lungs was assessed by counting every single vessel less than 100 
µm under microscope (400X). Transverse lung sections were stained with van Gieson’s 
elastic method. Vessels with double elastic laminae occupying more than 50% of the 
circumference were regarded as fully muscularized while less than 50% as partially 
muscularized (Figrue 2.2). The proportion of muscularized vessels was quantified in the 
whole lung section from each animal and expressed as a percentage of total vessels 
counted (% muscularized vessels). Counting was performed twice and blindly to the group 
of the animals. 
Haematoxyline & eosin (HE) stained cardiac sections were used to assess cross sectional 
area (CSA) and minimal diameter of RV cardiomyocyte. The average CSA and minimal 
Feret’s diameter were quantified with ImageJ 1.46b (National Institutes of Health, USA). 
At least 40 myocytes cut transversely at the level of nucleus from 10 different areas 
chosen randomly were measured in each animal. 
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Figure 2.2. Transverse lung sections stained with van Gieson’s elastic method showing muscularized 
vessles with double elastic lamina. Non-muscularized group is defined by single layer vessel wall. Paritally 
muscularized group is defined by double elastice lamina accounting for < 50% of the vessel wall while fully 
muscularized group > 50%. 
3.1.6. Protein extraction 
Frozen tissues were smashed into powder in a mortar, which was pre-cooled at -80°C and 
maintained at low temperature with liquid nitrogen. 200mg of tissue powder were added 
into 2ml self-lock micro test tubes (Eppendorf, Hamburg, Germany), which contained one 
5mm stainless steel bead (Qiagen, Crawley, UK) in each and 1ml phosphate buffer 
(100mM DO4 [K2HPO4:KH2PO4 = 3:1], 1mM EDTA, 1mM DTT) supplemented with 
protease inhibitor (1 tab in 5ml, Roche). Tissues were further homogenated by Tissue 
Lyser II (Qiagen) at speed 30Hz for 2 minute. After high-speed centrifuge for 5 minutes, 
supernatants were taken, aliquoted and the concentrations of protein homogenates were 
measured immediately with BCA protein assay (Thermo Scientific, Epsom, UK). Protein 
homogenates were kept at -80°C till next use and precipitated residues were kept at -80°C 
for histone extraction. 
3.1.7. RNA isolation 
100 mg of frozen tissue powder were transferred into 1ml of TriPure isolation reagent 
(Roche) at 4°C. After fully homogenated and centrifuged, supernatants were taken and left 
at room temperature for 5 minutes, and then separated into aqueous and organic phase by 
addition of 200µl of chloroform. DNA and proteins were removed from the aqueous phase 
containing RNA by subsequent centrifugation. Pure RNA was precipitated by addition of 
500µl isopropanol, washed with 70% ethanol in diethylpyrocarbonate-treated water 
Non-muscularized Fully muscularizedPartially muscularized
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(DEPC- H2O, Invitrogen) and finally dissolved in appropriate volume of DEPC-H2O. The 
concentration of RNA was determined by NanoDrop ND1000 (Thermo Scientific) and the 
purity was detected with agarose gel electrophoresis. The isolated RNA was kept at -80°C.  
3.1.8. Histone extraction 
Tissue residues from protein extraction were washed twice with ice-cold PBS containing 
5mM sodium butyrate to retain levels of histone acetylation. Lysis buffer (10mM Tris, 
50mM sodium bisulfate, 10mM MgCl2, Sacarose 8.6%, 1% Triton X-100) was added to 
the tissues on ice for 15 minutes. After thorough homogenation, the supernatants were 
removed and the pellets were washed with lysis buffer and then Tris-EDTA (10mM Tris, 
13mM EDTA). Precipitated nuclei were suspended in 50µl of ice-cold dH2O. 50µl of 
0.4M sulfuric acid was added to the samples, vortexed, and kept on ice overnight. 
Following centrifuge at 15000 rpm for another one hour, histone was precipitated as white 
pellets in 1ml acetone at -20°C overnight. Dry pellets were then resuspended in dH2O for 
measurement of histone concentration with Bradford assay (Bio-Rad, Hemel Hempstead, 
UK).   
3.2. In vitro pharmacological study 
3.2.1. Reagents 
• VPA and SAHA stocks were prepared as previously described and diluted to 
target concentration in medium before treatment started. The treatment doses 
were determined on the basis of previous cancer studies235 and tests of serial 
concentration, VPA 1-2mM and SAHA 2-10µM, for different time points, from 
24 to 72 hours.  
• PDGF (50 ng/ml) was used to stimulate proliferation of HPSMC (human PDGF-
BB, eBioscience, Hatfield, UK) 64. 
• TNF-α (10 ng/ml) was used to stimulate cytokine release from HPAEC (R&D 
Systems, Abingdon, UK) 236. 
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3.2.2. Treatment experiment in HPSMC 
Harvested HPSMCs were seeded in sterile 6-well, 24-well tissue culture plates or T75 
flasks at a density of 15000 cells per cm2 and allowed to attach overnight. Cells were then 
deprived from serum for 24 hours before stimulation with PDGF (50 ng/ml) or exposure 
to hypoxia (O2=2%) with/without HDAC inhibitors for 72 hours. At the end of exposure, 
cells were harvested for proliferation/cell death assessment, biochemical studies or fixed 
for immunostaining. All the experiments were executed in at least triplicate with separate 
cell preparation.  
3.2.3. Proliferation assessment 
Treated cells were harvested from 24-well plates after 72-hour treatment and counted with 
hemocytometer. Proliferation was further assessed with WST-1 cell proliferation assay 
(water soluble tetrazolium, Roche) and BrdU cell proliferation assay (bromodeoxyuridine, 
Millipore, Watford, UK).  For WST-1 assay, cells were split at a density of 4x103 cells per 
well in 100µl culture medium containing PDGF (50 ng/ml) with/without HDAC inhibitors. 
Cells were split into a 96-well plate and incubated for 72 hours. 4 hours before the end of 
treatment, 10µl of Cell Proliferation Reagent WST-1 was added into each well. The platet 
were read in a spectrophotometer microplate reader to measure absorbance at 450nm as 
reference wavelength was 600nm. 
For BrdU assay, cells were plated at a density of 2x104 cells per well in 100µl culture 
medium in a 96-well plate. 100µl of test reagents (PDGF and HDAC inhibitors), which 
had been diluted to twice the desired final concentration, were added into each well and 
cells were incubated for 72 hours. BrdU reagent was diluted according to the manufacture 
instruction 24 hours before the end of treatment. Cells were then fixed with supplied 
fixing solution and incubated with anti-BrdU monoclonal antibody (100µl per well) for 
one hour at room temperature. Washed thoroughly with washing buffer, they were 
incubated in peroxidise-conjugated goat anti-mouse IgG (1:2000) for 30 minutes at room 
temperature, followed by 30-minute incubation with TMB peroxidise substrate 
(tetramethylbenzidine, supplied) in the dark. The results were read immediately in a 
spectrophotometer microplate reader to measure absorbance at 450nm after stop solution 
was added to terminate the reaction. 
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3.2.4. Cell death analysis 
Treated cells were harvested from 6-well plates after 72-hour treatment, washed in PBS 
and stained with 50 µg/ml of propidium iodide (PI, Sigma-Aldrich) in PBS for 30 minutes 
in the dark. Samples were analyzed immediately with Beckton-Dickinson Fluorescent-
activated cell sorting (FACS) Calibur flow cytometer system with Cell Quest software 
(Beckton-Dickison, Oxford, UK) and Cyflogic version 1.2.1 (CyFlo Ltd, Turku, Finland), 
488nm wavelength light used for excitation. The results were presented as the percentage 
of stained cells, representing necrotic or late apoptotic cells with penetrable plasma 
membrane to PI. 
3.2.5. Cell cycle distribution 
Treated cells were harvested from 6-well plates after 72-hour treatment and washed in 
PBS. 70% ethanol was added slowly to permeabilize cell membrane on vortexing and kept 
at least overnight at -20°C. Cells were stained with 50 µg/ml of PI in PBS for 30 minutes 
in the dark and analyzed immediately with FACS. The results were presented as the 
percentage of cells in G1, S and G2/M phase. 
3.2.6. Protein expression analysis 
Treated cells were harvested from T75 flasks after 72-hour treatment and centrifuged at 
2500rmp for 8 minutes at 4°C. Cell pellets were washed with PBS, snap frozen in liquid 
nitrogen for few seconds, and resuspended in 100µl of TGN buffer (0.05M Tris, 0.15M 
NaCl, 10% (v/v) glycerol, 0.05M β-glycerophosphate, 1% (v/v) Tween 20, 0.2% (v/v) 
Nonidet P40) with protease inhibitor (1 tab in 5ml, Roche). Cells were left on ice for 30 
minutes and vortexed every 10 minutes. After high speed centrifugation, supernatants 
were collected to measure protein concentrations. Protein expression levels were analyzed 
with Western Blotting as described in 3.3.1. 
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3.2.7. Inflammatory stimulation in HPAEC 
Equal amount of HPAECs were seeded in each well of a 6-well plate. At 80% confluence, 
cells were treated with HDAC inhibitors, 2mM VPA or 10µM SAHA, for 24 hours. 8 
hours after treatment started, TNF-α was added in at a final concentration of 10 ng/ml. At 
the end of treatment, supernatants were collected for cytokine array described in 3.3.4. 
3.3. Biochemical analysis 
3.3.1. Western blot analysis 
Equal amounts of protein homogenates (50µg) were resolved by SDS-PAGE on a 4-12% 
or 12% bis-tris gel (Invitrogen), depending on the size of the target protein, and 
transferred to a nitrocellulose membrane (Amersham, GE Healthcare, UK). The 
membranes were blocked in 5 % non-fat milk in TBS-tween (TBS, 0.1% Tween 20) with 
agitation for one hour and then incubated with purified mouse polyclonal antibodies 
against human HDAC1-4 (1:1000, Cell Signalling Technology) and Bcl-2 (1:1000, BD 
Biosciences, Oxford, UK), purified rabbit polyclonal antibodies against human HDAC5, 7, 
PARP (poly ADP ribose polymerase), p21 (1:100, Abcam, Cambridge, UK) and survivin 
(1:1000, Novus Biologicals) and purified goat polyclonal antibodies against human TIMP-
1 (1:2000, R&D Systems) in 5% bovine serum albumin (BSA, Sigma-Aldrich) in TBS-
tween overnight at 4°C on a shaking platform. TBS was diluted from 10X TBS (24.2g 
Tris base, 80g NaCl in 1 liter H2O, pH was adjusted to 7.6 with HCl). After washed in 
TBS-tween three times, 5 minutes each, they were incubated in horseradish peroxidise 
(HRP)-conjugated secondary antibodies against mouse (1:2500, GE Healthcare), rabbit 
(1:10000, Sigma-Aldrich) and goat (1:1000, R&D Systems) in 5% non-fat milk in TBS-
tween for one hour at room temperature on a shaking platform. The membranes were then 
washed three times again, 5 minutes each, and the proteins were detected by Novex® ECL 
chemiluminescent substrate reagent kit (Invitrogen). Optical densities of individual bands 
were measured and protein expression was standardized to α-actin (mouse monoclonal, 
1:5000, Sigma-Aldrich) for RV and β-actin (mouse monoclonal, 1:10000, Sigma-Aldrich) 
for other tissues. 
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3.3.2. RT-PCR 
Total RNA (500ng) and the primer oligo(dT)16 (250ng), mixed with DEPC-H2O, were 
pre-heated to 70°C and then cooled on ice for cDNA synthesis. 20µl of reagents, 
containing ImProm-IITM reaction buffer, 3mM MgCl2, 20U of Recombinant RNAsin® 
Ribonuclease Inhibitor (Promega Corp, Madison, WI, USA), 0.5mM of each 
deoxynucleoside triphosphate, and 1µl of ImProm-IITM Reverse Transcriptase 
(Promega Corp), were incubated at 25ºC for 5 min (anneal step), followed by an 
extension step at 42°C for one hour and a final step at 70ºC for 15 min (heat-inactivate). 
mRNA expression of  HIF-1α, BMPR2 and β-actin was quantified by TaqMan® real-
time RT-PCR with a GeneAmp 7500 Fast System (Applied Biosystems, Carlsbad,CA, 
USA). A 10-fold dilution of RT reaction for each sample was analyzed using TaqMan® 
Gene Expression Assays (Applied Biosystems) with commercially available specific 
primer-probes: HIF-1α (Rn00577560_m1), BMPR2 (Rn01437208_m1) and β-actin 
(Rn01437208_m1) (Applied Biosystems). Real-time PCR reactions were set following 
the manufacture instructions:  one initial step at 95ºC for 10 minutes for holding, 
followed by a 40-cycle step, which was 15 seconds at 95°C for denaturation and one 
minute at 60°C for annealing or extension. Threshold cycle (Ct) values obtained for 
each gene were converted to the linear form using the term 2–∆∆Ct as a value directly 
proportional to the copy number of mRNA 237, where ∆∆Ct was the Ct value 
normalized to β-actin and referenced to the values obtained for each gene under 
normoxic conditions.  
3.3.3. Histone acetylation assessment 
Histone acetylation was assessed with Western blotting. Equal amounts of histone extracts 
(10µg) were resolved by SDS-PAGE on a 12% bis-tris gel (Invitrogen) and transferred to 
a nitrocellulose membrane (Amersham). The membranes were blocked in 5 % non-fat 
milk in TBS-tween with agitation for one hour and then incubated with purified rabbit 
polyclonal antibodies against human acetyl-histone H3 (1:20000), acetyl-histone H3 
lysine9 (acH3K9, 1:20000), acetyl-histone H4 (1:2000) and acetyl-histone H4 lysine12 
(acH4K12, 1:2000, Millipore) in 5% BSA in TBS-tween overnight at 4°C on a shaking 
platform. After washed in TBS-tween three times, 5 minutes each, they were incubated in 
  
78 
HRP-conjugated secondary antibodies against rabbit (1:10000, Sigma-Aldrich) in 5% non-
fat milk in TBS-tween for one hour at room temperature on a shaking platform. The 
membranes were then washed three times again, 5 minutes each, and the proteins were 
detected by chemiluminescent reagent (Invitrogen). Optical densities of individual bands 
were measured and acetyl-histone expression was standardized to total histone H3 (rabbit 
polyclonal, 1:10000, Millipore) or total histone H4 (rabbit polyclonal, 1:2000, Millipore), 
which were executed on parallel gels as loading control. The data were presented as ratio 
of acetyl-histone over total histone. 
3.3.4. Cytokine array 
Human and rabbit cytokine array kits were purchased from R&D Systems. For animal 
study, tissue powder from individual animals in the same group were poured together and 
homogenated in PBS with protease inhibitors (1 tab in 5ml, Roche), followed by addition 
of Triton X-100 to a final concentration of 1%. After centrifuged at 10000g for 5 minutes 
to remove cellular debris, BCA protein assay was performed to determine the 
concentration. Samples were stored at -80°C until being used. Equal amounts of tissue 
homogenates (250µg) were added to 0.5ml supplied blocking buffer and adjusted to a 
final volume of 1.5ml with supplied array buffer. For cell study, 1.6ml of culture 
supernatants were added directly to 0.8ml of blocking buffer and adjusted to a final 
volume of 3ml. with array buffer. Then samples were mixed with 15µl detection antibody 
cocktail and incubated at room temperature for one hour. At the same time, nitrocellulose 
membranes pre-coated with anti-cytokine antibodies (cytokine array panel A) were 
incubated in blocking buffer for one hour on a rocking platform. After incubation, 
sample/antibody mixtures were added to membranes and incubated overnight at 4°C on a 
rocking platform. After washed with supplied washing buffer three times, 10 minutes each, 
the membranes were incubated in Streptavidin-HRP-conjugated secondary antibodies 
(1:2000, supplied in the kit) in array buffer for 30 minutes at room temperature on a 
rocking platform. The membranes were then washed three times again, 10 minutes each, 
and exposed to chemiluminescent reagent (Invitrogen). Optical densities of individual dots 
were measured and cytokine expression was standardized to pre-coated positive control on 
each membrane. Corresponding signals on different arrays were compared to determine 
the relative change in cytokine levels between samples. 
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3.3.5. Immunohistochemistry 
Dewaxes and rehydrated transverse lung sections were incubated in 3% hydrogen 
peroxide for 5 minutes and subjected to heat-induced antigen retrieval in 0.2% citric acid 
(pH was adjusted to 6 with 1M NaOH) at 80°C for 10 minutes. Sections were incubated in 
diluted normal goat serum (1 to 5 in PBS, Cell Signalling Technology) for 20 minutes and 
then immunostained with purified mouse antibody against HDAC1 (1:50, Cell Signalling 
Technology) and rabbit antibody against Ki67 (1:50, Thermo Scientific), HDAC5 (1:50, 
Cell Signalling Technology) in PBS for one hour at room temperature, followed by 
incubation in SignalStain® Boost IHC Detection Reagent (HRP) against mouse or rabbit 
(one drop, Cell Signalling Technology) for 30 minutes. Subsequently, sections were 
incubated in DAB (3,3'-diaminobenzidine) chromogenic substrate for 10 minutes (one 
DAB tablet in 10ml d H2O with 10µl H2O2, Sigma-Aldrich) before counterstain in filtered 
light green or HE for 3 seconds.  
3.4. Statistics 
All the results are presented as mean ± SEM and ‘n’ refers to the number of patients or 
animals per group. Statistical analysis was performed with GraphPad Prism version 4 
(GraphPad Software, San Diego, CA, USA). One-way ANOVA was applied for data of 
multiple group comparisons whereas unpaired, nonparametric t test with Mann-Whitney 
modification was used between two groups. Statistical significance was regarded as p 
value<0.05. 
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Chapter 3:  
HDAC EXPRESSION IN PH 
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1. Introduction 
To investigate the role of HDACs in the pathogenesis of PAH and their clinical relevance, 
the first crucial question is whether histone acetylation status is altered in the diseased 
lung. Aberrant expression and recruitment of HDACs have been reported in many human 
cancers 154, 163, 238, 239. Elevated expression levels of zinc-dependent HDACs are 
extensively found in different human cancer cell lines or tumour samples, relative to 
normal tissue. Some studies also indicate that the expression levels of HDACs positively 
correlate to prognosis of cancer patients 240. Increased HDAC expression/activity results in 
imbalance between histone acetylation and deacetylaton, inducing abnormal transcription 
of key genes in charge of proliferation and apoptosis. PAH is now recognized as a 
proliferative disorder sharing cancer-like properties, but our knowledge of epigenetics in 
PAH is very limited. In this chapter, I examine HDAC protein expression in IPAH patient 
lungs and PH animal models. 
The chronic hypoxic PH rat as well as the transgenic BMPR2 mouse were used. Alveolar 
hypoxia is a potent stimulus leading to pulmonary vasoconstriction and subsequently 
vessel remodelling 241. Continuous exposure to hypoxia creates PH acutely in the first few 
days and reaches a plateau after 1 to 2 weeks. This effect can be reversed by exposing 
animals back to normal air. As previously described in chapter 1, mutations in BMPR2 is 
the only identified genetic defect linked to human PAH. However, mutation in BMPR2 
alone does not guarantee the development of PAH, but predisposes. Transgenic mice with 
BMPR2 deficiency have been increased susceptibility to hypoxia-induced pulmonary 
hypertension. The exact molecular mechanism is not clear yet, but endothelial dysfunction 
affecting the pulmonary vasculature was suggested 242. 
Expression of the anti-apoptotic protein, Bcl-2, was also assessed along with HDACs. 
Governing mitochondrial outer membrane permeability, Bcl-2 controls the initiation of 
programmed cell death. Overexpression of Bcl-2 is responsible for resistance to apoptosis 
in proliferative disorders and its expression levels are associated with severity in a range 
of malignancies 243.  Therefore, Bcl-2 can be used as a proliferative indicator. 
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2. Objectives 
• To examine protein expression levels of class I and II HDACs in lungs from IPAH 
patients.  
• To examine protein expression levels of class I and II HDACs in tissues from rats 
exposed to chronic hypoxia for different time points. 
• To examine protein expression levels of HDACs in lungs from transgenic mice 
deficient in BMPR2, under normoxic and hypoxic conditions. 
 
3. Methods and Protocols 
3.1. Chronically hypoxic rats 
Male Spraque-Dawley rats (220-250 gram) were divided into four groups (n≥6): 
1) NC: normoxia control 
2) 2D: hypoxia for two days 
3) 1W: hypoxia for one week  
4) 2W: hypoxia for two weeks 
3.2. Transgenic mice with BMPR2 deficiency 
Mice with and without established BMPR2 deficiency were divided into four groups: 
1) Wild type mice under normoxia condition 
2) BMPR2-deficient mice under normoxia condition 
3) Wild type mice expose to hypoxia for two weeks 
4) BMPR2-deficient mice expose to hypoxia for two weeks 
 
 
  
83 
At the end of exposure, haemodynamic parameters were measured and tissues were 
collected for further biochemical and histological investigation immediately as described 
in Methods. PAP was measured only in rats but not in mice due to the accessibility to 
pulmonary artery. 
4. Results 
4.1. HDAC expression in humans and rats 
4.1.1. HDAC1 and HDAC5 expression in human lungs 
Increased protein expression levels of HDAC1 (p<0.0005) and HDAC5 (p<0.005) were 
observed in lungs from patients with IPAH, accompanied by the increase in anti-
proapoptotic factor, Bcl-2 (p<0.0005), compared with control lung tissues (Figure 3.1).  
 
Figure 3.1. Protein expression levels in human lung extracts. (A) HDAC1, (B) HDAC5, (C) Bcl-2, (D) 
representative bands. Control: lobectomy; IPAH: IPAH patients. The data are presented as mean± SEM of 
fold change relative to control. n=21 in control and 12 in IPAH. ** p<0.005, *** p<0.0001 compared with 
control group. 
  
84 
4.1.2. HDAC1 and HDAC5 expression in hypoxic rat lungs 
Exposing rats to chronic hypoxia induced PH gradually over two weeks, characterized by 
elevated mean PAP (p<0.05) and significant RV hypertrophy (p<0.005) along the two-
week time course (Figure 3.2). Two-fold increases in both mean PAP and RV 
hypertrophy index were seen after two-week hypoxic exposure. 
 
Figure 3.2. Haemodynamic phenotype of rats exposed to hypoxia for different time points. (A) PAP, mean 
pulmonary artery pressure, (B) RV/LV+sep, right ventricular hypertrophy. NC: normoxia control; 2D: 
hypoxia for two days; 1W: hypoxia for one week; 2W: hypoxia for two weeks. The data are presented as 
mean± SEM. n≥3 in each group. * p<0.05, ** p<0.01 compared with NC.  
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HDAC1 protein expression in lungs from hypoxic rats was increased during hypoxia 
exposure (p<0.05) and reached 4-fold over normoxia control after two-week hypoxia 
whereas HDAC5 expression was strikingly increased by over 15-fold after one-week 
hypoxia and maintained relatively stable thereafter (p<0.005). Bcl-2 expression was 
increased up to 3-fold over control after two-day hypoxia and remained elevated during 
the two-week period (p<0.05, Figure 3.3). 
 
Figure 3.3. Protein expression levels in lung extracts from rats exposed to hypoxia for different time points. 
(A) HDAC1, (B) HDAC5, (C) Bcl-2, (D) representative bands.  NC: normoxia control; 2D: hypoxia for two 
days; 1W: hypoxia for one week; 2W: hypoxia for two weeks. The data are presented as mean± SEM of fold 
change relative to NC. n≥3 in each group. * p<0.05, ** p<0.005 compared with NC group. 
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4.1.3. HDAC2 and HDAC3 expression in human and rat lungs 
In contrast to increases in HDAC1, protein expression of other two class I HDACs, 
HDAC2 and HDAC3, in lungs from IPAH patients and hypoxic rats were showed a 
gradual decline (Figure 3.4).  
 
Figure 3.4. Protein expression levels in lung extracts from humans and rats exposed to hypoxia for different 
time points. (A) HDAC2 in humans, (B) HDAC2 in rats, (C) HDAC3 in humans, (D) HDAC3 in rats. 
Control: lobectomy; IPAH: IPAH patients; NC: normoxia control; 2D: hypoxia for two days; 1W: hypoxia 
for one week; 2W: hypoxia for two weeks. The data are presented as mean± SEM of fold change relative to 
control or NC. n≥9 in each group. * p<0.05, *** p<0.0005 compared with control or NC group. 
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4.1.4. HDAC4 and HDAC7 expression in human and rat lungs 
Protein expression of other two class II HDACs, HDAC4 and HDAC7, in lungs from 
IPAH patients and hypoxic rats was measured. HDAC4 expression was significantly 
increased in patient lungs (p<0.05), but slightly increased in rats exposed to two-day 
hypoxia and decreased afterwards. HDAC7 expression in lungs increased in both IPAH 
patients and hypoxic rats (Figure 3.5).  
 
Figure 3.5. Protein expression levels in lung extracts from humans and rats exposed to hypoxia for different 
time points. (A) HDAC4 in humans, (B) HDAC4 in rats, (C) HDAC7 in humans, (D) HDAC7 in rats. 
Control: lobectomy; IPAH: IPAH patients; NC: normoxia control; 2D: hypoxia for two days; 1W: hypoxia 
for one week; 2W: hypoxia for two weeks. The data are presented as mean± SEM of fold change relative to 
control or NC. n≥7 in each group. * p<0.05, ** p<0.005 compared with control or NC group. 
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4.1.5. HDAC expression in rat RV and kidney 
HDAC1 and HDAC5 protein expression in RV from hypoxic rats was increased during 
hypoxia exposure as they were in lung tissues. Interestingly, no significant changes in 
HDAC1 expression were observed in kidney (Figure 3.6). 
 
 
Figure 3.6. Protein expression levels in tissue extracts from rats exposed to hypoxia for different time points. 
(A) HDAC1 in RV, (B) HDAC5 in RV, (C) HDAC1 in kidney, (D) representative bands.  NC: normoxia 
control; 2D: hypoxia for two days; 1W: hypoxia for one week; 2W: hypoxia for two weeks. The data are 
presented as mean± SEM of fold change relative to NC. n≥3 in each group. * p<0.05 compared with NC 
group. 
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4.2. Immunohistochemistry 
HDAC1 immunoreactivity was predominantly localized to the nuclei of vascular cells and 
weakly to epithelium, while HDAC5 displayed a relatively specific distribution in 
cytoplasm of vascular cells in IPAH lung tissues (Figure 3.7B). Both of HDAC1 and 
HDAC5 exhibited weak expression in control lobectomy lung tissues (Figure. 3.7A) 
 
Figure 3.7. Distribution of HDAC1 and HDAC5 immunostaining in human lungs. (A) Sections from 
lobectomy, (B) Sections from patients with IPAH. Both HDAC1 and HDAC5 are stained in brown with HE 
counterstaining. 
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In lungs from chronically hypoxic rats, HDAC1 showed a similar distribution of 
expression to that seen in IPAH patients, prominent in the nuclei in the vascular cells of 
muscularized vessels. This co-localized to Ki67 staining. HDAC5 was principally 
expressed in the cytoplasm of vascular cells lining the vascular wall. However, nuclear 
staining of HDAC5 was observed as well. Immunoreactivity of both of HDAC1 and 
HDAC5 were weak in the epithelium and alveolar cells (Figure. 3.8). 
 
Figure 3.8. Distribution of HDAC1 and HDAC5 immunostaining, co-localized to van Gieson’s elastic 
(EVG) and Ki67 stain, in lungs from rats exposed to chronic hypoxia for 4 weeks. HDAC1, HDAC5 and 
Ki67are stained in brown with HE counterstaining. 
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4.3. HDAC1 expression in BMPR2 deficient mice 
Elevation of mean PAP and RV hypertrophy were noted in transgenic BMPR2 deficient 
mice in normal air. Exposure to chronic hypoxia induced further increase in mean PAP 
and RV hypertrophy in BMPR2 deficient mice (Figure 3.9). 
 
Figure 3.9. Haemodynamic phenotype of transgenic mice exposed to hypoxia for two weeks. (A) PAP, 
RVSP, right ventricular systolic pressure, (B) RV/LV+sep, right ventricular hypertrophy. WT: wild type; 
BMPR2: BMPR2 deficient. The data are presented as mean± SEM. n≥7 in each group. * p<0.05, ** p<0.005, 
*** p<0.0005, **** p<0.0001 compared with WT normoxia, ## p<0.005, ### p<0.0005 compared with 
BMPR2 normoxia, x p<0.05, xxx p<0.0005 compaed with BMPR2 hypoxia.  
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No significant differences in HDAC1 or Bcl-2 protein expression were found between 
lungs from wild type and BMPR2 deficient mice under normoxic condition (Figure 3.10). 
However, both were significantly increased in BMPR2 deficient mice after 2 week 
hypoxia exposure (HDAC: p< 0.001, Bcl-2: p<0.05, Figure 3.11). 
 
Figure 3.10. Protein expression levels in lung extracts from transgenic mice exposed to normal air. (A) 
HDAC1, (B) Bcl-2. WT: wild type; BMPR2: BMPR2 deficient. The data are presented as mean± SEM of 
fold change relative to WT. n=7 in each group. 
 
Figure 3.11. Protein expression levels in lung extracts from transgenic mice exposed to hypoxia for two 
weeks. (A) HDAC1, (B) Bcl-2. WT: wild type; BMPR2: BMPR2 deficient. The data are presented as mean± 
SEM of fold change relative to WT. n=7 in each group. * p<0.05, ** p<0.005 compared with WT group. 
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5. Discuission 
Analysis of HDAC expression provided the following findings: 
 Expression levels of HDAC1, HDAC5 and Bcl-2 were significantly elevated in lungs 
from patients with IPAH. 
 Expression levels of HDAC1, HDAC5 and Bcl-2 were significantly elevated in lungs 
from chronically hypoxic rats. 
 Expression levels of HDAC1 and HDAC5 were significantly elevated in RV from 
chronically hypoxic rats. 
 HDAC1 and HDAC5 expression was prominent in remodelled pulmonary vessles. 
 Expression levels of HDAC1 and Bcl-2 were significantly elevated in lungs of 
BMPR2-deficient mice exposed to hypoxia. 
This study demonstrated for the first time alternations in the protein expression of class I 
and class II HDACs in lungs from IPAH patients. The pattern of HDAC expression was 
replicated in lungs from rats with hypoxia-induced pulmonary hypertension. The hypoxia 
model is characterised by the rapid development of structural changes in pulmonary 
arterioles, involving muscularization, proliferation of vascular cells and inflammatory cell 
infiltration 244.  
Rats exposed to continuous hypoxia developed elevated mean PAP and RV hypertrophy 
in the first two weeks. Similar altered expression of all the examined HDACs, including 
class I, HDAC1, 2, 3, and class II, 4, 5, 7, in this model was shown in the rat model and 
human IPAH,. Among them, HDAC1 and HDAC5 were shown prominently increased in 
IPAH patients and in both lungs and RV from hypoxic rats, along with hypoxia-induced 
physiological changes. HDAC expression in the kidneys was unchanged in these animals, 
indicating that the observed HDAC changes in lungs and RV are related to the 
pathological events in pulmonary circulation induced by hypoxic stimulus, indicating 
tissue-specific involvement of HDACs.  
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Immunohistochemical assessment revealed strong nuclear overexpression of HDAC1 and 
increased cytoplasmic expression of HDAC5 lining at the remodelled vascular lesions, co-
localizing to nuclear expression of the proliferative marker, Ki67 245.  
HDACs are normally expressed in all eukaryotic cells and regulate many genes engaged 
in cell proliferation, differentiation and survival. Aberrant expression and recruitment of 
HDACs to transcriptional regions repressing certain tumour suppressor genes have been 
implicated in cancerous transformation. A variety of specific alternations in individual 
HDAC expression has been described in different types of human malignancies, especially 
class I HDACs. For example, HDAC1 is overexpressed in gastric, pancreatic, colorectal, 
prostate and hepatocellular cancers, and correlates with poor prognosis 158, 160, 246, 247. The 
increase in HDAC1 and HDAC5 in human IPAH and lungs from pulmonary hypertensive 
rats, together with the increased expression in survival marker Bcl-2, are consistent with 
the proliferative, apoptosis-resistant vascular pathology that characterizes pulmonary 
hypertension. 
On the other hand, decreased expression of the other class I HDACs, HDAC2 and 
HDAC3, was observed in the diseased lungs. It has been known that individual HDACs 
may partially compensate for one another 248. HDAC2, which is genetically homologous 
to HDAC1 with 86% identity at amino acid level, has considerable functional overlapping 
and redundancy with HDAC1 in the regulation of proliferation, apoptosis and cancerous 
transformation 249. Many reports have shown up-regulation of one of them occurs with 
inactivation of the other 250-252. However, more recent studies have indicated that HDAC1 
has distinct and noncompensable functions in the regulation of cell proliferation and 
tumourigenesis 248. HDAC3, crucial in lipid metabolism and endothelial integrity, may 
have more interactions with other HDACs by shuttling between the nucleus and cytoplasm 
253
. In my study, the reduction of HDAC2 and HDAC3 may be explained a compensatory 
reaction to HDAC1 overexpression. In addition to HDAC5, expression of other class II 
HDACs, especially HDAC7, was also increased in the diseased lungs. HDAC7 has  
recognized involvement in endothelial function, smooth muscle cell differentiation, 
angiogenesis and vascular remodelling 213-215. Increased expression of HDAC7 has been 
reported in cancer as well 254.  
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The consistent changes in expression in patients and hypoxic rats suggest a role for 
HDACs in the pathogenesis of PH. The predominant localization of HDAC1 and HDAC5 
to distal muscularized vessels reveals that they appear to participate in the remodelling 
processes and supports these HDACs as drug targets.  
While HDAC and Bcl-2 expression was no different between wild type mice and 
transgenic BMPR2-deficient mice under normoxic conditions, both were significantly 
increased in transgenic mice under hypoxic stimuli. Although a genetic linkage between 
BMPR2 mutations and human PAH has been identified, the typically low penetrance 
indicates that additional factors are required to initiate the disease. As a member of the 
TGB-β superfamily, inflammatory hits have been implicated in BMPR2-predisposing PH. 
This result suggests a possible role for HDAC1 in BMPR2 signalling during hypoxia-
induced PH.  
A complex range of downstream signalling of BMPR2 mutations have been proposed, 
among which variations within the smad family maybe potentially responsible for the 
infrequent cause to the disease 255. However, the knowledge of epigenetic links to BMPR2 
is less known. Previous studies revealed that smad-dependent recruitment of HDAC1 can 
modulate BMP transcriptional activity 256. Further investigation is worthy to establish the 
epigenetic insight of BMPR2 in PH. 
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Chapter 4:  
HDAC INHIBITORS PARTIALLY 
REVERSE HYPOXIA-INDUCED PH 
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1. Introduction 
Animal models provide invaluable information regarding the pharmacological effects of 
drugs and mechanistic insights into disease development.. Several animal models have 
been developed to generate a PAH phenotype and resemble human pathology. 
Unfortunately, none of them perfectly recapitulates human PAH.  The chronic hypoxic rat 
model is the most commonly used due to its predictability and reproducibility within a 
wide range of animal species. Following the findings of alternations in HDAC expression 
in the hypoxic model, pharmacological experiments were performed to understand its 
possible relationship to the PH phenotype. Two protocols typically conducted in 
pharmacological research were used, namely prevention and recovery. The former refers 
to treatment given before disease development while the latter means treatment given to 
groups with established PH. 
In this chapter, the effect of two HDAC inhibitors, VPA and SAHA, were evaluated. The 
rationale of the investigation is that both VPA and SAHA have been approved for human 
use and are well tolerated clinically. Thus, both can be translated to treat human PAH. In 
the first part, the preventive effects of VPA were examined since increased HDAC 1 
expression was seen in both rat and human lungs, and in the next part, the effects of both 
were assessed under the recovery protocol. 
 
2. Objective 
• To evaluate the pharmacological effects of VPA on the development of PH in the 
chronically hypoxic rat model. 
• To evaluate the pharmacological effects of VPA and SAHA on established chronic 
hypoxia-induced PH in rats. 
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3. Methods and Protocols 
3.1. Hypoxia prevention study: 
Male Spraque-Dawley rats (220-250 gram) were divided into four groups (n=6 each 
group):  
1) NC: normoxia control  
2) HC: hypoxia control 
3) low VPA: hypoxia with low dose VPA 100mg/kg/day p.o. (in drinking water)  
4) high VPA: hypoxia with high dose VPA 300mg/kg/day p.o. 257 
Animals were weighed every other day. Treatment dose was adjusted by weighing 
drinking bottles daily and calculating intake. Animals were pre-treated for four days and 
then exposed to hypoxia in the chamber as previously described for 2 weeks (as the 
flowchart below). The treatment was continued during the exposure. 
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3.2. Hypoxia recovery study: 
Male Spraque-Dawley rats (220-250 gram) were divided into five groups (n=9-12 each 
group):  
1) NC: normoxia control 
2) 2WH: two-week hypoxia control (starting point of treatment) 
3) 4WH: four-week hypoxia control  
4) VPA: hypoxia with VPA 300mg/kg/day p.o  
5) SAHA: hypoxia with SAHA 50mg/kg/day p.o. (in drinking water with HOP-β-CD) 258 
Animals were weighed every other day. Treatment dose was adjusted by weighing 
drinking bottles daily and calculating intake. Animals were exposed to hypoxia for four 
weeks, and treatment was begun 2 weeks before the end of experiment (as the flowchart 
below). 
 
 
 
At the end of exposure, haemodynamic parameters were measured and tissues were 
collected for further biochemical and histological investigation immediately as described 
in Methods. 
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4. Results 
4.1. VPA prevents hypoxia-induced PH: haemodynamics 
Two-week exposure to hypoxia resulted in a two-fold increase in mean PAP (HC: 
33.6±0.7 mmHg v.s. NC: 16.7±0.5 mmHg, p<0.01, Figure 4.1A), RVSP (HC: 54.2±2.6 
mmHg v.s. NC: 26.1±0.8 mmHg, p<0.005, Figure 4.1B) and RVH (HC: 0.58±0.02 v.s. 
NC: 0.26±0.01, p<0.005, Figure 4.1C) compared to the control group. 
VPA treatment with two doses, 100mg/kg/day or 300mg/kg/day, significantly attenuated 
the hypoxia-induced rise in mean PAP (low VPA: 26.7±1.0 mmHg, high VPA: 24.1±1.2 
mmHg v.s. HC: 33.6±0.7 mmHg, p<0.01, Figure 4.1A), but the mean PAP in VPA 
treatment group remained higher than the control group. VPA treatment, 100mg/kg/day 
and 300mg/kg/day, also attenuated the increased RVSP (low VPA: 44.1±3.6 mmHg, high 
VPA: 40.2±2.5 mmHg v.s. HC: 54.2±2.6 mmHg, Figure 4.1B). However, only the high 
dose VPA group showed significant reduction (p<0.005).  
Hypoxia-induced RV hypertrophy was significantly attenuated by low dose VPA (-73%) 
and high dose (-89%) treatment (low VPA: 0.34±0.01, high VPA: 0.30±0.02, p<0.005, 
Figure 4.1C). A trend towards a dose-dependent effect was noted (p=0.0645). 
No significant changes were found in heart rate and systemic mean BP between groups 
(Figure 4.1D). The physiological data from the hypoxia prevention study is presented in 
Table 4.1. 
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Figure 4.1. Prevention study: VPA was administered during 2 weeks hypoxia. (A) PAP, mean pulmonary 
artery pressure, (B) RVSP, right ventricular systolic pressure, (C) RV/LV+sep, right ventricular hypertrophy, 
(D) Mean BP, systemic mean blood pressure. NC: normoxia; HC: hypoxia for 2 weeks; low VPA: hypoxia 
with VPA 100 mg/kg/day; and high VPA: hypoxia with VPA 300 mg/kg/day.  The data are presented as 
mean± SEM. n=6 in each group. * p<0.01, ** p<0.05 compared with HC, # p<0.05, ## p<0.005 compared 
with NC.  
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Group NC HC Low VPA High VPA 
N number 6 6 6 6 
RV 
Systolic (mmHg) 26.1±0.8 54.2±2.6 44.1±3.6 40.2±2.5 
Max dp/dt (mmHg/s) 688±41 1429±55 966±138 879±99 
Pulmonary 
Mean (mmHg) 16.7±0.5 33.6±0.7 26.7±1.0 24.1±1.2 
Pulse (mmHg) 11.4±0.7 24.0±7.1 22.6±1.5 16.2±2.5 
Systemic 
Pressure (mmHg) 87.3±2.3 82.8±5.3 78.5±2.8 79.6±2.2 
Heart rate 308±21 383±15 340±17 299±26 
General 
BW (gram) 286±8 266±3 250±5 233±4 
RV/LV+septum 0.26±0.01 0.58±0.02 0.34±0.01 0.30±0.02 
RV/BW 0.61±0.03 1.09±0.03 0.74±0.02 0.67±0.04 
Left lung/BW 1.53±0.05 2.27±0.07 2.13±0.05 2.09±0.11 
NC: normoxia control; HC: hypoxia control; Low VPA: VPA 100mg/kg/day; High VPA: VPA 300mg/kg/day; 
BW:body weight 
 
Table 4.1. The physiological data of hypoxia prevention study. 
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4.2. VPA prevents hypoxia-induced PH: histology 
Transverse lung sections stained with van Giessen’s elastic method showed a substantial 
increase in the percentage of muscularized distal pulmonary vessels (HC: 59.2±3.6% v.s. 
NC: 5.7±1.2%, p<0.005, Figure 4.2). This was attenuated (-~20%) with VPA treatment 
(low VPA: 46.1±5.7%; high VPA: 47.9±3.8% v.s. HC: 59.2±3.6%, p<0.01, Figure 4,2). 
Lung mass was augmented with hypoxia exposure but no significant effect of VPA was 
seen in the study (Figure 4.2). 
 
 
 
Figure 4.2. Effects of VPA on hypoxia-induced pulmonary vascular muscularization. (A,B,C,D) Histology 
figures with van Gieson’s elastic stain, (E) Quantified by the percentage of vessels with double elastic 
lamina, (F) Left lung weight over body weigtht ratio. NC: normoxia; HC: hypoxia for 2 weeks; low VPA: 
hypoxia with VPA 100 mg/kg/day; and high VPA: hypoxia with VPA 300 mg/kg/day.  The data are 
presented as mean± SEM. n=6 in each group. * p<0.01 compared with HC, ## p<0.005 compared with NC.  
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4.3. VPA and SAHA partially reverse hypoxia-induced PH: 
haemodynamics 
To further examine the effects of HDAC inhibition, VPA and the pan-HDAC inhibitor, 
SAHA, were investigated after established PH in the rat. The increase in mean PAP, 
RVSP and RVH after two-week hypoxia were maintained for the following two weeks 
(PAP: 2WH: 30.0±1.3 mmHg, 4WH: 31.9±2.0 mmHg v.s. NC: 15.6±0.5 mmHg, 
p<0.0001; RVSP: 2WH: 47.0±3.2 mmHg, 4WH: 49.0±4.0 mmHg v.s. NC: 24.7±0.8 
mmHg, p<0.0001; RVH: 2WH: 0.46±0.02, 4WH: 0.45±0.02 v.s. NC: 0.29±0.01, 
p<0.0001, Figure 4.3).  
Treatment with either VPA or SAHA from the second to the fourth week significantly 
reduced mean PAP (VPA: 23.3±1.6 mmHg, SAHA: 23.2±1.8 mmHg v.s. 4WH: 31.9±2.0 
mmHg, p<0.005, p<0.01, respectively, Figure 4.3A). Compared to baseline, these two 
inhibitors partially reversed the hypoxia-induced increased mean PAP (VPA: 23.3±1.6 
mmHg; SAHA: 23.2±1.8 mmHg v.s. 2WH: 30.0±1.3 mmHg, p<0.01, Figure 4.3A). 
Similarly, the increased RVSP was significantly reduced by VPA and SAHA treatment, 
compared to both control group and baseline (VPA: 37.1±3.3 mmHg; SAHA: 32.1±2.4 
mmHg v.s. 4WH: 49.0±4.0 mmHg, p< 0.005, p<0.05, respectively; v.s. 2WH: 47.0±3.2 
mmHg, p<0.05, Figure 4.3B). 
Consistent with the reduction in blood pressure, RVH was also attenuated by VPA (-
56.5%) and SAHA (-59.7%) treatment (VPA: 0.36±0.01 and SAHA: 0.35±0.01 v.s. 
4WHC: 0.45±0.02, p<0.005; Figure 4.3C). Compared to baseline, both HDAC inhibitors 
achieved partial reversal of RVH (VPA: -58.8% and SAHA -61.8%) (VPA: 0.36±0.01 
and SAHA: 0.35±0.01 v.s. 2WH: 0.46±0.02, p<0.005; Figure 4.3C). 
No significant changes in heart rate or systemic SBP were observed (Figure 4.3D). The 
physiological data from the hypoxia recovery study is shown in Table 4.2. 
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Figure 4.3. Recovery study: VPAand SAHA were administered during last 2 weeks of four-week hypoxia 
exposure. (A) PAP, mean pulmonary artery pressure, (B) RVSP, right ventricular systolic pressure, (C) 
RV/LV+sep, right ventricular hypertrophy, (D)SBP, systemic systolic blood pressure. NC: normoxia; 2WH: 
hypoxia for 2 weeks; 4WH: hypoxia for 4 weeks; VPA: hypoxia with VPA 300 mg/kg/day; SAHA: hypoxia 
with SAHA 50 mg/kg/day.  The data are presented as mean± SEM. n≥9 in each group. * p<0.05, ** p<0.005 
compared with 4WH, x <0.05, xx <0.005 compared with 2WH, ## p<0.005, ### p<0.0005 compared with 
NC.  
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Group NC 4WH VPA SVPA 
N number 12 12 12 9 
RV 
Systolic (mmHg) 24.7±0.8 49.0±4.0 37.1±3.3 32.1±2.4 
Max dp/dt (mmHg/s) 783±90 1796±158 1433±160 1474±163 
Pulmonary 
Mean (mmHg) 15.6±0.5 31.9±2.0 23.3±1.6 23.2±1.8 
Pulse (mmHg) 9.7±1.4 18.8±1.8 17.6±2.9 15.3±3.5 
Systemic 
Pressure (mmHg) 86.8±1.9 92.0±6.0 90.3±4.1 89.0±5.7 
Heart rate 328±24 335±25 322±17 341±19 
General 
BW (gram) 379±13 391±11 391±8 292±15 
RV/LV+septum 0.29±0.01 0.45±0.02 0.36±0.01 0.35±0.01 
RV/BW 0.60±0.03 0.77±0.08 0.65±0.04 0.67±0.03 
Left lung/BW 1.13±0.03 1.34±0.02 1.43±0.04 1.58±0.06 
NC: normoxia control; 4WH: hypoxia control; VPA: VPA 300mg/kg/day; SAHA: SAHA 50mg/kg/day; 
BW:body weight 
 
Table 4.2. The physiological data of hypoxia recovery study. 
 
4.4. VPA and SAHA partially reverse hypoxia-induced PH: 
histology 
The percentage of muscularized peripheral distal pulmonary arteries was significantly 
increased after two-week hypoxia and maintained at a high level (2WH: 59.2±0.6%, 4WH: 
58.4±2.5 v.s. NC: 5.7±0.5%, p<0.001, Figure 4.4). Treatment with VPA and SAHA 
showed a significant reduction in vascular muscularization compared to two-week and 
four-week hypoxia (VPA: 48.1±2.1%, SAHA: 47.0±2.6% v.s. 2WH: 59.2±0.6%, p<0.005, 
p<0.05, respectively; v.s. 4WH: 58.4±2.5, p<0.05, Figure 4.4). 
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Figure 4.4. Effects of VPA and SAHA on hypoxia-induced pulmonary vascular muscularization. (A) 
Histology figures with van Gieson’s elastic stain, (B) Quantified by the percentage of vessels with double 
elastic lamina. NC: normoxia; 2WH: hypoxia for 2 weeks; 4WH: hypoxia for 4 weeks; VPA: four-week 
hypoxia with VPA 300 mg/kg/day; and SAHA: four-week hypoxia with SAHA 50 mg/kg/day.  The data are 
presented as mean± SEM. n≥6 in each group. * p<0.01 compared with 4WH, x p<0.05, xx p<0.005 
compared with 2WH, # p<0.05 compared with NC.  
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4.5. VPA and SAHA partially reverse hypoxia-induced PH: 
biochemistry 
4.5.1. Protein expression 
Protein analysis of lung tissues from these animals revealed four-week exposure to 
hypoxia induced a 35% increase in Bcl-2 expression levels. Treatment with either VPA or 
SAHA reduced the Bcl-2 expression to near the normal range (p<0.05). In contrast, both 
treatments increased p21 expression levels compared to hypoxia control (p<0.05) (Figure 
4.5). 
 
 
Figure 4.5. Protein expression levels in rat lung extracts from chronic hypoxia treatment study. (A) Bcl-2, 
(B) p21. NC: normoxia; 4WH: hypoxia for 4 weeks; VPA: hypoxia with VPA 300 mg/kg/day; SAHA: 
hypoxia with SAHA 50 mg/kg/day. Data are presented as mean ± SEM of fold change relative to NC. n=6.  
* p<0.05 compared with 4WH, # p<0.05 compared with NC. 
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4.5.2. Histone acetylation 
Consistent with HDAC inhibition, H3 and H4 acetylation levels were both significantly 
increased by over 60% in SAHA-treated lungs (p<0.05). However, treatment with VPA 
resulted in slight but not statistically significant elevations in histone acetylation (Figure 
4.6A-C).  
Interestingly, total histone levels were also elevated in the rat lungs with hypoxia 
exposure, and this was reduced by VPA and SAHA treatment (Figure 4.6D). The total 
histone levels in lungs were observed to correlate with mean PAP (r=0.35, p<0.05).  
 
Figure 4.6. Histone expression levels in rat lung extracts from chronic hypoxia treatment study. (A) 
Acetylated H3, (B) Acetylated H4, (C) Total histone levels, (D) The correlation between total histone levels 
and mean PAP, r=0.35, n=39, p<0.05. NC: normoxia; 4WH: hypoxia for 4 weeks; VPA: hypoxia with VPA 
300 mg/kg/day; SAHA: hypoxia with SAHA 50 mg/kg/day. Data are presented as mean ± SEM of fold 
change relative to NC. n=6. * p<0.05 compared with 4WH, # p<0.05 compared with NC. 
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Further analysis of the single lysine residue on histone tails, lysine 3 on H3 (H3K9) and 
lysine 12 on H4 (H4K12), revealed an increase in H3K9 acetylation under SAHA 
treatment (p<0.05). However, a discrepancy was observed in H4K12 acetylation in that 
VPA and SAHA treatment led to mild increases to the same extent (Figure 4.7). 
 
 
Figure 4.7. Histone expression levels in rat lung extracts from chronic hypoxia treatment study. (A) 
AcH3K9: acetylated H3 lysine 9, (B) AcH4K12: acetylated H4 lysine 12. NC: normoxia; 4WH: hypoxia for 
4 weeks; VPA: hypoxia with VPA 300 mg/kg/day; SAHA: hypoxia with SAHA 50 mg/kg/day. Data are 
presented as mean ± SEM of fold change relative to NC. n=6. * p<0.05 compared with 4WH. 
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4.5.3. mRNA expression 
The mRNA expression of HIF-1α was significantly increased by exposure to hypoxia, 
compared to normoxia control (p<0.05). Both VPA and SAHA treatment attenuated this 
rise (p<0.05, Figure 4.8A). There was no significant change in BMPR-2 expression in 
lungs during chronic hypoxia exposure. However, VPA but not SAHA treatment induced 
a significant increase in BMPR-2 expression in comparison to 2WH and 4WH group 
(P<0.01) (Figure 4.8B). 
 
 
Figure 4.8. mRNA expression levels in rat lung extracts from chronic hypoxia treatment study. (A) HIF-1α, 
(B) BMPR2. NC: normoxia; 2WHL hypoxia for 2 weeks; 4WH: hypoxia for 4 weeks; VPA: hypoxia with 
VPA 300 mg/kg/day; SAHA: hypoxia with SAHA 50 mg/kg/day. Data are presented as mean ± SEM of fold 
change relative to NC. n=6.  * p<0.05 compared with 4WH, x p<0.05 compared with 2WH, # p<0.05 
compared with NC.  
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5. Discussion 
5.1. VPA prevents hypoxia-induced PH 
The VPA prevention study in the hypoxia-induced PH model provided the following 
findings: 
 VPA treatment was well tolerated in the treated animals without perceptible adverse 
effects. 
 VPA treatment significantly prevented elevation of pulmonary arterial and right 
ventricular pressure without influence on systemic blood pressure. 
 VPA treatment significantly prevented right ventricular hypertrophy.  
 VPA treatment significantly prevented pulmonary distal vascular remodelling. 
 The pharmacological effects were in a dose-dependent trend, but not statistically 
significant. 
These data suggest that VPA has protective effects against hypoxia-induced PH phenotype, 
physiologically and histologically. However, the direct contribution of HDAC inhibition 
cannot be determined from this study. VPA is a multi-functional agent with diverse 
molecular targets, especially GABAergic and sodium channel blocking effects, which 
might affect blood pressure 169. Actually, in the animal experiment, a possible synergic 
effect of VPA with the anaesthesic midazolam, which can enhance GABA function on its 
receptor, was noted. A caution here is that the multiple non-HDAC-related functions of 
VPA may obscure its pharmalogical effects. In fact, even though VPA has been 
commonly prescribed for neuropsychiatric disorders, especially bipolar disorder, the 
mechanisms of action are still far from fully understood. Seemingly, GABAergic 
transmission plays a major role in mood-stabilization, but this alone is insufficient to 
explain the long-term effects of VPA. A variety of adjuvant mechanisms have been 
proposed and  explored 257, e.g. inactivation of GSK3 259, alternations in lipid metabolism 
260and promotion of neurotropic/neuroprotective factors261. However, their clinical 
relevance remains to be validated. In this study, the used dose was adopted according to 
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literature data which show to reach the therapeutic ranges in serum concentration of 
humans 257, 262. Although, dose-dependent effects of VPA based on the two chosen doses 
were reported in previous studies, they were not statistically significant in the 
haemodynamics.  
Nevertheless, the value of VPA is the fact that it has been widely prescribed for a long 
time and well tolerated according to the record. Its pharmacology and related side effects 
have been well documented that promise the translational accessibility to other clinical 
purposes. Additional advantages can be attributed to the cost and easy administration. 
5.2. VPA and SAHA partially reverse hypoxia-induced PH 
Treatment study in hypoxia-induced PH model provided the following findings: 
 VPA and SAHA treatment was well tolerated in the treated animals without 
perceptible adverse effects, but decelerate the growth rate 
 VPA and SAHA treatment significantly partially reversed elevation of pulmonary 
arterial and right ventricular pressure without influence on systemic blood pressure. 
 VPA and SAHA treatment significantly partially reversed right ventricular 
hypertrophy.  
 VPA and SAHA treatment significantly partially reversed pulmonary distal vascular 
remodelling. 
 VPA and SAHA treatment significantly decreased Bcl-2 and increased p21 
expression in lung tissues. 
 VPA and SAHA treatment significantly increased histone acetylation in lung tissues. 
 VPA and SAHA treatment significantly decreased HIF-1α expression in lung tissues. 
Chronic treatment with VPA or SAHA had remarkable effects on hypoxia-induced PH in 
the rat. Both VPA and SAHA treatment attenuated the elevation in mean PAP and RVSP 
by around 50%, RV hypertrophy by over 60% and pulmonary vascular muscularization by 
20%. VPA treatment seemed to have more potent effects on the RV than the pulmonary 
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vasculature. Quantification of vascular muscularisation is more challenging than 
measuring heart weight but this is not the only explanation.  
The inhibitory effects of VPA and SAHA on HDAC activity is supported by increased 
lung histone H3 and H4 acetylation levels. Compared with VPA, SAHA had a more 
significant effect on histone acetylation. VPA inhibits the activity of class I HDACs, but 
SAHA is a broad-spectrum inhibitor covering all the zinc-dependent HDACs (class I, II 
and IV). This may explain the higher potency on total histone acetylation. HDAC inhibitor 
effects may be lysine-specific. Modification of specific lysines in histone tails have been 
linked to gene regulation in cancerous transformation, such as H3K9 and H4K16 263, 264. 
The analysis of lysine acetylation showed that acetylation of H3K9 highly correlated to 
acetylation of total H3 but the acetylation of H4K12 was paradoxical, VPA and SAHA 
seems to induce similar levels of acetylation. This finding suggests that the lysine-
specificity of different HDAC inhibitors may contribute to the different pharmacological 
effects. 
Biochemical analysis provides a clue that the therapeutic effects of VPA and SAHA on 
hypoxia-induced PH might be, at least in part, attributed to anti-proliferation. This 
hypothesis is evidenced by the following findings: 
 The elevated protein expression of Bcl-2 in lungs induced by hypoxia was attenuated 
by VPA and SAHA. Increased levels of Bcl-2 prevents the release of cytochrome c 
from the mitochondrial intermembrane space and results in resistance to apoptosis. 
Inhibition of overexpressed Bcl-2 shifts back the imbalance and induces apoptosis 265. 
Both VPA and SAHA have been reported to act on neoplastic disorders through 
downregulation of Bcl-2, and simultaneous activation of its counterparts, pro-
apoptotic factors, Bid and Bim 184, 185, thereby increasing the ratio of pro- to anti-
apoptotic proteins. In the hypoxia study, both of them exerted similar anti-
proliferative effects on PH rats, suggesting pulmonary vascular remodelling was one 
of the targets. 
 In parallel with downregulation of Bcl-2, VPA and SAHA upregulated the CDK 
inhibitor p21, leading to cell cycle arrest. P21 serves as a gatekeeper in cell cycle 
progression at G1/S phase and normally regulated by tumour suppressor protein p53 
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266
. Induction of p21 arrests cell growth and inhibits proliferation. Growing evidence 
has indicated that most HDAC inhibitors promote p21 expression in both a p53-
dependent and p53-independent manner 174, 176. Furthermore, cell-growth-arrest 
induced by increased p21 expression has been associated with selective sensitivity to 
HDAC inhibitor-induced cell death in transformed cells 185. The shifts in p21 and 
Bcl-2 expression give support to the view that HDAC inhibition participates in the 
restoration of balance between proliferation and apoptosis in pulmonary vascular 
remodelling. 
 Total histone levels were increased in the chronic hypoxic rat lung and the rise was 
attenuated by treatment with VPA or SAHA. Total histone levels correlate with mean 
PAP. Upregulation of core histones may represent an increase in the chromatin 
content of cells compatible with a hyper-proliferative status. This observation also 
supports the anti-proliferative effects of VPA and SAHA. 
Previous studies have revealed that HDACs regulate angiogenesis via HIF-VEGF 
transduction. HIFs are the principle mediators of the tisue response to decreased oxygen 
level. HIFs increase oxygen delivery through upregulating several angiogenesis genes, 
such as VEGF, and adjust oxygen utilization through metabolic shifts, both of which 
promote survival in hypoxic conditions. Overexpression of HADC1 upregulates HIF-1α 
and vascular endothelial growth factor (VEGF) indirectly, via suppression of p53 and von 
Hippel–Lindau (VHL) genes expression 267. HDAC1 and HDAC3 have been shown to 
directly regulate HIF-1α stability and transcriptional activity via interaction with the 
oxygen-dependent degradation domain 268. HIF-1α plays a key role in hypoxia-induced 
pulmonary hypertension but is also upregulated in human IPAH 269. The increased HIF-1α 
mRNA levels in hypoxic rat lungs were reduced by both VPA and SAHA treatment, 
indicating a role for anti-angiogenesis in the therapeutic effects in addition to anti-
proliferation.   
Interestingly, BMPR2 mRNA expression in hypoxic rat lungs was upregulated by VPA 
but not SAHA treatment. Restoring BMPR2 function has been considered to be a 
therapeutic option in PAH but may be challenging and inadequate for reversing the 
pathological changes 116. The dissociation between VPA and SAHA in BMPR2 expression 
suggests class-dependent functions of HDAC inhibition.  
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In conclusion, VPA and SAHA treatment prevents and ameliorates chronic hypoxia-
induced PH as evident from improvement of pulmonary and cardiac haemodynamics, 
reversal of RV hypertrophy and reduction of pulmonary vascular muscularization. The 
underlying mechanisms can be attributed to induction of apoptosis and inhibition of 
proliferation. 
The major limitation of this study is that chronic hypoxia can not fully reflect the 
pathology of PAH in humans. For example, hypoxia exposure does not lead to intimal 
fibrosis or plexiform lesions 270. Whether hypoxia stimuli are obligatory for the initiation 
of PAH is controversial. This model is more relevant to PH from pre-existing lung 
diseases such as chronic obstructive pulmonary disease, pulmonary parenchymal diseases 
and living at high altitude (WHO class III). In addition, the HDAC doses used in the study 
were adopted from published studies in cancer, with moderate to high dose within the 
range of safe tolerated doses. A more exacting experimental design would explore a series 
of different doses. 
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Chapter 5:  
HDAC INHIBITORS AMELIORATE 
MCT-INDUCED PH 
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1. Introduction 
The limitation of animal experiments is the fact that no any existing animal model 
completely reproduces human diseases. Using more than one model to validate the 
pharmacological effects raises more confidence and rationale towards clinical trials. 
Following the findings from hypoxia experiments that both VPA and SAHA seem to 
alleviate the PH phenotype, it is worthwhile to further testify the pharmacological effects 
on other models. As chronic hypoxia model is regarded as a model for more reversible and 
less severe PH, MCT-induced PH is relatively irreversible and more severe, especially in 
terms of vascular remodelling and inflammation.  
MCT is a toxic pyrrolizidine alkaloid, activated in the liver to become active form and 
resulting in direct endothelial injury in pulmonary vessels. A single subcutaneous or 
intraperitoneal injection of MCT can simply develop PH with striking vascular 
remodelling, neointimal thickening, dramatic perivascular inflammatory cells infiltration 
and eventually lethality. MCT model is also significantly associated with advanced RV 
hypertrophy and dysfunction 271. Therefore, MCT model offers a useful platform to 
investigate the pharmaceutical effects on pulmonary vascular remodelling and 
inflammatory reactions more specifically.  
In this chapter, the effects of chronic treatment of VPA and SAHA were tested in 
established MCT-induced PH. To avoid animal mortality from rapid progression of PH 
and right heart failure, end point haemodynamic, histological and biochemical assessment 
were performed in four weeks after MCT injection. 
 
2. Objectives 
• To evaluate the pharmacological effects of VPA and SAHA on established MCT-
induced PAH in rats. 
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3. Methods and Protocols 
Male Spraque-Dawley rats (220-250 gram) were divided into five groups (n=6-12 each 
group):  
1) Ctrl: healthy control 
2) M12: MCT for 12 days 
3) M26: MCT for 26 days 
4) VPA: MCT-injected with VPA 300mg/kg/day p.o  
5) SAHA: MCT-injected with SAHA 50mg/kg/day p.o. (in drinking water with HOP-β-
CD) 258 
MCT was injected subcutaneously into rats on Day 0. End point measurement of M12 
group was performed on Day 12 as starting point of treatment. Treatment with VPA or 
SAHA was administrated through drinking water as previously described for the 
following two weeks. Animals were weighed every other day. Treatment dose was 
adjusted accordingly by weighing drinking bottles daily. End point measurement of other 
groups was done on Day 26 (as the flowchart below). 
 
 
 
 
  
120
4. Result 
4.1. VPA and SAHA ameliorate MCT-induced PH: 
haemodynamics 
MCT led to a minimal elevation in mean PAP 12 days after injection and rapidly reached 
up to over 30mmmHg in 26 days (M12: 17.9±1.6 mmHg, M26: 31.1±2.0 mmHg v.s. Ctrl: 
16.1±0.6 mmHg, p<0.0001, Figure 5.1A). MCT did not cause changes in RVSP as well as 
RVH in 12 days but increased significantly both in 26 days (RVSP: M12: 26.1±2.2 
mmHg, M26: 54.9±4.5mmHg v.s. Ctrl: 25.9±0.8 mmHg, p<0.005; RVH: M12: 0.28±0.01, 
M26: 0.46±0.04 v.s. Ctrl: 0.27±0.01, p<0.005, Figure 5.1B,C).  
Treatment with SAHA for two weeks significantly reduced mean PAP while VPA only 
cause slight reduction without statistical significance due to higher difference within 
group (VPA: 27.6±2.4 mmHg, SAHA: 21.3±1.4 mmHg v.s. M26: 31.1±2.0mmHg, 
p<0.05, Figure 5.1A). Similarly, SAHA reduced MCT-induced elevation of RVSP 
significantly while VPA tended to reduce but not significantly (VPA: 46.7±4.7 mmHg, 
SAHA: 38.2±2,1 mmHg v.s. M26: 54.9±4.5mmHg, p<0.05, Figure 5.1B). 
MCT for 26 days also induced remarkable RVH (M12: 0.28±0.01, M26: 0.46±0.04 v.s. 
Ctrl: 0.28±0.01, p<0.005, Figure 5.1C), which was significantly attenuated by SAHA 
treatment (-73.4%) and mildly improved by VPA (-29.1%) (VPA: 0.41±0.03, SAHA: 
0.32±0.00 v.s. M26: 0.45±0.02, p<0.005, Figure 5.1C).  
No significant changes in heart rate or systemic SBP were observed in SAHA-treated 
group. However M26 and VPA seemed to cause a slight drop in systemic SBP (Figure 
5.1D). The physiological data of MCT recovery study is demonstrated in Table 5.1. 
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Figure 5.1. Recovery study: treatment with VPA and SAHA were started  12 days after MCT injection and 
continued for another two weeks. (A) PAP, mean pulmonary artery pressure, (B) RVSP, right ventricular 
systolic pressure, (C) RV/LV+sep, right ventricular hypertrophy, (D)SBP, systemic systolic blood pressure. 
Ctrl: healthy control; M12: 12-day MCT; M26: 26-day MCT; VPA: MCT with VPA 300 mg/kg/day; SAHA: 
MCT with SAHA 50 mg/kg/day.  The data are presented as mean± SEM. n≥6 in each group.                           
* p<0.05, ** p<0.005 compared with M26, ## p<0.005, ### p<0.0005 compared with Ctrl.  
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Group Control MCT26 VPA SVPA 
N number 6 11 6 6 
RV 
Systolic (mmHg) 25.9±0.8 54.9±4.5 46.7±4.7 38.2±2.1 
Max dp/dt (mmHg/s) 783±48 1605±104 1006±115 1012±78 
Pulmonary 
Mean (mmHg) 16.1±0.6 31.1±2.0 27.6±2.4 21.7±1.4 
Pulse (mmHg) 11.0±0.9 42.8±9.5 23.1±5.0 20.2±3.8 
Systemic 
Pressure (mmHg) 93.4±6.3 78.6±5.7 70.7±3.7 98.1±4.5 
Heart rate 306±14 288±17 298±20 322±18 
General 
BW (gram) 322±4 297±15 302±9 278±7 
RV/LV+septum 0.27±0.01 0.46±0.04 0.41±0.03 0.32±0.00 
RV/BW 0.55±0.01 0.90±0.09 0.79±0.06 0.64±0.01 
Left lung/BW 1.34±0.03 2.46±0.28 1.99±0.08 2.12±0.08 
MCT26: MCT control; VPA: VPA 300mg/kg/day; SAHA: SAHA 50mg/kg/day; BW:body weight 
 
Table 5.1. The physiological data of MCT recovery study. 
 
4.2. VPA and SAHA ameliorate MCT-induced PH: histology 
MCT for 12 days raised significantly peripheral distal pulmonary arteriolar 
muscularization and MCT for 26 days further augmented this phenotype (M12: 
58.0±1.7%, M26: 79.8±1.0 v.s. NC: 5.7±0.5%, p<0.005, Figure 5.2). Both VPA and 
SAHA treatment showed significant reduction in vascular muscularization compared to 
26-day MCT exposure (VPA: 72.0±1.1%, SAHA: 69.2±2.1% v.s. M26: 79.8±1.0%, 
p<0.005, Figure 5.2) and partial reversal compared to 12-day MCT exposure (VPA: 
72.0±1.1%, SAHA: 69.2±2.1% v.s. M12: 58.0±1.7%, p<0.005, Figure 5.2). 
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Figure 5.2. Effects of VPA and SAHA on MCT-induced pulmonary vascular muscularization. (A) 
Histology figures with van Gieson’s elastic stain, (B) Quantified by the percentage of vessels with double 
elastic lamina. Ctrl: healthy control; M12: 12-day MCT; M26: 26-day MCT; VPA: MCT with VPA 300 
mg/kg/day; SAHA: MCT with SAHA 50 mg/kg/day.  The data are presented as mean± SEM. n=6 in each 
group. ** p<0.005 compared with M26, ## p<0.005 compared with Ctrl.  
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To assess the myocyte hypertrophy at histological level, cross sectional area (CSA) and 
minimal Feret’s diameter were measured. Both of these two indexes were significantly 
increased at 26-day MCT group (p<0.005, Figure 5.3). Treatment with VPA reduced the 
rise in CSA significantly (p<0.05, Figure 5.3A) while SAHA had a more potent reduction 
in both CSA and myocyte diameter (p<0.005, Figure 5.3). 
 
 
 
Figure 5.3. Effects of VPA and SAHA on MCT-induced pulmonary RV myocyte hypertrophy. (A) Cross 
sectional area, (B) Myocyte diameter. Ctrl: healthy control; M26: 26-day MCT; VPA: MCT with VPA 300 
mg/kg/day; SAHA: MCT with SAHA 50 mg/kg/day.  The data are presented as mean± SEM of fold change 
relative to Ctrl. n=6 in each group. * p<0.05, ** p<0.005 compared with M26,# p<0.05,  ## p<0.005 
compared with Ctrl.  
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4.3. VPA and SAHA ameliorate MCT-induced PH: biochemistry 
4.3.1. Protein expression 
Similar to the findings in hypoxia study, protein expression levels of Bcl-2 in the lungs 
from the animals exposed to 26-day MCT were increased by 50% (p<0.05, Figure 5.4A). 
Treatment with SAHA brought back the Bcl-2 expression to a relatively lower level than 
control significantly (p<0.01), while VPA seemingly caused a moderate reduction without 
statistical significance (Figure 5.4A). Nevertheless, both VPA and SAHA significantly 
promoted p21 expression levels compared to 26-day MCT, with relatively higher levels in 
SAHA (p<0.05) (Figure 5.4B). 
 
 
Figure 5.4. Protein expression levels in rat lung extracts from MCT treatment study. (A) Bcl-2, (B) p21. 
Ctrl: healthy control; MCT: 26-day MCT; VPA: MCT with VPA 300 mg/kg/day; SAHA: MCT with SAHA 
50 mg/kg/day.  The data are presented as mean± SEM of fold change relative to Ctrl. n=6 in each group. * 
p<0.05 compared with MCT, # p<0.05 compared with Ctrl. 
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To further confirm the hyper-proliferative phenotype induced by MCT, expression levels 
of another marker, survivin, were analyzed, which revealed survivin was highly expressed 
in 26-day MCT group by a nearly 10-fold increase over healthy control (p<0.05). 
Treatment with VPA and SAHA both dramatically decreased survivin expression levels 
by around 50% (p<0.05, Figure 5.5). 
 
 
Figure 5.5. Protein expression levels of survivin in rat lung extracts from MCT treatment study. Ctrl: 
healthy control; MCT: 26-day MCT; VPA: MCT with VPA 300 mg/kg/day; SAHA: MCT with SAHA 50 
mg/kg/day.  The data are presented as mean± SEM of fold change relative to Ctrl. n=6 in each group. * 
p<0.05 compared with MCT, # p<0.05 compared with Ctrl. 
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4.3.2. Histone acetylation 
The effects on HDAC inhibition were assessed by the acetylation levels of H3 and H4. 
The acetylation level of H3 was slightly decreased in 26-day MCT (p<0.05) which was 
reversed mildly by VPA (p=0.067) and strongly by SAHA (+34%, p<0.05, Figure 5.6A). 
On the other hand, the acetylation level of H4 was significantly increased by both VPA 
(+100%) and SAHA (+50%) compared to 26-day MCT (p<0.0001, Figure 5.6B).  
 
 
 
Figure 5.6. Histone expression levels in rat lung extracts from MCT treatment study. (A) Acetylated H3, (B) 
Acetylated H4. Ctrl: healthy control; MCT: 26-day MCT; VPA: MCT with VPA 300 mg/kg/day; SAHA: 
MCT with SAHA 50 mg/kg/day.  The data are presented as mean± SEM of fold change relative to Ctrl. n=6 
in each group. * p<0.05, p<0.0001 compared with M26, # p<0.05 compared with Ctrl. 
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4.3.3. Cytokine assay and expression 
To examine the effects of VPA and SAHA on inflammatory responses to MCT-induced 
PH in the lung, selected cytokines and chemokines were screened by R&D system rat 
cytokine array panel A. The original results are displayed in Figure 5.7. 
 
Abbreviations: PC, positive control; CINC, cytokine-induced neutrophil chemoattractant; CNTF, ciliary 
neurotrophic factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; sICAM-1, soluable 
intercellular adhesion molecule-1; IFN-γ, interferon-gamma; IL, interleukin; IP-10, IFN-γ-induced protein 
10; LIX, lipopolysaccharide-induced chemokine (C-X-C motif); MIG, monokine induced by IFN-γ; MIP, 
macrophage inflammatory protein; RANTES, regulated by T cells, activation upon secretion; CXCL, 
chemokine (C-X-C motif) ligand; TIMP-1, tissue inhibitor of metalloproteinases; TNF-α, tumour necrosis 
factor alpha; VEGF, vascular endothelial growth factor; NC, negative control. 
  
 
Figure 5.7. Cytokine and chemokine array in rat lung extracts from MCT treatment study. (A) Array data on 
developed X-ray films, (B) Array coordincates, (C) Reference to represented cytokine and chemokine. Ctrl: 
healthy control; MCT: 26-day MCT; VPA: MCT with VPA 300 mg/kg/day; SAHA: MCT with SAHA 50 
mg/kg/day.   
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Noticeable elevation induced by 26-day MCT was observed in TIMP-1, IP-10, IL-4, IL-17, 
CINC-2α/β and MIP-3α. The elevation was attenuated under VPA or SAHA treatment, as 
SAHA led to greater reduction in nearly all of these cytokines (Figure 5.8). 
 
Figure 5.8. Cytokine levels detected by cytokine array in rat lung extracts from MCT treatment study. (A) 
TIMP-1, (B) IP-10, (C) IL-4, (D) IL-10, (E) CINC-2α/β, (F) MIP-3α. Data are presented as fold change 
relative to Ctrl. Samples from each group (n=6) were poured together with eqaul amounts. Ctrl: healthy 
control; MCT: 26-day MCT; VPA: MCT with VPA 300 mg/kg/day; SAHA: MCT with SAHA 50 
mg/kg/day.   
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To further confirm the findings from cytokine array, protein expression levels of TIMP-1 
were analyzed by Western blotting. MCT for 26 days induced a six-fold increase in 
TIMP-1 (p<0.005) compared to healthy control and VPA reduced the elevation by 50% 
while SAHA almost brought the levels back to the normal range (p<0.005, Figure 5.9). 
 
 
Figure 5.9. Protein expression levels of TIMP-1 in rat lung extracts from MCT treatment study. Ctrl: 
healthy control; MCT: 26-day MCT; VPA: MCT with VPA 300 mg/kg/day; SAHA: MCT with SAHA 50 
mg/kg/day.  The data are presented as mean± SEM of fold change relative to Ctrl. n=6 in each group. ** 
p<0.005 compared with MCT,  ## p<0.005 compared with Ctrl. 
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5. Discussion 
Treatment study in MCT-induced PH model provided the following findings: 
 VPA and SAHA treatment was well tolerated in the treated animals without 
perceptible adverse effects, but decelerate the growth rate 
 VPA and SAHA treatment significantly ameliorated elevation of pulmonary arterial 
and right ventricular pressure without influence on systemic blood pressure. 
 VPA and SAHA treatment significantly ameliorated right ventricular hypertrophy.  
 VPA and SAHA treatment significantly ameliorated pulmonary distal vascular 
remodelling. 
 VPA and SAHA treatment significantly decreased Bcl-2 and survivin, and increased 
p21 expression in lung tissues. 
 VPA and SAHA treatment significantly increased histone acetylation in lung tissues. 
 VPA and SAHA treatment inhibited the release of several inflammatory mediators in 
lung tissues, such as TIMP-1 and IP-10. 
Similar to the findings from hypoxia study, VPA or SAHA treatment ameliorated 
established PH induced by MCT. SAHA reduced the elevated mean PAP and RVSP by 
around 60% and hypertrophied RV by over 70% compared with MCT control. 
Histological assessment of RV hypertrophy by measuring myocyte diameter and area 
demonstrated a 70% reduction, which is consistent with the haemodynamic measurement. 
Animals were well tolerated with VPA and SAHA during the whole period of treatment. 
However, a mild deceleration in growth was noted in SAHA treated group. The 
therapeutic effects of VPA treatment appeared to be less convincing on MCT model. The 
failure in gaining the statistical significance is due to a higher within-group difference in 
VPA treated group, suggesting the susceptibility to VPA is relatively diverse in MCT 
model. Nevertheless, histological assessment revealed VPA treatment attenuated 
pulmonary vascular muscularization to a similar degree to SAHA.  
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The effects on HDAC inhibition were evidenced by increased histone H3 and H4 
acetylation as they were in hypoxia study. Interestingly, VPA exhibited an even higher 
increase in H4 acetylation than SAHA but not in H3 acetylation. The inconsistence with 
hypoxia study may be due to different pathological mechanisms between two models and 
implies that “histone codes” can be composed and adjusted in response to different 
conditions. 
MCT-induced model has been recognized a more severe model owing to more profoundly 
pulmonary vascular remodelling, involving medial hypertrophy, extracellular matrix 
secretion, arteriolar muscularization, thrombi formation, increased endothelial 
permeability, perivascular inflammatory cells infiltration and inflammatory mediators 
release 93, 272. Protein analysis showed the compatible alternations with hypoxia study 
which are downregulation of Bcl-2 and upregulation of p21 by VPA and SAHA treatment. 
The anti-proliferative effects of these two inhbitors can be further confirmed by the 
changes in survivin expression. As an anti-apoptotic protein as Bcl-2, survivin has been 
linked to human PAH more specifically 81. Treatment with VPA and SAHA both reduced 
the elevated survivin expression, suggesting a prominent anti-proliferative effect on MCT 
model. 
Accumulating evidence has implicated the role of inflammation in the pathogenesis of 
PAH. The cytokine screening in rat lungs revealed that several inflammatory mediators 
were association with attenuation of MCT-induced PH phenotype by VPA and SAHA 
treatment. One with the strongest significance is TIMP-1. TIMP-1 acts to inhibit most of 
the known MMPs and control ECM remodelling. It also promotes cell proliferation, 
inhibits apoptosis and involves in tissue inflammation and fibrotic formation. Aberrant 
activity of TIMP-1 along with its downstream MMPs has been reported in smooth muscle 
cells from patients with IPAH 79. Imbalance between TIMP-1 and MMPs featured by 
augmentation of TIMP-1 and ECM deposition plays a crucial role in vascular remodelling 
273
. Rebuilding the balance between TIMP-1 and MMPs by suppressing overactive TIMP-
1 may reverse severe PAH by ameliorating vascular remodelling and repairing 
dysfunctional endothelium 274. Biochemical analysis in MCT treatment study showed a 
humongous elevation in TIMP-1 induced by MCT, which was significantly attenuated by 
VPA and SAHA, implicating the potential targets of HDAC inhibition. 
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Both VPA and SAHA treatment ameliorated the rise of IP-10, which was elevated in 
lungs from MCT-treated rats. IP-10, secreted mainly by monocytes, endothelial cells and 
fibroblasts in response to INF-γ, is a chemoattractant for monocytes, macrophages, T cells, 
natural killer cells and dendritic cells 275. It is important for T cell adhesion to endothelial 
cells. Serum IP-10 level is reported elevated in patients with PAH and associated with 
survival 92. A previous study indicated the activation of IP-10 is paralleled with 
deacetylation of histone and HDAC activity is required for INF-γ stimulation 276. 
Consistently, VPA and SAHA might block the HDAC-dependent transcription of IP-10, 
leading to impaired recruitment of immune cells and exerting anti-inflammatory effects in 
MCT-induced PH model.  
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Chapter 6:  
HDAC INHIBITORS IN  
HPSMC AND HPAEC 
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1. Introduction 
Based on the results from in vivo experiments, HDAC inhibitors VPA and SAHA are 
shown encouraging effects on improving PH pathology, possibly via anti-proliferation and 
anti-inflammation. In order to clarify the cellular mechanisms, especially to identify 
whether HDAC inhibition can target pulmonary vascular remodelling, the 
pharmacological effects of these two are testified in in vitro system. 
Pulmonary vascular remodelling is a multi-cell-dependent process involving nearly all 
elements of vascular structure, among which endothelial cells and smooth muscle cells are 
recognized to take crucial parts in the whole event. Endothelial dysfunction has been 
identified as a possible initiator of vascular remodelling 57. Endothelial cells are also 
acting as a main source of many growth factors like PDGF and VEGF, vasoactive 
mediators, such as eNOS and endothelin, and inflammatory mediators, including IL-6, IL-
8, IP-10, RANTES and fractalkine. Secondary to endothelial injury, underlying smooth 
muscle cells undergo both hypertrophy and hyperplasia and become resistance to 
apoptosis. The overgrowth of smooth muscle cells, accompanied with over-activated 
fibroblasts and deposition of ECM as well as recruited immune cells, results in restriction 
of pulmonary circulation and eventual occlusion. Pharmacological experiments in primary 
cell culture of endothelial cells and smooth muscle cells provide the information of cell-
specific effects and help to unravel the molecular mechanisms. 
Hyper-proliferative smooth muscle cells and pro-inflammatory endothelial cells are 
established to mimic the cellular system in human PAH. Stimulated proliferation of 
smooth muscle cells are achieved by PDGF-BB. Growing evidence has suggested a vital 
role of PDGF in the pathogenesis of PAH. Overexpression of PDGF and the receptors has 
been identified in PAH patients 64, 64 PDGF induces a higher growth rate in HPSMC from 
patients with IPAH than cells from normal control 277. PDGF receptor antagonist, imatinib, 
has been shown potential efficacy in treatment of PAH in pre-clinical and clinical studies. 
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To create a pro-inflammatory cell system, endothelial cells are stimulated by TNF-α. 
TNF-α is the primary regulator in systemic inflammatory reactions, inducing other 
inflammatory mediators release. Elevation of circulating TNF-α has been reported in 
IPAH patients. This elevation correlates to cardiac index and functional performance 88. 
In this chapter, VPA and SAHA are tested in these two stimulated cell systems to assess 
their effects on proliferation and inflammation. 
2. Objectives 
• To evaluate the pharmacological effects of VPA and SAHA on PDGF-stimulated 
HPSMC 
• To evaluate the pharmacological effects of VPA and SAHA on TNF-α-stimulated 
HPAEC 
 
3. Methods and Protocols 
3.1. Human pulmonary smooth muscle cell (HPSMCs) 
Harvested HPSMCs were seeded and allowed to attach overnight before 24-hour serum 
deprivation. PDGF-BB (50 ng/ml) stimulation or exposure to hypoxia (O2=2%) with or 
without VPA (1mM, 2mM) or SAHA (2.5µM, 10µM) for 72 hours is conducted 
subsequently (Figure 6.1). At the end of exposure, cells were harvested to assess 
proliferation by cell counting, WST-1 assay and BrdU incorporation assay; cell death by 
viability staining with PI (50µg/ml), cell cycle analysis by FACS, protein analysis by 
Western blot and immunostaining. All the experiments were executed in at least three 
times with separate cell preparations. 
3.2. Human pulmonary artery endothelial cells (HPAECs) 
Confluent HPAECs in equal amount are treated with 2mM VPA or 10µM SAHA for 24 
hours. 10 ng/ml TNF-α was added 8 hours after treatment starts. At the end of treatment, 
cell culture supernatants are collected for cytokine array (Figure 6.2). 
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Figure 6.1. Morphology of human pulmonary smooth muscle cells with and without PDGF-BB 
stimulation.
 
Figure 6.2. Morphology of human pulmonary arterial endothelial cells. 
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4. Result 
4.1. Human pulmonary smooth muscle cell (HPSMCs) 
4.1.1. VPA and SAHA inhibit stimulated proliferation 
Exposure to hypoxia for 72 hours stimulated HPSMC proliferation by over 30% (p<0.05) 
and this rise was inhibited by both VPA and SAHA in a dose-dependent trend based on 
cell counts. The low doses of both bought cell counts back to the baseline (VPA, p<0.005; 
SAHA, p<0.05) while high doses seemed to further reduced proliferation (p<0.005, Figure 
6.3A).  
Stimulated cell proliferation with PDGF-BB (50ng/ml) for 72 hours lead to a 80% 
increase in cell counts (p<0.05). The increase was attenuated by VPA or low dose SAHA 
while high dose SAHA further reduced the proliferation (p<0.005, Figure 6.3B).   
 
 
Figure 6.3. Effect of histone deacetylase inhibition on stimulated proliferation of human pulmonary smooth 
muscle cells based on cell counts. (A) hypoxia-induced proliferation, (B) PDGF-induced proliferation. NC: 
normoxia control; HC: hypoxia control; HV1: hypoxia+VPA 1mM; HV2: hypoxia+VPA 2mM; HS2.5: 
hypoxia+SAHA 2.5µM; HS10: hypoxia+SAHA 10µM; Ctrl: control; PC: PDGF control; PV1: PDGF+VPA 
1mM; PV2: PDGF+VPA 2mM; PS2.5: PDGF+SAHA 2.5µM; PS10: PDGF+SAHA 10µM. The data are 
presented as mean± SEM of fold change relative to NC or Ctrl. n≥4. * p<0.05, ** p<0.005 compared with 
HC or PC, + p<0.05 compared with HV1, # p<0.05 compared with NC or Ctrl. 
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To further confirm the effects of these two HDAC inhibitors on stimulated HPSMC 
proliferation, WST-1 and BrdU incorporation assay were employed. WST-1 assay showed 
the PDGF-induced proliferation (p<0.05) was moderately inhibited by VPA or SAHA, no 
significantly dose-dependent effects in VPA (p<0.005, Figure 6.4A). BrdU assay revealed 
a two-fold increase induced by PDGF, which was mildly attenuated by VPA (p<0.05) and 
SAHA arrested cell growth at the baseline compared with control group, both in a dose-
dependent manner (p<0.05, Figure 6.4B). 
 
Figure 6.4. Effect of histone deacetylase inhibition on PDGF-stimulated human pulmonary smooth muscle 
cells in culture. (A) WST-1 assay, (B) BudU incorporation. Ctrl: control; PC: PDGF control; PV1: 
PDGF+VPA 1mM; PV2: PDGF+VPA 2mM; PS2.5: PDGF+SAHA 2.5µM; PS10: PDGF+SAHA 10µM. 
The data are presented as mean± SEM of fold change relative to Ctrl. n=8. * p<0.05, ** p<0.005 compared 
with PC, + p<0.05 compared with PV1, x p<0.01 compared with PS2.5, # p<0.05, ### p<0.0005 compared 
with Ctrl. 
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4.1.2. SAHA leads to cell death 
Viability staining indicated that exposure to SAHA led to an increase in proportion of PI 
stained cells (6.9~8.8%) representing dead or dying cells, while no significant change was 
observed in the VPA treated group. 
 
Figure 6.5. FACS analysis of viability staining with PI in HPSMC stimulated with PDGF 50 ng/ml for 72 
hours, with or without VPA or SAHA treatment. The calculations of defined areas were done by software 
Cyflogic v1.2.1. Each experiment was repeated at least 3 time3 with separate cell preparations.  
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4.1.3. VPA and SAHA arrest cell cycle at G1/S phase 
FACS analysis revealed that both VPA and SAHA arrested cell growth at the G1-S phase, 
reversing the shift caused by PDGF stimulation. The percentage of cells in G1 (PDGF: 
55.6%) was higher in VPA (VPA 1mM: 63.4%; VPA 2mM: 69.0%, p<0.05) and SAHA 
treated cells (SAHA 2.5µM: 71.5%; SAHA 10µM: 71.4%, p<0.05), along with lower 
percentage of cells in G2/M phase in both VPA and SAHA treated groups (Figure 6.6). 
 
 
Figure 6.6. FACS analysis of cell cycle distribution in HPSMC stimulated with PDGF 50 ng/ml for 72 
hours, with or without VPA or SAHA treatment. The calculations of defined areas were done by software 
Cyflogic v1.2.1. Each experiment was repeated at least 3 time3 with separate cell preparations.  
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4.1.4. Biochemistry 
Biochemical analysis of cell lysates showed that Bcl-2 expression was induced by PDGF 
stimulation which was reduced by high dose of SAHA treatment (Figure 6.7A). Both VPA 
and SAHA led to increased p21 expression in cells in a seemingly dose-dependent manner 
(Figure 6.7B).  Furthermore, SAHA treatment at 10 µM resulted in PARP cleavage to an 
85kDa fragment, suggesting induction of apoptosis (Figure 6.7C).  
 
Figure 6.7. Protein expression levels in HPSMC lysates from PDGF stimulation study. (A) Bcl-2, (B) p21, 
(C) PARP and representative bands. Ctrl: control; PC: PDGF control; PV1: PDGF+VPA 1mM; PV2: 
PDGF+VPA 2mM; PS2.5: PDGF+SAHA 2.5µM; PS10: PDGF+SAHA 10µM. The data are presented as 
mean± SEM of fold change relative to Ctrl. Each experiment was repeated at least 3 times with separate cell 
preparations. * p<0.05 compared with  PC, # p<0.05 compared with Ctrl. 
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4.2. Human pulmonary artery endothelial cells (HPAECs) 
Human cytokine array panel A was used to examine the effects of VPA and SAHA on 
inflammatory mediators release from endothelial cells in response to TNF-α (Figure 6.8). 
 
Abbreviations: PC, positive control; C5/C5a, complement factor 5/5a; G-CSF, granulocyte colony-
stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; CXCL, chemokine (C-X-C 
motif) ligand; CCL, chemokine (C-C motif) ligand; sICAM-1, soluable intercellular adhesion molecule-1; 
IFN-γ, interferon-gamma; IL, interleukin; IP-10, IFN-γ-induced protein 10; MCP-1, monocyte chemotactic 
protein-1; MIF, macrophage migration inhibitory factor; MIP, macrophage inflammatory protein; RANTES, 
regulated by T cells, activation upon secretion; SDF, stromal cell-derived factor; TNF-α, tumour necrosis 
factor alpha; sTREM-1, soluble triggering receptor expressed on myeloid cells-1; NC, negative control. 
 
Figure 6.8. Cytokine levels detected by cytokine array in culture supernatants of TNF-α-stimulated human 
pulmonary arterial endothelial cells. (A) Array data on developed X-ray films, (B) Array coordincates, (C) 
Reference to represented cytokine and chemokine. The experiment was duplicated with separate cell 
preparations. Ctrl: control; TNF-α: TNF-α without HDAC inhibitors; VPA: TNF-α with VPA 2mM; SAHA: 
TNF-α with SAHA 10µM. 
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Several inflammatory mediators were induced by TNF-α, including IP-10, IL-2, IL-6, IL-
10, IL-12 p70, IL-13, IL-16, IL-17E, IL-23, IL-27, RANTES, CCL1, CXCL11, sICAM-1, 
G-CSF, GM-CSF, INF-γ, C5/C5a and GROα. The most eminent elevations were shown 
IP-10 and RANTES with ~45-fold increase. Exposure to SAHA led to a broad-spectrum 
inhibition of most of these mediators, especially in IL-2, IL-6, IL-16, IL-12 p70, IL-17E, 
IL-23, IL-27, CCL1, INF-γ and C5/C5a, in which SAHA nearly reversed the TNF-α-
induced elevations to the baseline level compared with control group. SAHA also led to a 
prominent reduction in IP-10 (from 45-fold to 7-fold) and moderated reduction in others 
like RANTES, sICAM-1, GM-CSF, CXCL11, IL-10 and IL-13 (selected results shown in 
Figure 6.9 and 6.10).  
Interestingly, effects of VPA seemed to be more diverse. Treatment with VPA prevented 
the elevation of IP-10, IL-2, IL-6, IL-10, IL-17E, IL-23, IL-27, RANTES, CCL1, and 
CXCL11. In contrast, VPA leads to further increase in G-CSF, GM-CSF, IL-12 p70, IL-
13, INF-γ and C5/C5a (selected results shown in Figure 6.9 and 6.10). 
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Figure 6.9. Cytokine levels detected by cytokine array in culture supernatants of TNF-α-stimulated human 
pulmonary arterial endothelial cells. (A) TNF-α, (B) IP-10, (C) IL-6, (D) RANTES, (E) IL-2, (F) IL-10. 
Data are presented as fold change relative to Ctrl. The experiment was duplicated with separate cell 
preparations. Ctrl: control; TNF-α: TNF-α without HDAC inhibitors; VPA: TNF-α with VPA 2mM; SAHA: 
TNF-α with SAHA 10µM. 
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Figure 6.10. Cytokine levels detected by cytokine array in culture supernatants of TNF-α-stimulated human 
pulmonary arterial endothelial cells. (A) CCL1, (B) CXCL11, (C) sICAM-1, (D) GM-CSF, (E) INF-γ, (F) 
IL-13. Data are presented as fold change relative to Ctrl. The experiment was duplicated with separate cell 
preparations. Ctrl: control; TNF-α: TNF-α without HDAC inhibitors; VPA: TNF-α with VPA 2mM; SAHA: 
TNF-α with SAHA 10µM. 
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5. Discuission 
The in vitro experiments using HDAC inhibitors in HPSMC and HPAEC provided the 
following findings: 
 VPA and SAHA treatment inhibited stimulated HPSMC proliferation. 
 SAHA treatment induced apoptosis in HPSMC. 
 VPA and SAHA treatment arrest cell cycle at G1/S phase in HPSMC. 
 VPA and SAHA treatment significantly decreased Bcl-2 and increased p21 
expression in HPSMC. 
 VPA and SAHA treatment inhibited the release of several inflammatory mediators 
from HPAEC stimulated by TNF-α. 
5.1. VPA and SAHA inhibit stimulated proliferation of HPSMCs 
Hyper-proliferation of pulmonary artery smooth muscle cells is a fundamental character in 
vascular remodelling. PDGF-stimulated smooth muscle cell growth is believed to take part 
in the remodelling process of PAH 278. On the other hand, hypoxia also promotes HPSMC 
growth in cultured system, but the role of hypoxia-induced smooth muscle cell 
proliferation is relatively controversial in PAH since whether hypoxic stimuli are required 
for the development of human PAH is undetermined. In my study, VPA and SAHA 
inhibited both PDGF- and hypoxia-induced HPSMC proliferation in a dose-dependent 
trend. In BrdU assay, exposure to SAHA nearly blocked PDGF-stimulated cell growth in 
low dose and further reduced cell number in high dose while VPA only caused mild 
inhibition (-10%) of proliferation. In contrast, WST-1 assay indicated no visual difference 
between VPA and SAHA as both of them led to mild to moderate (~25%) inhibition 
compared with PDGF control. This discrepancy could be explained by the fact that BrdU 
incorporation directly measures DNA synthesis in proliferating cells while WST-1 
evaluates viability based on metabolic activity of mitochondrial enzymes 279. This finding 
also suggested different behaviours in regulation of proliferation between VPA and SAHA.  
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The differences remained in the viability staining with PI which showed that SAHA 
resulted in an increased cell death whereas VPA did not. The cytotoxic effect of high dose 
SAHA was furthered confirmed by protein analysis that showed only SAHA in high dose 
significantly decreased Bcl-2 expression and resulted in PARP cleavage. Unexpectedly, 
VPA did not influence Bcl-2 expression in HPSMCs as it did in hypoxic rat lungs, 
suggesting other alternative targets of VPA in pulmonary vascular remodelling. 
A possible explanation is the induction of p21 in HPSMCs. Consistent with the results 
from animal studies, p21 expression was significantly increased by VPA and SAHA in 
dose-dependent trend. FACS analysis of cell cycle distribution showed that both of them 
arrested cell cycle at G1/S phase and prevented cells from entering mitosis. Collectively, 
the anti-proliferative effects on HPSMC derived from SAHA can be attributed to 
inhibition of cell growth by p21-regulated cell cycle arrest and simultaneously induction 
of apoptosis. On the other hand, VPA may inhibit cell proliferation by p21-regulated cell 
cycle arrest only but not induction of apoptosis. This conclusion agrees with previous 
studies that HDAC inhibition strongly activates the expression of p21 and therefore arrests 
cell proliferation in many cancer cell lines 280as well as other studies proved this HDAC-
p21-growth arrest signalling in other cells, including vascular smooth muscle cells in 
neointimal formation 226and fibroblasts in rheumatoid arthritis 281. This finding also fits in 
with the results from animal experiments, consolidating the role of p21 in response to 
HDAC inhibition in pulmonary vascular remodelling. 
Concern may be arisen that HDAC inhibitors commonly have selective cytotoxicity in 
most cancer cells, which was not strongly demonstrated in the PDGF-stimulated cell 
systems. Induction of apoptosis is believed a major part of the anti-neoplastic capacities of 
HDAC inhbitors. Nevertheless, the challenge is that PDGF stimulation in the in vitro 
setting is not equivalent to cancerous transformation. Caution has to be taken in 
interpreting information gained from these cellular systems. 
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5.2. VPA and SAHA inhibit inflammatory mediators release    
from HPAECs 
Consistent with the results that VPA and SAHA inhibited inflammatory mediators release 
in MCT model, in TNF-α-stimulated endothelial cells, these two HDAC inhibitors 
generated a broard-spectrum inhibition of pre-inflammatory transduction. HPAEC 
stimulated by TNF-α released a wide range of cytokines and chemokines, among which 
IL-6, IL-2, IL-10, IL-12, IL-13, IP-10 and RANTES have been previously shown to be 
associated with human PAH. Especially, overexpression of IL-6 has been repeatedly 
reported in IPAH patients, animal models and cellular systems 94-96 and thought to have a 
role in the pathogenesis. Overexpressed IL-6 can induce smooth muscle cell proliferation 
and endothelial cell apoptosis through multiple pathways, such as VEGF up-regulation, 
BMPR2 downregulation and TGF-β signalling. Furthermore, IL-6 signalling leads to 
recruit inflammatory cells, such as lymphocytes and monocytes, by stimulating release of 
other cytokines like fractalkine.  The inflammatory infiltration provides a major source of 
sustained IL-6 and further induces IL-6 release from vascular cells 282. Lowering IL-6 
levels has been shown clinical relevance in PAH patients 88and considered as a novel 
therapeutic target. In my study, treatment with SAHA efficiently prevented the release of 
IL-6 while VPA did mildly that indicates HDAC inhibition may have anti-inflammatory 
effects on stimulated endothelium. Actually, HDAC inhibition has been reported to 
disrupt IL-6 production in autoimmune disease.  
Another interesting target is RANTES, a chemokine attracting T cells, monocytes, 
basophils, eosinophils and natural killer (NK) cells. Elevated expression of RANTES 
mRNA, originated from pulmonary endothelium, is demonstrated in patients with severe 
PAH 90. In my study, VPA and SAHA both reduced the rise of RANTES released from 
endothelial cells, suggesting RANTES might be the therapeutic target connected to HDAC 
inhibition. 
The manipulation in IP-10 release observed in MCT model was supported by the finding 
that VPA and SAHA spectacularly blocked the induced-release from endothelial cells. 
The TNF-α-induced secretion of soluble intercellular adhesion molecule-1 (sICAM-1), 
also known as CD54, was attenuated by SAHA treatment. This downregulation may 
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contribute to prevent leukocytes from binding to endothelial cells and transmigrating into 
lung tissues 283. Collectively, the result implicates a role of anti-inflammatory effects in 
pharmacological HDAC inhibition. 
Noticeably, while SAHA was revealed consistently prominent inhibition of the release of 
most cytokines and chemokines in the study, the effect of VPA was less potent and 
relatively diverse. In some inflammatory mediators, including IL-6, IL-2, IL-10, IP-10 and 
RANTES, VPA treatment was displayed inhibitory effects, to a less degree compared with 
SAHA. However, in others, VPA had no effects, such as sICAM-1, or even reversely 
induced their release, which were INF-γ, G-CSF, GM-CSF, IL-12, IL-13 and C5/C5a. The 
probabilities can be interpreted by that, firstly, VPA owns multiple functions in addition to 
HDAC inhibition. Despite of the fact that VPA has been shown beneficial in clinical 
neurology and psychiatry, the current identified mechanisms of its action cannot provide 
satisfactory explanations and unknown underlying remains to be explored. Secondly, the 
class-specific of HDAC inhibition may vary the pharmacological effects. Recently, great 
efforts have been engaged into the development of isoform-specific HDAC inhibitors with 
expectation of more potency and less side effects.  
The effects of VPA and SAHA on endothelial proliferation were not evaluated in this 
thesis. Hyper-proliferative endothelial cells are manifested in PH in a hypothetical 
complex process, which an initial loss of endothelial cells occurs before the following 
exuberant proliferation of the surviving cells 284. This process ends up selecting apoptosis-
resistant proliferative vascular cells, forming the plexiform lesions. Experimental 
induction of endothelial apoptosis by VEGF receptor blocker SU5416 combined with 
chronic hypoxia generates severe PH 72. Accordingly, using the cellular system to examine 
the pharmacological effects on endothelial proliferation may be insufficient and has to be 
interpreted carefully. 
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1. Conclusions 
1.1. Pulmonary hypertension (PH) 
PH remains a life threatening disease without a cure, characterised by vasoconstriction, 
vascular remodelling, thrombosis and inflammation. New thinking argues that pulmonary 
vascular remodelling resembles a “neoplastic-like” vascular pathology, and may originate 
from an imbalance between proliferation and apoptosis, in favour of a pro-proliferative 
property in PH. Currently approved therapeutic options for PH are limited and primarily 
target the dysregulation of vessel tone. Although these treatments succeed in functional 
improvement and may affect the natural course of the condition, termination or reversal of 
the disease progression is still not achieved.  New strategies aimed directly at the 
structurally disorganized remodelling are urgently required.  
1.2. Histone deacetylase (HDAC) 
Epigenetic modifications regulate gene expression and affect a variety of physiological 
and pathological events. Histone acetylation, manipulating chromatin structure and 
transcriptional activity, plays a key role in proliferative and inflammatory disorders, 
especially cancer. Aberrant recruitment of HDACs to certain genomic regions is 
responsible for cancerous transformation by repressing tumour suppressor genes and 
enhancing oncogenic transcription. Apart from modifying histone on chromatin, HDACs 
can act directly on non-histone proteins and dominate downstream signalling transduction. 
HDAC inhibitors offer therapeutic benefit in cancer and suggest potential in other 
proliferative disorders, including PH. 
1.3. HDAC inhibitors in PH 
This thesis commenced with the finding of altered HDAC expression in lung tissue from 
PH patients and animal models. Specifically, the expression of HDAC1 and HDAC5 were 
increased along with pro-survival factor Bcl-2 in lung tissues from patients with IPAH. 
Elevated expression of these three enzymes was also found in lung and RV tissues from 
rats with chronic hypoxia-induced PH. Histological assessment revealed that 
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overexpressed HDAC1 and HDAC5 were localized to the vascular walls and associated 
with vascular muscularization in humans and rats. The levels of HDACs in rats correlated 
with the disease development, as measured by elevated PAP and hypertrophied RV. In 
chronic in vivo experiments, inhibition of HDACs by VPA and SAHA ameliorated and 
partially reversed the PH phenotype in two animal models, hypoxia and MCT. The 
molecular mechanisms accounting for the anti-vascular remodelling effects were partially 
related to anti-proliferation in vascular cells, evidenced by downregulation of Bcl-2, 
upregulation of p21 and downregulation of survivin, both Bcl-2 and p21 as survival 
markers and therapeutic targets in cancer 243, 285, 286. Increased histone acetylation support 
the claim that administration of these two inhibitors in animals decreased HDAC activity. 
These findings are consistent with observations in cancer and suggest that the pathology 
of PH can be modified by HDAC inhibitors. The in vitro experiments showed that VPA 
and SAHA modulated Bcl-2 and p21 in human pulmonary artery smooth muscle cells and 
inhibited stimulated cell growth, which suggest that VPA and SAHA can target directly 
pulmonary vascular remodelling. Furthermore, these two inhibitors also inhibited 
inflammatory mediator release in MCT models and human pulmonary artery endothelial 
cells, suggesting anti-inflammatory effects might be another contributor to their 
pharmacological effects. Collectively, these results provide a preclinical basis to support 
the therapeutic potential of HDAC inhibitors as a PH treatment. 
2. Discussions 
In this study, biochemical observations suggest that the therapeutic effects of VPA and 
SAHA are associated with anti-proliferation and anti-inflammation. These findings are 
consistent with current understanding of HDAC inhibition in cancer and inflammatory 
disorders 202, 287. 
2.1. HDAC inhibitors: anti-proliferative effects 
The therapeutic effects of HDAC inhibitors in malignant disease are based on their 
potential to inhibit cell proliferation and induce apoptosis. The anti-proliferative effects 
are conducted through multiple interacting pathways. Among them, p21 is one of the most 
studied factors, commonly upregulated in association with HDAC inhibitor-mediated cell 
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cycle arrest. Treatment with HDAC inhibitors increases p21 expression in parallel with 
hyperacetylation of histone H3 and H4 in its promoter region in various cancer cell types 
174
. This upregulaion of p21 is generally independent of p53. In the normal situations, p21 
is an essential guardian to maintain genetic stability by arresting cell cycle to allow 
damaged DNA to undergo repair and initiate programmed cell death when damaged. 
Among all the HDACs, HDAC1 is believed the most important in the regulation of 
proliferation 248. Deficiency of HDAC1 leads to lethal growth retardation in mice embryo 
and reduced proliferation rates in embryo stem cells, coinciding with elevated expression 
of CDK inbhitors, not only p21 but also p27. The loss of HDAC1 induces concomitant 
increased expression of other class I HDACs (HDAC2 and HDAC3), but the 
compensation is inadequate 248, 288. This indicates that HDAC1 has a pivotal function in 
regulating proliferation by its effects on cell cycle gatekeepers. The HDAC inhibitor-cell 
cycle arrest is not exclusive to cancer cells but is also observed in vascular smooth muscle 
cells in in vivo models of vascular injury 226. Consistently, in our PH models, HDAC1 
expression increases in line with disease development and VPA and SAHA, both of which 
inhibit HDAC1, upregulate p21 and attenuate proliferative vascular remodelling. 
During the course of this thesis, Stenmark et al have described the effect of HDAC 
inhibition in cellular models based on adventitial fibroblasts (PH-Fibs) and 
morphologically distinct cells of hematopoetic origin (R-cells), which were isolated from 
the adventitial and the medial layer of distal pulmonary arteries of chronically hypoxic 
claves 289. Both cell types display a stable hyper-proliferative / apoptosis resistant 
phenotype, even under serum deprived ex-vivo conditions 237. Class I HDAC catalytic 
activity is significantly elevated in PH-Fibs compared to fibroblasts from control group 229. 
Recent unpublished data (in collaboration with our group) revealed that HDAC1 mRNA 
expression levels, but not HDAC2 or HDAC3 mRNA levels, are significantly increased in 
R-cells compared to smooth muscle cells from control animals. VPA and SAHA exert 
greater inhibitory effects on proliferation in both PH-Fibs and R-cells compared to control 
cells under serum starved condition, suggesting specific modulation of epigenetically 
altered signalling pathways in these cells. Simultaneously, these cells express significantly 
lower levels of p21 and FOXO3 (forkhead box O3) and higher levels of Bcl-2 and 
survivin compared to cells from control animals. Exposure to VPA or SAHA results in 
elevation of p21 and FOXO3 expression as well as reduced Bcl-2 and survivin in these 
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cells, further supporting the hypothesis that VPA and SAHA can target apoptosis-resistant 
remodelled cells in PAH. 
On the other hand, my study suggests involvement of mitochondrial apoptotic factors in 
HDAC inhibitor-mediated effects on pulmonary vascular remodelling 185. Retrieval of 
apoptotic function, evidenced by VPA and SAHA downregulation of Bcl-2 in lung tissue, 
would be expected to induce cell death and contribute to reversing vascular remodelling. 
Noticeably, the effects of VPA on induction of apoptosis seem to be less significant in the 
in vitro study, reflecting class- or isoform-specific impacts of HDAC inhibition on 
molecular mechanisms. 
In addition to indirect manipulation of transcription by chromatin modification, HDAC 
inhibitors can directly affect the acetylation status of several proteins. For example, 
Romidepsin can activate tumour suppressor gene p53 and thereby enhance p21 signalling. 
The acetylation status of p53 is highly related to its transcriptional activity 177. This was 
not examined in this thesis. 
Another interesting pathway which might take part in HDAC inhibitor-mediated anti-
proliferation is the inactivation of Akt. Akt, a serine/threonine protein kinase, also referred 
to as protein kinase B (PKB), has been extensively studied as a key pro-survival factor 290, 
291
 and implicated in many proliferative disorders 292. Activation of Akt by 
phosphorylation boosts cells to overcome the checkpoints in the cell cycle by suppressing 
p21 293, 294 and is also associated with upregulation of Bcl-2 295. Overactivity of Akt 
signalling causes a shift of vascular smooth muscle cells from a contractile to synthetic 
phenotype 296, leading to proliferation, migration and fibrosis, and thereby play a role in 
vascular remodelling and myocardial hypertrophy. Recent studies report that HDAC 
inhibition can downregulate Akt signalling through a histone acetylation-independent 
route 297. Preliminary data from our lab has shown that VPA and SAHA inhibit Akt 
activity in lungs from chronically hypoxic rats (Huang, unpublished data). These data 
suggested a possible interplay of Akt/Bcl-2/p21 with HDAC inhibition, leading to anti-
proliferative effects (Figure 7.1). 
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Figure 7.1. HDAC inibition exerts anti-proliferative effects via cell cycle arrest and apoptotic induction. 
HDACi: HDAC inhibitor 157, 294, 295, 297. 
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2.2. HDAC inhibitors: transformation-selectivity 
HDACs are expressed in almost all the cell types and control the expression of a number 
of genes. This gives concern that global inhibition of HDACs may result in universal 
transcriptional activation and cytotoxic effects on normal cells. Surprisingly, experience to 
date suggests this is not a major issue.  
First of all, HDAC inhibitors generally only alter a relatively small percentage of genes 
and proteins. Gene profiling analyses point out that HDAC inhibitors only affect 2-17 % 
of total genes, depending on the nature of HDAC inhibitors, concentration, time course, 
and most importantly, the cell types 298. Global analysis of acetylated proteins in human 
cells using mass spectrometry revealed that less than 10 % out of 3600 lysine acetylation 
sites on 1750 proteins are changed in response to SAHA and MS-275 299.  
Second, transformed cells are more sensitive to HDAC inhibitor-induced anti-proliferative 
effects 161, 300. HDAC inhibitor-upregulation of p21 arrests cell cycle at G1/S phase in 
transformed and non-transformed cells; however, normal cells are insensitive whereas 
transformed cells are susceptible to HDAC inhibitor-mediated apoptosis. The exact 
mechanisms are not determined yet, but might be hypothetically explained by exclusive 
signalling pathways or failure of defective rescue in cancer. Several molecular pathways 
specifically aberrant in transformed cells are targeted by HDAC inhibition, such as 
IGF/Akt, IL-6, TNF/ NF-κB and survivin anti-apoptotic pathways. Moreover, the cell 
cycle checkpoints may play a role in the selective cytotoxicity of HDAC inhibitors. Cells 
with checkpoint defects enter deviant mitosis and subsequent death through a 
compensatory bypass of mitotic spindle checkpoint when exposed to HDAC inhibitors, 
while cells with intact function of checkpoints are exempt from this lethal mitosis. Loss of 
checkpoint function may be the weak point of transformed cells in HDAC inhibitor-
mediated cytotoxicity. 
Third, normal cells seem to have higher capacity for recovery from HDAC inhibition 
during non-exposure intervals because the binding of HDAC inhibitors to target sites are 
rapidly reversible in most cases. A supportive observation is that patients receiving SAHA 
were found only a transient accumulation of acetylated histones in normal peripheral 
mononuclear cells without effect on leukocyte count 301. 
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Finally, although HDACs generally lead to compact chromatin, preventing transcriptional 
factors from accessing target genes, inhibition of HDACs does not necessarily promote 
global transcription. While activating transcription from certain genomic regions, other 
transcriptions can be repressed. For example, knoct-out of HDAC1 in mice embryonic 
stem cells upregulates 5% of total genes but downregulate 3% simultaneously 154. This 
suggests HDAC inhibitors reform specific gene programmes rather than simply activate 
all promoters 
2.3. HDAC inhibitors: anti-inflammatory effects 
Anti-inflammatory properties have emerged as an important element of the therapeutic 
benefits of HDAC inhibitors. Their pleiotropic effects on angiogenesis and the immune 
system may not only be beneficial in inflammatory disorders but also contribute to their 
anti-neoplastic activity. In in vivo systems, HDAC inhibitors influence differentiation, 
survival and proliferation of distinct non-cancerous immune cell populations, both of 
innate and acquired immune systems 302. This impact is relevant to pulmonary vascular 
remodelling in PAH. In my study, treatment with VPA or SAHA altered the release of 
several PH-relevant cytokines and chemokines, including IL-6, IL-2, IL-4, RANTES and 
IP-10. Similarly, the PH-Fibs from Stenmark et al displayed an epigenetically altered pro-
inflammatory phenotype, defined by elevated expression of IL-1β, IL-6, MCP-1, stromal 
cell-derived factor-1 (SDF-1), and RANTES, which may contribute to chronic 
inflammatory reactions in the pulmonary vasculature 229. Consistently, R-cells expressed 
higher levels of several pro-inflammatory factors such as MCP-1, IL-6 and SDF-1 289, 
which were significantly reduced by VPA and SAHA treatment (unpublished data). 
Collectively, these results implicate the extensive involvement of HDACs in regulating 
pro-inflammatory activation which could be targeted therapeutically in PH. However, 
although HDAC inhibitors have been shown to be promising in preclinical studies and 
more and more compounds have entered clinical trials, currently approved agents, SAHA 
and Romidepsin, are only licenced for cutaneous T cell lymphoma. The fact that CTCL 
appears to be more sensitive to HDAC inhibitors than other solid tumours, including other 
cutaneous malignancies such as melanoma and skin squamous cell carcinoma 303, 
implicates a cell-specific effect and extrapolation to other diseases has to be carefully 
tested. But growing evidence suggests that anti-inflammation might have a more powerful 
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and critical role in therapeutic effects of HDAC inhibitors than what they have been 
thought. 
2.4. HDAC inhibitors: class or isoform specificity 
As the first attempt of using HDAC inhibitors in PH in this thesis, I chose VPA and 
SAHA, mainly because of their accessibility and clinical relevance. Covering different 
classes HDACs, these two inhibitors can provide a preliminary view of class-dependent 
differences. With the emerging roles of individual HDAC isoforms in cancer and other 
diseases, the importance of the development of isoform-specific HDAC inhibitors has 
attracted growing attention. 
The functional pleomorphism in HDACs provides a plausible rationale for using selective 
HDAC inhibitors to target specific HDACs involved in pathological events and spare 
those responsible for protective effects. Ideally, selectively inhibition of a specific class or 
isoform of HDAC is expected to achieve higher efficacy and lower toxicity. However, 
clinical evidence supporting the concept that selective HDAC inhibitors are superior to 
pan-HDAC inhibitors is quite limited. One challenge is that HDACs work in a multiple 
interacting complex. Selective inhibition of asingle subtype of HDAC inevitably leads to 
compensatory reactions in other HDACs, which could be detrimental. Better 
understanding of the individual functions and interactions among HDCAs is required for 
the development of selective inhibitors. On the other hand, using selective inhibitors in 
preclinical studies helps to clarify these mysteries and optimize the choice for clinical use. 
2.5. Novelty and value 
The value of this study is that it is the first attempt to tackle PH from epigenetic insights. 
This study provides a new concept that epigenetics may have a role in the pathogenesis 
and help to unravel some important questions in PH. It also, for the first time, shows that 
two HDAC inhibitors currently in clinical use, VPA and SAHA, have promising effects in 
PH animal models. This treatment targeting pulmonary vascular remodelling may 
generate synergic effects when combined with conventional vasoactive therapies. More 
and more HDAC inhibitors with different specificity have been designated, and they can 
be a new category worthwhile taking into consideration as novel treatments for PH. 
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3. Limitations 
A few limitations to this study have to be evaluated with caution. First, although the 
chronic hypoxia- and MCT-induced PH rat models have been shown to have practical 
value in evaluating treatments for PH, neither of them replicates the full spectrum of 
pathologies in human PAH. For example, these two models do not develop the human 
PAH form of plexifom lesions. Obviously, preventing or reversing the elevated PAP, 
hypertrophied RV and increased muscularization of pulmonary arteries in these models is 
not equivalent to "dissolving" the obstructive vascular lesions and plexogenic arteriopathy 
in human PAH.  
Second, there is no evidence that the maximal pharmacological effects of these two 
inhibitors have been achieved. The relationship between dosage and effect were not well 
established in this study. The doses used here were based on cancer studies, which may 
not be appropriate for PH. On the other hand, side effects as well as morbidity are always 
major concerns in translational pharmacology. Although VPA and SAHA did not cause 
any appreciable adverse effects in the studies reported here, mild growth retardation in the 
treated groups was noted. Furthermore, VPA has multiple functions, which can mask the 
real effects of HDAC inhibition.  
Third, HDAC activity is a central indicator of the efficacy of HDAC inhibitors, which is 
important for determining whether the phenotypical improvements truly result from 
HDAC inhibition. In this study, HDAC activity was assessed indirectly by acetylation 
status of total histone. Although this provides a high-level signal of HDAC activity, it 
does not reflect catalytic changes in individual HDACs. As a sum of total acetylated 
histone, it alone cannot present the lysine-specific modification, which may differ upon 
exposure to different inhibitors. Most importantly, increased histone acetylation is not 
necessarily the result of HDAC inhibition, but can be attributed to activation of HATs. 
Moreover, cardiac function was not formally assessed. RV hypertrophy has 
conventionally been thought secondary to increased pulmonary resistance, but RV 
function can conversely affect the pulmonary circulation. In the study, seemingly more 
profound impacts on RV hypertrophy than PA pressure or vascular remodelling in treated 
groups suggest possible direct effects on RV.  
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The current experience of HDAC inhibitors in cancer treatment primarily refers to zinc-
dependent HDACs (classes I, II and IV). Nevertheless, growing evidence has implicated 
the role of class III HDACs, sirtuins, which is exclusively of different homology to the 
other HDACs 304.  Sirtuins are linked to longevity, ageing processes, metabolism and 
vascular homeostasis, and have the potential in cancer 219, 305. For example, Resveratrol, 
an activator of SIRT1, exerts anti-inflammatory, anti-oxidant and anti-proliferative effects 
in pulmonary vasculature and prevents MCT-induced PH in rats 306. However, the 
functions of sirtuins were not assessed in this thesis. 
Finally, evaluation of inflammatory responses in lung tissues and endothelial cells is 
inadequate to consolidate the regulatory function of VPA and SAHA on the immune 
system. Immune cells have to be involved.  
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Figure 7.2. Summary of  the study demonstrating that HDAC inhibitors target vascular remodelling. 
HDACi: HDAC inhibitor. 
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4. Future plans  
 The possible molecular mechanisms are demonstrated by the downstream read-outs 
Bcl-2, p21 and survivin. A more precise connection between these pathways and 
histone acetylation can be established by certain techniques such as mass 
spectrometry, RNA array and chromatin immunoprecipitation. Insights into the 
genetic and molecular basis of HDAC inhibition will help to understand the 
pathogenesis of PH and guide to development of optimal therapeutic strategies. 
 The class- and isoform-specificity of HDACs needs to be explored. As the functional 
roles of individual HDACs are clarified, more and more selective inhibitors are 
becoming available. Comparison of the pharmacological effects between HDAC 
inhibitors with different specificity as well as manipulation of certain subtype of 
HDACs, such as sirtuins, will also provide information on mechanistic insights of 
HDAC modifications. 
 The impressive effects of VPA and SAHA on RV hypertrophy give a good rationale 
for examining RV function in detail, which can be achieved by isolated perfused 
heart system (Langendorff), cardiac output measurement and imaging approaches 
such as echocardiography.  
 To further identify the link between HDAC inhibitors, PH and inflammatory 
reactions, cellular systems including immune cells and fibroblasts should be studied. 
Human peripheral leukocytes, which are relatively easy to be obtained, can be a 
useful tool to assess the immune responses in PH. 
 Following the encouraging findings of this study and the fact that few HDAC 
inhibitors are safely used in clinic, the ultimate goal is to conduct a proper clinical 
trial with double blind design and randomized controls to investigate the therapeutic 
potential in human PH. 
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